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CHAPTER 1 
General review 
1.1 Myotonie dystrophy 
1.1.1 Clinical picture 
Myotonic dystrophy (DM) was first recognized as a disease entity at the 
beginning of the 20th century. Batten and Gibb (1909) and Steinert (1909) 
independently described a series of patients with atrophy and weakness of the 
face and distal limb muscles in combination with the inability to relax the 
muscles after forceful contraction (myotonia). Steinert reported detailed 
pathological studies in one of his patients with myotonic dystrophy, and 
stressed the occurrence of a "myopathic progressive dystrophy" (Steinert, 
1909). Before these landmark publications, DM had been lumped together 
with different myotonic syndromes under the diagnosis of myotonia congeni-
ta or Thomsen disease (Thomsen, 1876). It is now known that myotonia 
occurs in several distinct genetic disorders, notably in myotonia congenita 
(various types), in paramyotonia congenita, in periodic paralysis (2 types) 
and in the Schwartz Jampel syndrome (Harper, 1989). DM is by far the most 
frequent of the inherited myotonias as judged from a survey performed by 
Becker and co-workers (Grimm, 1976; Becker, 1977). By 31 December 
1960, this group had collected information on 562 patients with DM living in 
the Federal Republic of Germany and West Berlin, on 168 patients with 
recessive generalized myotonia, and on 116 cases of dominant myotonia. 
However, the authors recognized that underascertainment was still a major 
problem for each of the disorders in their sample. Another important early 
contribution to the study of DM was the description by Greenfield (1911), by 
Fleischer (1918), and by Vogt (1921) of ocular cataract in DM. Vogt (1921) 
commented on the characteristic finding of multiple, small, dustlike or 
gleaming opacities that were found exclusively in the cortex of the lens and 
that were intermingled with red or green (rarely with yellow or blue) 
crystals. He also showed that the apparent colour of the crystals was due to 
the dispersion of light from his slit lamp. These early descriptions of myoto-
nia, muscle weakness, and cataract established what are now regarded as the 
most characteristic signs of myotonic dystrophy. However, even these early 
reports noted the involvement of other organ systems, specifically testicular 
atrophy and frontal balding in males, as well as reduced intelligence and lack 
of initiative (Curschmann, 1912; Curschmann, 1925). Many other symptoms 
may occur in myotonic dystrophy (table 1.1.2). A full discussion would be 
beyond the scope of this thesis and only a few other clinically relevant 
problems will be mentioned here. 
Difficulty in swallowing is frequent in DM and may lead to aspiration. If the 
oesophagus is dilated, aspiration may occur during sleep, and the clinical 
picture may be that of unexplained recurring bronchopneumonia. Megacolon 
is also frequent, and occasional patients with intestinal pseudo-obstruction 
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have been reported. Cognitive impairment (especially in cases of childhood 
or congenital onset) and hypersomnolence (with or without central alveolar 
hypoventilation) are not uncommon. Thomasen (1948) studied 101 patients 
with DM and confirmed previous observations of reduced initiative and a 
satisfied care-free temperament. Although mental changes form a characteris-
tic part of the clinical picture, little is known about the neuropathological 
substrate. Thalamic inclusion bodies, and intracytoplasmatic inclusion bodies 
in the putamen, caudate nucleus, substantia nigra and cerebral cortex have all 
been reported as well as minor abnormalities in gyral architecture (Ono et al. 
1987). Studies using CT and MRI scanning of the brain have demonstrated 
cerebral atrophy, focal white matter changes, anterior temporal lobe lesions 
and occasional calcification of the basal ganglia (Huber et al. 1989; Avraha-
mi et al. 1987). A recent report has emphasized the presenile occurrence of 
abundant neurofibrillary tangles, especially in the parahippocampal area of 
the brain. (Kiuchi et al. 1991). The exact relationship (if any) between the 
clinical changes and the neuroradiological and neuropathological changes is 
obscure. 
General anaesthesia in DM patients carries increased risk because of the 
possibility of prolonged apnoea, increased sensitivity to central depressant 
medication, aspiration, succinylcholine induced muscle contracture, or 
cardiac rhythm disturbances followed by cardiac arrest (Aldridge, 1985). 
Cardiac illness in DM is infrequent, but subclinical cardiac involvement in 
DM is very common (Moorman et al. 1985). Sudden death occurred in 4% 
in one study (Moorman et al. 1985). Occasional patients may require 
pacemaker implantation. All DM patients should have regular review for 
cardiac symptoms as well as ECG testing (anonymous, 1992). 
Based on experience with more than 50 DM families, I believe that specific 
symptoms cluster in some DM families. As a case in point, we have studied 
a large Dutch DM family, in which two siblings were repeatedly hospitalized 
for intestinal pseudo-obstruction (Brunner et al. 1992a). Another observation 
of intestinal pseudo-obstruction in siblings with DM has been made (C.J. 
Höweler, personal communication). Pleomorphic adenoma of the salivary 
glands, which is another very rare complication of DM (Jóhannesson et al. 
1978; personal observations), has also been observed in siblings (C. Hö-
weler, personal communication). Perhaps the most persuasive evidence for 
an unusual familial presentation of DM is found in a large Dutch pedigree, 
where all clinically affected family members showed significant polyneuro-
pathy (Spaans et al. 1986). Polyneuropathy was the sole symptom in 4 
additional members of the family who had inherited the DM gene as judged 
from genetic linkage studies (Brunner et al. 1991b). Other possible examples 
of familial clustering of symptoms can be found in the literature (Brunner et 
al. 1992a). For many specific symptoms, the exact frequency in DM patients 
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is unknown. This renders it very difficult to assess whether an observed 
familial clustering of symptoms could be due to chance alone. A possible 
explanation for clustering of symptoms is the existence of modifier genes 
(Haldane, 1941; Ravin and Waring, 1939). In fact, the selection for genes 
that modify the deleterious effects of autosomal dominant mutations was 
invoked by Fischer (1931) as one of the main forces in evolution. The many 
possible interactions of the myotonic dystrophy gene product(s) at the 
cellular level (see Brook et al. 1992 for review) suggest that a mutation in 
other genes involved in the same metabolic pathway or cellular structure 
could set the stage for selective dysfunction of specific organs or cell types 
affected by the DM mutation. 
Further clinical aspects of DM are reviewed extensively in a recent mono-
graph on DM (Harper, 1989). 
1.1.2 classification of DM in clinical subtypes; and anticipation 
Age at onset is the single most important factor determining the clinical 
picture in myotonic dystrophy. This was first recognized by Fleischer 
(1918). Three main clinical forms of DM are often recognized (Dyken, 
1969; Harper, 1989). Congenital onset DM typically presents with polyhy-
dramnios during the 3rd trimester of pregnancy. At birth, severe hypotonia 
is found, with diminished respiration and swallowing (Vanier, 1960; Harper, 
1975). Some cases show talipes or arthrogryposis. Respiratory function may 
or may not improve sufficiently to allow survival (Rutherford et al. 1989). 
Most individuals with congenital-onset DM subsequently show mild to 
moderate mental retardation (Harper, 1975) with poor prognosis for normal 
family life and ultimately gainful employment. Long term complications 
include recurrent otitis, articulation defects, persistent disabling talipes, 
recurrent gastro-intestinal malfunction, and possibly early death due to 
aspiration pneumonia (O'Brien and Harper, 1984). 
Adult onset DM is characterized by onset in adolescence or early adulthood. 
This group of patients presents with the classical picture of myotonia and 
muscle weakness, with or without cataract or additional features as shown in 
table 1.1.2 (Höweler, 1988; Harper, 1989). 
Late onset myotonic dystrophy is a very mild condition. In most cases, 
cataract is the only feature. 
While most patients will fit into this simple classification scheme, some 
evidence exists that further groups should be defined. For instance, O'Brien 
and Harper (1984) noted that some of the siblings of their congenital-onset 
cases showed mental retardation without the typical congenital features of 
hypotonia, or breathing and swallowing problems. Such childhood-onset 
cases have been mentioned by others, too (Bundey, 1982; Höweler, 1986; 
Koch et al. 1991). Furthermore, Höweler (1986) and more recently Koch 
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and co-workers (1991) divided their adult onset cases into two subgroups, 
that is early adult and late adult (Höweler, 1986) or early adult and adult 
(Koch et al. 1991). This leads to the following classifications, mainly based 
on the age at onset: 
TABLE 1.1.1 
Congenital 
Childhood 
Early adult 
Late adult 
Senile 
Mild 
Koch et al. 1991 
< 1 year 
1-10 years 
11-20 years 
21-40 years 
cataracts only 
Höweler, 1986 
at birth 
0-9 years 
10-29 years 
30-49 years 
>50 years 
Fleischer (1918) was the first to describe the progression of disease severity 
in families with myotonic dystrophy. DM may present with presenile or 
senile cataract in the first generation, while the next generation shows 
classical (i.e. adult onset) DM. In the third generation, patients will show 
either childhood onset or congenital onset of DM (Höweler, 1986). Howe-
ver, the number of liveborn children in this generation is decreased, due to 
infertility, celibacy and pregnancy loss (Fleischer, 1918; Klein, 1958; 
Höweler, 1986; Veillette et al. 1989; Koch et al. 1991). In fact, none of the 
childhood onset or early adult onset males in the series of Höweler (1986) 
and of Koch et al. (1991) had any offspring. 
Fleischer noted that different families with DM were often related through 
common ancestors for whom no history of disease was known. He suggested 
that DM could be transmitted for many generations with no ill effect, with 
the possible exception of cataract (Fleischer, 1918). Fleischer's findings have 
been confirmed in pedigree studies in various countries (Mathieu et al. 1990; 
Lotz and van der Meyden, 1985; Klein, 1958; personal observations). Each 
of these studies showed that DM families often have distant common ances-
tors and therefore supported the concept of significantly lower expression in 
earlier generations than in later generations of a DM family. Bell (1947) 
noted that the disease presented earlier in subsequent generations, and that 
this antedating was accompanied by the extension of signs from one tissue to 
another, e.g. from the lens of the eye to muscular tissue, and perhaps to 
nervous tissue. She also noted an excess of mildly affected or asymptomatic 
fathers (59%) who had transmitted the disease (Bell, 1947). A similar excess 
of males among mildly affected transmitters of the disease was found by 
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Klein (1958). 
The phenomenon of increasing severity and earlier onset with each genera-
tion, has become known as anticipation. Recently, extensive reviews of the 
history of anticipation in DM have been published (Höweler, 1986; Harper, 
1989; Harper et al. 1992). In brief, Fleischer's original observation was 
widely accepted, until the geneticist Penrose pointed out that anticipation had 
not been documented in other species, and that selection biases, inherent to 
the study of human inherited disease might also account for the phenomenon 
(Penrose, 1948). These selection biases included ascertainment through 
severely affected individuals, as well as reduced fertility of severely affected 
individuals. Such biases would prohibit the ascertainment of mildly affected 
offspring born to a severly affected parent (complementary pairs), since these 
children would be either asymptomatic at the time of examination (and thus 
considered unaffected) or nonexistent, because of selective infertility. This 
view was adopted by most geneticists (with a few notable exceptions such as 
the study by Klein (1958)), until the study of Höweler showed that in 14 DM 
families, 60 of 61 parent-child pairs showed anticipation (Höweler, 1986; 
Höweler et al. 1989). This study has recently been duplicated in 40 Ameri-
can DM families with almost identical results (Ashizawa et al. 1992b). The 
molecular mechanisms involved in anticipation and in the congenital form of 
DM will be further discussed in sections 1.3.4 and 1.5. 
TABLE 1.1.2 
Organ systems that are affected in myotonic dystrophy, and major symptoms 
ORGAN SYSTEM SYMPTOMS 
Muscles Myotonia; atrophy and weakness of predominantly 
the facial, masticatory, neck, forearm, and 
lower leg musculature 
Heart Atrioventricular conduction disturbance; atrial 
fibrillation; sudden cardiac death 
Lungs Aspiration pneumonia; alveolar hypoventilation; 
respiratory insufficiency 
Gastrointestinal Swallowing defect; delayed emptying of oesopha-
gus and stomach; crampy abdominal pain; 
diarrhoea or obstipation; megacolon; intestinal 
pseudo-obstruction 
Uterus Spontaneous abortion or premature birth; 
reduced voluntary muscle power during second 
stage of labour; postpartum haemorrhage; 
retained placenta 
Eyes Cataract; retinal degeneration; hypotonia 
Endocrine Testicular atrophy; irregular menses; 
peripheral insulin resistance 
Adnexa Premature balding; pilomatrixoma 
Brain Apathy and inertia; mental retardation; 
hypersomnolence; increased sensitivity to 
sedatives 
Peripheral nerves Reduced nerve conduction velocity; 
polyneuropathy 
Heart, lung, brain Anaesthetic complications 
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1.1.3 Biochemical studies into the pathogenesis of DM 
Before the nature of the mutation became known, a large number of studies 
had been performed in order to define the basic biochemical defect in DM. 
These studies have provided several clues that point towards a generalized 
dysfunction of cell membranes. The myotonia itself probably reflects a 
disturbance of the normal process of depolarization and repolarization of the 
muscle membrane (Rüdel and Lehmann-Horn, 1985). This is supported by 
the finding that myotonia may be experimentally induced by activators of 
protein kinase С through lowering of the sarcolemmal chloride conduction 
(Brinkmeyer and Jockusch, 1987). However, abnormal chloride conduction 
is not the basic defect in DM (Rüdel and Lehmann-Horn, 1985). In fact, a 
report of tight linkage between a skeletal muscle chloride channel gene 
(CLC-1) on chromosome 7 and both autosomal dominant myotonia congenita 
(Thomsen disease) and autosomal recessive generalized myotonia (Becker 
disease) suggests that genetic defects involving this chloride channel cause 
generalized myotonia. This is further supported by a point mutation (Phe-to-
Cys) in two families with autosomal recessive generalized myotonia (Koch et 
al. 1992). On the other hand, linkage and mutation analysis in families with 
paramyotonia congenita (PC), hyperkalemic periodic paralysis (HYPP) and 
acetazolamide-responsive myotonia congenita suggests that these disorders 
are caused by allelic defects in a skeletal muscle sodium channel gene on 
chromosome 17q (Ptacek et al. 1991; Ptacek et al. 1992; McClatchey et al. 
1992a; McClatchey 1992b). A mutation in the homologous sodium channel 
gene has been demonstrated in myotonic mice (Steinmeyer et al. 1991) and 
in Quarter horses with periodic paralysis (Rudolph et al. 1992). 
Other findings pointing to membrane abnormalities in DM include abnormal 
protein kinase activity in the erythrocyte membrane (Roses and Appel, 1973; 
Roses and Appel, 1974), abnormal results of electron spin resonance studies 
of erythrocytes (Butterfield et al. 1974), increased calcium influx in erythro-
cytes (Plisker et al. 1978), lowered temperature response of membrane 
phosphorylation in erythrocytes (Vickers et al. 1979), defective phospholipid 
metabolism in the erythrocyte (Grey et al. 1980), increased fragility of the 
band 3 membrane protein of erythrocytes (Tsuchiya et al. 1983), abnormal 
platelet function (Bornstein et al. 1988), whole body insulin resistance 
(Moxley et al. 1984), reduced insulin binding to cultured fibroblasts (Hudson 
et al. 1987), expression of the apamin receptor on muscle cell membranes 
(Renaud et al. 1986), abnormalities of the fast sodium current in cultured 
muscle cells (Rüdel et al. 1989), increased release of potassium after ische-
mic excercise (Wevers et al. 1990), and altered Ca2+ homeostasis of 
cultured muscle cells (Jacobs et al. 1991). The studies of Roses and Appel 
(1973; 1974) on abnormal protein kinase activity have recently received 
indirect support from the finding that the myotonic dystrophy mutation 
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involves the expansion of a trinucleotide (CTG) repeat at the 3' end of a 
transcript encoding a protein kinase family member (Brook et al. 1992; Fu et 
al. 1992; Jansen et al. 1992b). This subject will be discussed further in 
section 1.3.2. 
1.2 Towards cloning of the DM gene 
1.2.1 Genetic mapping of DM 
1.2.1.1 Protein polymorphisms 
Myotonic dystrophy was the first major autosomal disorder to show genetic 
linkage in man, when Mohr suggested linkage of DM to the Lewis and 
Lutheran blood groups (Mohr, 1954). At that time the relationship between 
the secretor status and the Lewis blood group was unclear. It was subse­
quently realized that the expression of the Lewis blood group antigen was 
dependent on the secretor status of an individual. Greenwalt (1961) confir­
med that Lewis-Lutheran linkage was in fact secretor-Lutheran linkage. 
Studies by Renwick and coworkers (1971) and by Harper and coworkers 
(1972) confirmed linkage between DM and the secretor locus. It was not 
until several years later that the addition of the peptidase D gene (PEPD) 
(O'Brien et al. 1983) and the complement component 3 gene (C3) (Eiberg et 
al. 1983) to this linkage group allowed assignment of the DM gene to 
chromosome 19, since both C3 and PEPD had previously been assigned to 
this chromosome through the study of somatic cell hybrids (McAlpine et al. 
1976; Whitehead et al. 1982). 
1.2.1.2 Early DNA polymorphisms: C3 and APOC2 
The detection of polymorphism at the DNA level in the form of restriction 
fragment length polymorphisms (RFLP's) has greatly facilitated the creation 
of genetic maps on which disease loci may be placed (Botstein, 1980). The 
first RFLP to be studied in DM was detected by using the gene for the third 
component of complement (C3) as a probe. Combining data from the C3 SstI 
RFLP and the C3 protein polymorphism in their sample with data from the 
previous study of Eiberg and colleagues (1983), Davies and coworkers 
(1983) arrived at a lod score of 3.36 at θ = 0.05 between DM and C3 in 
males. In females, no linkage could be established. The authors hypothesized 
that these discrepant results might be due to more frequent recombination in 
females than in males. That recombination frequency should be higher in 
females than in males had been previously suggested by Haldane based on 
data from various animal species (1922), and confirmed for specific human 
chromosomes by Keats (1982). 
The next RFLP proved to be much closer to the DM locus. A study by Shaw 
et al. (1985) yielded a maximum lod score of 7.87 at θ = 0.04 (both sexes 
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combined) between DM and a set of RFLP's at the locus for Apolipoproteir 
C2 (APOC2). Close linkage between DM and APOC2 was subsequently 
confirmed by several groups (Hulsebos et al. 1985; Регісак-Vance et al. 
1986; Bird et al. 1987). Compiling recently published linkage data (table 
1.2.1), the DM-APOC2 lod score is now well over 90 at a recombination 
frequency of 0.02-0.03 (Le Beau et al. 1989). 
TABLE 1.2.1: Data on APOC2-DM linkage 
Reference Zmax. θ 
Brunner et al. (1989b) 19.91 0.02 
Komeluk et al. (1989) 31.08 0.01 
Yamaoka et al. (1990) 27.53 0.04 
Harleyetal. (1991b) 17.07 0.03 
At first it was unclear whether the DM gene was on the short or on the long 
arm of chromosome 19. Linkage to C3 and PEPD appeared to indicate a 
genetic localization on 19p (Lusis et al. 1985; Lusis et al. 1986), while 
linkage with APOC2 was more consistent with a localization on 19q (Shaw 
et al. 1986; Hulsebos et al. 1985). This apparent discrepancy was resolved 
by the reassignment of PEPD to 19q (Davis et al. 1987) and the exclusion ol 
DM from the C3-19cen interval on 19p (Friedrich et al. 1987). 
1.2.1.3 Use of hybrid cell lines 908K1 and WILFM2 to generate clones 
from the DM region 
With all the data pointing towards a localization of DM on the proximal long 
arm of chromosome 19, two groups set out to generate a panel of somatic 
cell hybrids containing small pieces of chromosome 19. These somatic cell 
hybrids were used to isolate and to map genes and polymorphic DNA 
sequences that might be relevant to the search of the DM gene. As a starting 
point, both groups used a cell line (908K1 or WILFM2) containing a single 
der (19;X) chromosome with the breakpoint on chromosome 19 occurring al 
19ql3.2 (Hulsebos et al. 1986; Brook et al. 1986). These studies succeeded 
in accurately localizing a large number of genes and anonymous DNA 
fragments to specific intervals of the long arm of chromsome 19 (Schonk el 
al. 1989; Schonk et al. 1990; Brook et al. 1987; Brook et al. 1991; see also 
Schonk, 1991 for review). However, all polymorphic markers that were 
localized to the proximal long arm of chromosome 19 by this approach 
turned out to be further away from the DM gene than APOC2 (Shaw et al. 
1986; Brunner et al. 1989a; Harley et al. 1991b). The first marker to appeal 
as closely linked to DM as APOC2 was probe LDR152, that defines a Mspl 
and a PstI polymorphism at locus D19S19. This probe had been isolated 
from a flow-sorted library that was enriched for human chromosome 19. A 
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iod score of 15.4 was reported without recombination (Bartlett et al. 1987). 
Somewhat surprisingly, this locus was later shown to be further away from 
DM than APOC2 (Yamaoka et al. 1990). Reinspection of the original 
linkage data by the same group of investigators suggests that the absence of 
recombination between DM and D19S19 in the original study may have been 
influenced by a preponderance of male méioses, the assumption again being 
that this segment of chromosome 19 has a smaller cross-over frequency in 
male méioses than in female méioses (Yamaoka et al. 1990). Other loci were 
described that appeared promising at first, but were subsequently shown to 
map further away from DM than APOC2. In particular, a clone (BCL3) 
from a lymphoma cell line translocation breakpoint, and a Na+, K+-ATPase 
a subunit gene (ATP1A3) did not bring the search any closer to the DM 
gene, although they helped in further ordering of the 19ql2-ql3.2 region 
(Komeluk et al. 1989; Harley et al. 1988). The ATOE and APOCl genes 
likewise were shown to be further from DM than the APOC2 gene (Smeets 
et al. 1988; Smeets et al. 1989; Brunner et al. 1989b; Walsh et al. 1990), 
although all three apolipoprotein genes are tightly linked, both physically 
(Smit et al. 1988a; Smit et al. 1988b) and genetically (Myklebost and Rogne, 
1986; Myklebost and Rogne, 1988; Humphries et al. 1984). A critical step 
in the progress towards the DM gene was made when somatic cell hybrid 
studies showed that the gene for muscle type creatine kinase (CKM) maps 
physically close to the APOC2 gene in 19ql3.2 (Stallings et al. 1988), and 
linkage analysis showed that the CKM gene could be as close to the DM 
gene as APOC2, or possibly closer (Brunner et al. 1989a). The demonstrati-
on that the distal breakpoint in the parental cell lines 908K1 and WILFM2 
was within the CKM gene (Smeets et al. 1990; Brook et al. 1991) then 
targeted attention to the region of chromsome 19 just distal to the 19ql3.2 
endpoint of these somatic cell hybrid cell lines. Confirmation of a genetic 
localization of the DM gene distal to both APOC2 and CKM was subse-
quently obtained from the study of individual cross-over events (Brunner et 
al. 1989b; Johnson et al. 1989; Korneluk et al. 1989; Walsh et al. 1990; 
Yamaoka et al. 1990; Harley et al. 1991). The coding sequence of the CKM 
gene was investigated in a DM patient, but no translationally significant 
mutation was found (Bailly et al. 1991). It was shown that in a previously 
characterized cross over event with markers at the APOC2 and CKM loci, 
the DM gene also recombined with newly discovered polymorphisms at the 
ERCC1 locus (Smeets et al. 1991; Shutler et al. 1991). Since the ERCC1 
and ERCC2 genes had been shown to lie distal to the 908K1 translocation 
breakpoint (Smeets et al. 1990), these findings excluded the DM gene from 
the previously constructed somatic cell hybrids (Smeets, 1991; Brook et al, 
1991). 
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1.2.1.4 Genetic markers distal to ERCC1 
Redefining the localization of the DM gene as 19ql3.2-ql3.3 (Smeets et al. 
1991) led to the search for distal flanking markers from 19ql3.3. Most 
efforts in this direction used the 20ХР3542-Ы cell line (Stallings et al. 
1988) as the basis for further cloning of the DM genetic area. Markers distal 
to DM include the protein kinase С gene (Johnson et al. 1988) and the 
anonymous markers pEWRBl.1/4 (D19S50) (Korneluk et al. 1989), and 
pl34c (D19S51) (Johnson et al. 1990; Tsilfidis et al. 1991a). The latter locus 
was shown to be closely linked genetically, at a recombination frequency of 
approximately .006 (Tsilfidis et al. 1991a). However, this locus has not yet 
been physically linked to the DM gene region (Buxton et al. 1992). Shutler 
and coworkers (1992) cloned 350 kb of genomic DNA extending from 
ERCC1 in a telomeric direction. In addition, they further characterized a 
previously reported DM-ERCC1 cross-over family (Smeets et al. 1991, 
Shutler et al. 1991). In this family, the recombinant event was shown to 
have occurred distal to D19S118 (Tsilfidis et al. 1991b). This excluded 
approximately 200kb of sequence between ERCC1 and D19S118 as the site 
of the DM gene. The segment of chromosome 19 that contains the DM 
mutation was reduced to at most 300 kb by the detection of a cross over 
event that placed the anonymous marker pX75b (D19S112) distal to DM 
(Jansen et al. 1992a). The cloning of the DM genetic region (Aslanidis et 
al., 1992; Figure 1.2.1.4) was completed with the identification of two 
overlapping yeast artificial chromosome (YAC) clones and several cosmids 
containing D19S118 and D19S119 (Korneluk et al. 1991) on the proximal 
side of DM and D19S112 on the distal side of DM. 
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1.2.2 Linkage disequilibrium 
The first indication of linkage disequilibrium in DM was found in a study of 
French Canadian families from the Saguenay-Lac-Saint-Jean area (Laberge et 
al. 1985; Laberge, 1989). In these studies, the E4 allele of APOE was 
significantly overrepresented in DM patients in comparison with unaffected 
controls. The observed allelic association was attributed to a founder effect, 
since it is known that this population is descended from a small group of 
immigrants from France at the end of the 17th and the beginning of the 18th 
century. In fact, extended genealogical reconstruction has later shown that all 
of 746 DM patients in this area are descendant from a single ancestral couple 
who were married in 1661 (Mathieu et al. 1990). Subsequent studies of 
several APOC2 polymorphisms in 23 French-Canadian families from other 
parts of Canada again demonstrated linkage disequilibrium (MacKenzie et al. 
1989). This group of investigators expanded their findings by performing 
extensive haplotype analysis with 10 RFLPs on a set of 87 DM chromo­
somes. The results indicated that most DM patients in the French Canadian 
population have one of two ancestral mutations (Korneluk et al. 1991b). In a 
small study of IS Finnish families, significant linkage disequilibrium was 
again found between DM and АЮС2, but not between DM and CKM 
(Nokelainen et al. 1990). Gennarelli and coworkers (1991) also did not 
detect linkage disequilibrium between DM and CKM in 59 DM families 
from Italy and Spain. 
A very important step in the progress towards the DM gene was the identi­
fication of strong linkage disequilibrium between D19S63 (Brook et al. 1991) 
and DM in the "outbred" British population. The results suggested that at 
least 58% of the DM patients in the British population, as well as in the 
French-Canadian population have the same ancestral mutation (Harley et al. 
1991a). Unfortunately, the authors did not further elaborate this hypothesis. 
However, at this point it was clear that the DM mutation behaved in an 
unusual fashion compared to other autosomal dominant mutations, since for a 
condition having such obvious negative consequences on fertility (Hòweler, 
1986) many new mutations would be required to maintain the gene frequen-
cy. The strong linkage disequilibrium between DM and D19S63 was quickly 
confirmed in other laboratories (Cobo et al. 1992; and our own unpublished 
data). Less marked linkage disequilibrium was also observed with the 
D19S112 marker, distal to DM (Jansen et al. 1992). 
1.3 The DM mutation 
1.3.1 Identification of the DM gene 
Recently, several groups simultaneously reported the discovery of the DM 
mutation. Each of these groups relied on the genetic map generated over a 
period of 6 years as has been outlined in the previous section. Harley and 
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coworkers (1992a), Buxton and coworkers (1992a), and Aslanidis and 
coworkers (1992) screened genomic clones from the previously defined 
candidate region for expressed sequences. Each group reported that one of 
their cDNA clones detected a DNA fragment that is larger in DM patients 
than in normal subjects. Individual families showed increasing expansion of 
the unstable fragment in subsequent generations, suggesting a biological 
explanation for the anticipation phenomenon (see section 1.1.2). In addition, 
Harley and coworkers (1992a) reported that a second (Eco RV) polymorp-
hism at this locus (D19S95) is in almost complete linkage equilibrium with 
DM, since the larger allele was found on 74/75 DM chromosomes, but only 
on 140/232 normal chromosomes. They suggested that it was likely that most 
cases of DM have a common origin, most likely a small insertion or duplica-
tion with an inherent ability to expand (Harley et al. 1992). Fu and cowor-
kers (1992) arrived at the DM mutation by screening YAC clones from the 
previously defined DM genetic region (Jansen et al. 1992a; Shutter et al. 
1992; Aslanidis et al. 1992) for trinucleotide repeats. This strategy was 
based on similarities in the unusual pattern of inheritance between DM and 
the fragile X syndrome, a point that had previously been made by Sutherland 
and coworkers (1991). They identified a cosmid (pMDYl) containing a CTG 
trinucleotide repeat sequence that showed expansion in DM patients. They 
further showed that the CTG trinucleotide repeat is part of the 3'-untrans-
lated region of a gene that shows homology to protein kinase genes (Fu et al. 
1992). Simultaneously, Brook and coworkers (1992) and Mahadevan and 
coworkers (1992b) reported that the expansion occurred in this CTG trinu-
cleotide repeat sequence, and that the repeat was part of the 3'-untranslated 
region of a gene with possible serine-threonine protein kinase activity. Jansen 
and coworkers (1992b) showed that the CTG trinucleotide repeat sequence in 
the homologous mouse gene contains only 5 trinucleotides and is interrupted 
by two A residues. Alternatively spliced isoforms were found in both human 
and mouse cDNAs prepared from brain and heart mRNA. Whether these 
isoforms have different functions in vivo is unclear. Jansen and coworkers 
(1992b) further demonstrated that the DMR-B15 gene, which contains the 
CTG trinucleotide repeat is expressed at low levels in almost all tissues. 
High-level expression was observed in skeletal muscle, heart and various 
organs containing smooth muscle. Another gene (DMR-N9), which is located 
in close proximity to DMR-B15 is most strongly expressed in brain and 
testis. Thus, one may speculate that the expression of DMR-N9 is also 
affected by the expansion of the CTG trinucleotide repeat. 
1.3.2 Function of the putative DM gene 
Based on homology to conserved sequnece motifs, the putative DM gene 
product is considered to belong to the family of (serine-threonine) protein 
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kinases (Brook et al. 1992; Fu et al. 1992; Janssen et al. 1992b). It has been 
proposed that the putative protein kinase (or kinases) could play a significant 
role in the regulation of excitation-contraction coupling or maintenance of 
cellular physiology via regulation of protein-protein interactions in ion 
channels, or insulin-receptor signalling (Jansen et al. 1992b). 
Brook and coworkers (1992) noted strong similarity to the cAMP-dependent 
protein kinase (cAPK) and suggested that some of the known functions of 
cAPKs fît well with the diverse defects exhibited by DM patients. Such 
cAPK functions include phosphorylation of ion channels, control of glycogen 
and lipid metabolism through cell signalling involving enzyme phosphorylati-
on and modification of gene expression. Some members of the serine-
threonine protein kinase family are known protooncogenes that are amplified 
and overexpressed in certain tumours. For example, the AKT2 gene, which 
maps to 19ql3.1-ql3.2 is amplified in ovarian carcinomas (Cheng et al. 
1992). In this regard, it may be worthwhile to examine gene expression in 
tumours that show association with DM such as pleomorphic adenomas of 
the salivary glands (Jóhannesson et al. 1978) and pilomatrixomas (Harper, 
1972; Chiaramonti and Gilgor, 1978; Delfino et al. 1985). 
It is to be expected that our knowledge of the biochemical basis of DM will 
greatly expand over the next few years. At present, only limited data are 
available. Questions concerning the cellular function and location of the 
putative protein kinase, the function of alternatively spliced isoforms (Jansen 
et al. 1992b), the possible involvement in DM of other genes from the CTG-
containing region of the chromosome, or the tissue distribution of repeat 
sequence mosaicism in DM patients have not yet been answered. However, 
the answers to these questions are necessary before a meaningful comparison 
can be made between the clinical phenotype and the primary disturbance of 
cellular function in this condition. Many other questions will undoubtedly 
present themselves as this part of the DM story gets underway. 
1.3.3 Origin of the DM mutation 
Genealogical studies (Fleischer, 1918; Howeler, 1986; Mathieu et al. 
1990; and unpublished results) suggest that in selected families the DM 
mutation may be at least several generations old. Based on the almost 
complete linkage disequilibrium between the expanded CTG trinucleotide 
repeat sequence and the D19S95 insertion polymorphism (Harley et al. 
1992a), as well as with other markers in the DM gene area (Harley et al. 
1992c) it has been suggested that all DM mutations are descended from a 
single ancestral mutation. Based on this assumption, one group has even 
attempted to correlate the distribution of DM in various countries and 
populations with the evolutionary tree of the human race (Ashizawa and 
Epstein, 1991). Stable transmission of expanded alleles over four generations 
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has been noted in individual families (Barceló et al. 1992). However, the 
suggestion that expanded alleles are often stably transmitted for several 
generations (Harper et al. 1992) is unlikely to be correct in view of their 
strong over-all tendency to expand further (e.g. Brunner et al. 1992b; and 
unpublished; see also paragraph 1.3.4). Rather, one would suspect that 
unstable expanded alleles are quickly eliminated from the population because 
of the reduced fertility of males with adult-onset disease (Höweler, 1986) 
and the reduced potential for procreation for childhood-onset and congenital-
onset cases of both sexes (O'Brien and Harper, 1984). For linkage disequili-
brium to exist, the unstable expanded repeat sequence should originate from 
a semi-stable premutated allele that can only be destabilized by a distinct 
event, either mutational or epigenetic. This theory has been further expanded 
in the case of the fragile X syndrome by Morton and MacPherson (1992). 
These authors suggested that 4 types of alleles exist at the fragile X locus: 5-
60 repeats (N); 52-150 repeats (S and Z) and >200 repeats (L). In this 
model, the S and Ζ alleles are similar in size, but differ in state, the S allele 
being relatively stable, while the Ζ allele is highly unstable. Based on 
estimates in the paper by Morton and MacPherson (1992), Chakravarty 
(1992) calculated the following frequencies: 
TABLE 1.3.3.1 
Allele 
N 
S 
Ζ 
L 
Type 
Normal 
Stable insert 
Unstable insert 
Mutation (symptomatic) 
Frequency 
0.9751 
0.0225 
0.0014 
0.0010 
Mean Age 
(generations) 
-
90 
2 
1.4 
The rate of conversion from S to Z, which is the critical step in this 3-step 
model was estimated as 1.1% per generation (Chakravarty, 1992). This 
model derives some support from the detection of limited linkage dise­
quilibrium between larger "normal" alleles at the fragile X locus (36-50) and 
marker haplotypes that had previously been shown to be overrepresented in 
fragile X patients (Richards et al. 1992c). 
It seems reasonable to assume that a very similar situation exists for DM. 
The fact that all chromosomes carrying the DM mutation have an insertion at 
locus D19S95, within an intron of the putative DM gene, whereas only 55% 
of normal chromsomes carry this insertion suggests that only a proportion of 
normal chromosomes has the potential to evolve into a DM chromosome. 
Indeed, Imbert and coworkers (1993) have suggested the presence of 3 
distinct groups of normal chromosomes. Chromosomes with 5 CTG trinu­
cleotide repeats always carry the D19S95 insertion, but chromosomes with 
11-15 CTG trinucleotide repeats generally do not. Larger normal alleles oí 
16-40 CTG trinucleotide repeats also carry the insertion (table 1.3.3.2). 
TABLE 1.3.3.2: CTG-trinucleotide number and D19S95 polymorphism 
CTG Frequency' D19S95 insert present 
trinucleotide 
number own data Imbert et al. 1993 
5 .45 8/8 104/104 
11-15 .45 0/11 12/149 
16-40 .10 6/6 34/34 
'Based on 382 chromosomes (Brook et al. 1992; Brunner et al. 1992b) 
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It is presently unknown, which proportion of all chromosomes carrying 
the lkb insertion at locus D19S95 (approximately 55% in the normal 
population) contain the presumed semistable premutated alleles (S in 
table 1.3.3.1). It may well be that only chromosomes with 16 or more 
CTG trinucleotides (10%) or a subgroup of these are at risk for further 
expansion. For instance, the frequency of alleles containing 20 or more 
CTG trinucleotide repeats is approximately 5% in Caucasians (Brook et 
al. 1992; Brunner et al. 1992b). Given the suggestion that all DM 
chromosomes are derived from a common ancestral chromosome 
(Harley et al. 1992a; Harley et al. 1992c) it would seem that the gene 
pool containing semi-stable premutated alleles must be much larger than 
has been calculated for fragile X. Also, the DM mutation has to be 
much older than the 90 generations that have been calculated in the case 
of the fragile X syndrome (Chakravarty, 1992). 
So far, it is unclear what constitutes the essential difference between the 
S class of semi-stable premutated alleles and the N class of normal 
alleles. At present, there are at least three possible scenarios: 
1. The 1 kb insertion at D19S95 found in 55% of the normal population 
is itself the initiating factor for the destabilization of the trinucleo-
tide repeat. This is unlikely, in view of the fact that approximately 
50% of DM chromosomes carry the smallest allele for a PstI poly-
morphism at the D19S63 locus (table 1.3.3.3). Since this allele is 
found on only 20% of normal chromosomes, and not itself in linkage 
disequilibrium with D19S95, the DM premutation pool is probably 
significantly smaller and contains only a fraction of all chromosomes 
carrying the D19S95 insertion. 
2. The 1 kb insertion at D19S95 is in linkage disequilibrium with a 
subgroup of alleles, presumably those with larger CTG trinucleotide 
repeats (e.g. those with 16 or more CTG trinucleotide repeats; Imbert 
et al. 1993). This hypothesis may be tested by comparing the 
distribution of 
alleles for D19S63 between chromosomes of different trinucleotide 
content. 
Premutated (S) alleles would be expected to show a significant excess 
of the 6.5kb allele for D19S63, as well as a reduced frequency of the 
6.8kb allele (table 1.3.3.3). 
A single ancestral mutation would have caused overrepresentation of 
the 6.5 kb allele in combination with an equal diminution of the 6.8 
and 7.1 kb alleles. Therefore, the overrepresentation of the 6.5 kb 
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allele and underrepresentation of the 6.8 kb allele of D19S63 does 
not prima facie seem compatible with a single ancestral chromosome 
from which all DM chromsomes have descended. A limited number 
(2-6) of ancestral DM chromosomes seems a more likely explanation. 
Data obtained by Imbert and coworkers (1993) strongly support this 
model, since the distribution of alleles at the D19S112 locus for DM 
chromosomes and for larger normal alleles containing ^ 19 CTG 
trinucleotides was virtually identical. The other large group of 
chromosomes containing the D19S9S insert are those with 5 CTG 
trinucleotides. These showed a very different distribution of alleles at 
the D19S112 locus, indicating that this allele is not a frequent origin 
of DM chromosomes. The authors suggested that between 1 and 4 
ancestral mutations were probably responsible for all DM chromoso-
mes and that alleles containing between 19 and 30 CTG trinucleotides 
(10% overall frequency) may constitute a reservoir for recurrent DM 
mutations. 
3. An unknown number of ancestral mutations have occurred which can 
give rise to unstable premutated (Z) alleles only if the lkb insertion at 
D19S95 is present on the same chromosome (cis-effect). Until the 
first bonafide expanded allele lacking the lkb D19S95 insertion has 
been documented, this scenario remains possible. However, the 
number of ancestral mutations should not be very large, because of 
the observed linkage disequilibrium with D19S63 (table 1.3.3.3). It is 
theoretically possible that under this scenario a few frequent mutati-
ons coexist with a larger number of rare mutations, a situation 
reminiscent of that found in cystic fibrosis. 
TABLE 1.3.3.3: Linkage disequilibrium between DM and D19S63' 
D19S63 DM non-DM 
PstI alleles (n=122) (n=436) 
1 (7.1 kb) .44 .58 
2 (6.8 kb) .07 .25 
3 (6.5 kb) .49 .17 
'Combined data from Harley et al. (1991a), from Cobo et al. (1992), 
and from our own laboratory (unpublished) 
1.3.4 Anticipation revisited 
As noted in previous sections, the number of CTG trinucleotidesin DM tends 
to increase further in successive generations and both the age at onset and 
the clinical phenotype correlate with the size of the mutation (Harley et al. 
1992b, Hunter et al. 1992). These findings have provided a biological basis 
for the observation that the onset of DM occurs earlier in successive genera-
tions (Fleischer, 1918; Ravin and Waring, 1939; Bell, 1947; Klein, 1958; 
Höweler et al. 1989). However, the factors governing the transition from 
minimally expanded CTG trinucleotide repeats found in subjects who are 
asymptomatic or have cataract as their only feature, to larger mutations 
associated with muscle weakness and clinical myotonia have not yet been 
elucidated. 
We studied 68 parent-child pairs (from 38 sibships) where the parent had 
less than 100 CTG trinucleotie repeats (Chapter 9). A correlaton between 
DM allele size in the parent and DM allele size in the offspring was found. 
A similar correlation has also been documented for the CCG trinucleotide 
expansion associated with the fragile X syndrome (Fu et al. 1991, Yu et al. 
1991, Heitz et al. 1992). 
An excess of mildly affected or asymptomatic male transmitters has previ-
ously been noted in DM families (Bell, 1948; Klein, 1958; Harper, 1989; 
Brunner et al. 1991). We demonstrated that this male excess is specifically 
associated with the first appearance of the clinical phenotype in the family 
(Brunner et al. submitted; Chapter 9). 
The basis for this male transmission bias appears to be the different magnitu-
de of the CTG expansion on male and female transmisión. In our study of 68 
parent-child pairs, the chance that a mutation of 60-79 CTG trinucleotides in 
the parent expanded to S 100 CTG trinucleotides in the offspring was 48/52 
for offsping of males and 7/16 for offspring of females (p= 0.0002), 
(Brunner et al. submitted; Chapter 9). Preliminary evidence for greater 
instability with male transmission was also obtained by others (Barceló et al. 
1993). 
If the rate of expansion is indeed greater with male than with female trans-
mission, this raises a number of questions. 
First, it is not clear, whther this male transmission bias is due to greater 
instability in male meiosis, in the mitotic divisions preceding meiosis, or in 
the mitotic divisions that occur in early embryogenesis. Alternatively, the 
apparent instability of paternally inherited DM mutations may simply reflect 
the larger number of cell divisions during male gametogenesis than during 
female gametogenesis (Edwards, 1989). 
Second, irrespective of its cause, the greater instability of paternally inheri-
ted alleles contrasts with the (almost) exlusively maternal inheritance of the 
most severe forms of myotonic dystrophy. This may partly reflect a greater 
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reduction in fertility of affected males than of females with onset of clinical 
signs in early adulthood or in childhood (Höweler, 1986). However, those 
affected males that are fertile, still do not have offspring with congenital-
onset DM. As discussed in paragraph 1.5, several explanations have been 
proposed for this phenomenon. Most of these explanations invoke a maternal 
factor other than the DM mutation itself. However, the finding that 11 cases 
of decreasing CTG repeat length were all paternally inherited (Ashizawa et 
al. 1992; Hunter et al. 1993; O'Hoy et al. 1993; Shelboume et al. 1992; 
Brunner et al. 1993) suggests that a paternal factor may be acting directly on 
the size of the DM mutation in the offspring. In fact, a combination of male 
infertility and selection against individual sperm bearing large expansions at 
the DM locus may explain the exclusively maternal origin of the severe 
congenital form of DM. Recent data on sperm samples from males with 
different disease severity also support the hypothesis of selection against 
larger DM alleles in sperm (G. Jansen, personal communication). 
Third, if CTG repeat expansion occurs not only during gametogenesis, but 
also in the (early) embryo, this raises the question whether genomic imprin-
ting may be involved in the different rate of repeat expansion of paternally 
and maternally derived alleles. Data from two different experiments indicate 
that the DM-kinase gene is expressed from both parental chromosomes in 
both mouse and man (G. Jansen et al. 1993). While this does not completely 
rule out a differential imprint affecting secondary DNA structure, it shows 
that genomic imprinting in the usual sense (i.e. uniparental expression at the 
RNA level) is not involved in DM. 
Further studies of trinucleotide repeat length in sperm from DM patients, but 
also in fetal tissues at different stages of embyogenesis, and possibly in tissue 
culture experiments should be of great value for further elucidation of the 
dynamics of the unstable mutation. 
1.3.5 Similarities to other conditions with unusual inheritance patterns 
1.3.5.1 Similarities to the fragile X syndrome and to X-linked spinal 
muscular atrophy 
A number of reviews have discussed the similarities between the first three 
disorders in which the mutation was found to consist of an expanded trinu-
cleotide repeat sequence (Richards and Sutherland 1992a, 1992b; Sutherland 
and Richards, 1992) Before the DM mutation was identified, expanded 
trinucleotide repeats had been identified in fragile X syndrome and in X-
linked spinal and muscular atrophy (La Spada et al. 1991; Fu et al. 1991; 
Verkerk et al. 1991; Yu et al. 1991; Oberlé et al. 1991). Some of the 
similarities (and a few differences) are given in table 1.3.5.1. Since recently, 
at least 40 genes have been identified that contain polymorphic trinucleotide 
repeats, this list will most likely expand over the next few years (Riggins et 
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al. 1992). In fact, since the initial preparation of this text, three more 
disorders were found to be associated with expanded trinucleotide repeats, 
namely Huntington's disease (the Huntington's disease collaborative research 
group, 1993), spinocerebellar ataxia type 1 (Orr et al. 1993), and FRAXE 
mental retardation (Knight et al. 1993). 
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1.3.5.2 Non-Mendelian patterns in Huntington's disease and in other 
disorders 
Since Mendel's laws imply that genes are transmitted from one generation to 
the next essentially unaltered, anticipation and imprinting are important 
modifications of these laws. It may be worthwhile to examine the literature 
for other conditions which also show unexplained deviations from the 
expected situation under strictly Mendelian inheritance. 
Both fragile X syndrome and DM show significant linkage disequilibrium 
between the disease mutation and polymorphisms in the adjacent DNA seg-
ments. This suggests a common origin of the mutation in different families 
(Richards et al. 1992; Harley et al. 1991a). The linkage disequilibrium in 
DM has been discussed in some detail in paragraphs 1.2.2 and 1.3.3. 
Another possible candidate for an unstable mutation was the gene for 
Huntington's disease (Harper et al. 1992a). Linkage disequilibrium (Skraa-
stad et al. 1992) and anticipation with parental sex effect (Ridley et al. 1988) 
had both been demonstrated in Huntington's disease. Also, the early onset 
form of Huntington's disease which is asssociated with prominent rigidity 
rather than choreic movements is almost exclusively inherited from the 
father. Since the initial preparation of this text, the mutation that causes 
Huntington's disease has indeed been shown to consist of an expanded 
trinucleotide (CAG) repeat (the Huntington's disease collaborative reseach 
group, 1993). 
Interesting observations have been reported for several disorders, that might 
turn out to be caused by an unstable mutation. Possible candidates include 
the finding of strong allelic association in Ashkenazi Jews between the gene 
for autosomal dominant torsion dystonia and RFLP markers on chromosome 
9 (Risen et al. 1990; Ozelius et al. 1992). Also, two recent pedigree studies 
appear to show earlier onset (and more severe symptoms) in successive 
generations of a family with neurogenic scapuloperoneal amyotrophy (De-
Long and Siddique, 1992) and of a family with cavernous hemangiomas of 
the brain (Steichen-Gersdorf et al. 1992). However, these reports concern 
single families that are rather small, and therefore some of the biases 
suggested by Penrose (1948) to account for the anticipation phenomenon may 
well be operative. Anticipation has also been suggested to occur in familial 
amyloid neuropathy (Sousa et al. 1991), in neurofibromatosis type 2 (Evans 
et al. 1992), and in myoclonic dementia (Little et al. 1986). 
An effect of parental sex on expression in offspring has been noted for 
monogenic disorders such as spinocerebellar ataxia and amyotrophic lateral 
sclerosis (Leone et al. 1992; Harding, 1981). Interestingly, an expanding 
(CAG) trinucleotide repeat has now been detected in a subset of families 
with spinocerebellar ataxia that maps to chromosome 6 (Orr et al. 1993). An 
effect of parental sex on transmission has also been noted for disorders that 
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are usually considered to show multifactorial inheritance such as epilepsy 
(Ottman et al. 1988), congenital heart defects (Nora and Nora, 1988), 
psoriasis (Traupe et al. 1992), and neural tube defects (Madman and Hamel, 
1992; Chatkupt et al. 1992). In most of these conditions, genomic imprinting 
(Reik 1989) may be an alternative explanation, as it is in hereditary glomus 
tumors (van der Mey et al., 1989) or in familial Angelman syndrome 
(Meijers-Heijboer et al. 1992; Wagstaff et al. 1992). However, it should not 
be overlooked that genomic imprinting and unstable mutations caused by 
expanded trinucleotide repeat sequences are not mutually exclusive mecha-
nisms. In fact, the extensive methylation of large expansions in the FMR-1 
gene shows that dynamic mutations affecting the DNA sequence may induce 
epigenetic effects that can perhaps influence gene function (Oberlé et al. 
1991; Richards and Sutherland, 1992b; Hansen et al. 1992; Sutcliffe et al. 
1992). 
1.3.6 Genotype-phenotype correlations 
Many monogenic disorders show variation in severity, age at onset and type 
of symptoms, both within and between families. This is called variable 
expressivity. In those cases where symptoms are completely lacking, the 
term non-penetrance is commonly used. Consistent differences between 
families may indicate that different mutations - either allelic or non-allelic -
are involved. However, differences within a single family - or between 
families carrying the same mutation - are more difficult to explain. Within 
the last few years, it has become apparent that such variability in expression 
may be due to any one of several mechanisms, usually involving mutations at 
additional loci, which together constitute the genetic background. Alternati-
vely, the mutation at the main locus may be influenced directly, either 
through a second mutation (as in the case of unstable mutations), through 
influence of the homologous (normal) chromosome, or through the process 
of genetic imprinting, wich is defined as functional inequality of maternal 
versus paternal copies of a gene or gene region (Cattanach and Kirk, 1985). 
Table 1.3.6 shows a compilation of various mechanisms of variable phenoty-
pic expressivity of single gene disorders. Some of these mechanisms have yet 
to be convincingly demonstrated in man (e.g. position effect variegation). On 
the other hand, it appears unlikely that this list should be complete in its 
present form. Rather, an increasing number of mechanisms, as well as 
combinations of these should be anticipated. Also, as indicated above, some 
of the mechanism listed are not mutually exclusive. For instance, it has been 
proposed that genetic imprinting is a function of sex-linked modifier genes 
(Sapienza, 1990). Others have stressed the possible role of heterochromatin 
formation in explaining both position effect variegation in Drosophila as well 
as genetic imprinting in man (Tartof and Bremer, 1990). Finally, Reik et al. 
(1989) postulated that anticipation in Huntington's disease could be caused 
by genomic imprinting. 
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TABLE 1.3.6.1: 
Mechanisms of variable expressivity of monogenic disorders 
MECHANISM 
Exogenous factors 
Heterogeneity of mutation 
Allelic 
Non-allelic 
Contiguous gene syndrome 
Intrafamiliar variability at main locus 
Second mutation 
Unstable mutation 
Imprinting 
Allelic modification 
Position effect variegation 
Anticipation 
Influences from other locus 
Non-allelic modifier 
Sex-limited/sex-influenced trait 
Somatic mosaicism 
Other 
Depletion of mitochondrial DNA 
Secondary mutation at other locus 
Abnormal karyotype 
REFERENCES 
Kappas et al. 1989 
Byers et al. 1991 
Parfrey et al. 1990 
Ballabio et al. 1990 
Howell et al. 1991; 
Goldfarb et al. 1992 
Verkerk et al. 1991 
van der Mey et al. 1989 
Cepellini et al. 1955 
Reuter et al. 1990 
Ridley et al. 1988 
Maestri and Beaty, 1992 
Egli et al. 1985 
Edwards et al. 1990 
Moraes et al. 1991 
Zeviani et al. 1989 
Garcia-Dorado et al. 1990 
In DM, the variability of the size of the unstable mutation appears to be the 
major factor determining the clinical phenotype (Harley et al. 1992b; 
Ashizawa et al. 1992b; Tsilfidis et al. 1992; Hunter et al. 1992; Hunter et 
al. 1993). The fact that correlations between the genotype (as determined 
from peripheral blood DNA samples) and the clinical phenotype are rather 
broad may be at least partly explained by the existence of somatic hetero-
geneity between different tissues of an individual. Other factors may also 
influence the pattern of expression of DM in individual cases. To some 
extent, this is supported by the finding of familial clustering of specific 
symptoms of DM (Brunner et al. 1992a). However, reports of this type of 
observation are strongly biased towards the unusual and only prospective 
studies can establish whether such familial clusters are truly nonrandom. 
It may be noted that a recent study of neurofibromatosis (NF) type 1, also 
concluded that the expression of specific NF1 traits was similar in close 
relatives, and that this trait-specific clustering was best explained by the 
influence of modifying genes (Easton et al. 1993). 
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1.4 Presymptomatic diagnosis of DM 
Myotonie dystrophy is one of the most frequent reasons for referral to our 
genetic counselling unit. Often, an apparently healthy family member is 
concerned about transmitting the disorder to future offspring. It has been 
shown repeatedly that detailed neurological examination, electromyography, 
and slit lamp examination will each detect highly specific signs in a small 
proportion of such asymptomatic individuals (Harper, 1989). Because of the 
many possible symptoms, several other clinical tests have previously been 
proposed for screening of at-risk individuals. No clear additional benefit has 
been demonstrated for any of these (reviewed in Harper, 1989). Nonetheless, 
when careful clinical testing has been performed, approximately 8% of 
asymptomatic young adults at 50% prior risk will still turn out to be gene 
carriers when examined by DNA analysis (Brunner et al. 1991a; Brunner et 
al. 1992b). 
DNA analysis with closely linked markers has been widely used for pre-
symptomatic as well as prenatal diagnosis (Meredith et al. 1986; Bird et al. 
1987; Norman et al. 1989; Thibault et al. 1989; Yamaoka et al. 1990; 
Milunsky et al. 1991; Mulley et al. 1991; Nokelainen et al. 1991; Lavedan 
et al. 1991). If both clinical testing and the analysis of linked DNA markers 
suggest that the consultand is not affected, the risk of possessing the DM 
gene drops to less than 1% for adult individuals at 50% prior risk. Predictive 
testing using linked genetic markers has generally proven effective in DM 
(Reardon et al. 1992), and very few diagnostic errors have been recognized 
in retrospect (Brunner et al. 1992b; Shelbourne et al. 1992). 
Current diagnostic protocols are all based on direct detection of the expanded 
CTG trinucleotide repeat sequence, although linked genetic markers are still 
used occasionally to confirm results from direct mutation analysis. Direct 
mutation analysis using PCR amplification of the expanded repeat sequence 
(Mahadevan et al. 1992b) has proven highly effective in excluding DM when 
the presence of two normal-sized CTG trinucleotide repeats can be demon-
strated (Brunner et al. 1992b; HJM Smeets and W Nillesen, personal 
communications). This method has also shown good results for the detection 
of expanded alleles in most families (e.g. Smeets et al. 1992; Brunner et al. 
1992b). However, in some cases the abnormal expanded allele is not visuali-
zed by PCR because of preferential amplification of the normal (smaller) 
allele. Therefore, in those cases where only a single normal allele can be 
seen after PCR, further testing is required. This may be done by Southern 
blotting of genomic fragments that contain the CTG trinucleotide repeat or 
by linkage analysis using closely linked polymorphic systems such as 
D19S112 (Jansen et al. 1992a). Other laboratories have decided to rely 
mainly on conventional Southern blotting of genomic fragments containing 
the repeat (Shelbourne et al. 1992; Myring et al. 1992). This circumvents the 
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problem of preferential amplification of the normal allele, at the cost of more 
laborious (and time-consuming) methodology. 
1.5 Congenital myotonic dystrophy 
Congenital myotonic dystrophy is characterized by reduced mobility and 
swallowing in utero (Pearse and Höweler, 1983). Reduced mobility causes 
positional limb deformities such as talipes equino varus. Insufficient swallo-
wing causes poly hydraminos, which may initiate premature birth. Following 
birth, severe respiratory problems are the rule (Rutherford et al. 1989). 
These may end in the demise of the affected child. In exceptional cases, the 
fetus may have severe lung hypoplasia caused by intrauterine immobility 
(personal observation). Surviving infants show a gradual increase in muscle 
strength over a period of weeks to months. The long-term prognosis is poor 
with regard to independent functioning. Mild to moderate mental retardation, 
in combination with residual muscular weakness and skeletal problems such 
as talipes often cause significant problems (O'Brien and Harper, 1984). After 
puberty, muscle weakness again progresses. 
The pathogenesis of the congenital form of DM is unknown. Several authors 
have commented on the immature aspect of the skeletal muscle fibers (Sarnat 
and Silbert, 1976; Saghal et al. 1983; Iannaccone et al. 1986; Farkas-
Bargeton et al. 1988) as well as of other organs (Young et al. 1981). In this 
regard, the observation that the DM gene product shows very high expressi-
on at the neurmuscular junction of type 1 fibers during innervation (B 
Wieringa, personal communication) suggests a possible pathogenetic mecha-
nism underlying the severe muscle hypotonia in the neonatal period. 
In 1972, Harper and Dyken discussed the striking preponderance of affected 
mothers compared to affected fathers of children with the congenital form of 
myotonic dystrophy (Harper and Dyken, 1972a). They suggested that a 
maternal environmental factor might interact with the presence of the DM 
gene in these children. The nature of this putative maternal factor is still 
unknown (see Harper, 1989 for review). Some authors have suggested the 
possibility that the mitochondrial genome (which is exclusively maternally 
inherited) might interact with the DM gene (Merrill and Harrington, 1985; 
Poulton, 1988; Poulton, 1992). However, determination of the complete 
mitochondrial DNA sequence in patients with congenital DM has excluded 
this possibilty (Thyagarajan et al. 1991). It has also been suggested that 
genomic imprinting might be involved in DM (e.g. Reik, 1989). This latter 
suggestion was particularly attractive because imprinting effects have been 
documented for the homologous region on chromosome 7 in mouse (Searle 
and Beechey, 1990; Cavanna et al. 1990; Saunders and Seldin, 1990). 
However, the DM-kinase gene is expressed from both chromosomes in both 
humans and mice (G. Jansen et al., 1993). 
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Koch et al. (1991) reported findings that appeared to strengthen the hypothe-
sis of maternal metabolites acting on a heterozygous offspring. Points in 
favour of this hypothesis are: 
- Congenital DM is exclusively maternally inherited. 
- The severity of the clinical picture increases in subsequent siblings in 
sibships containing a congenital case (fraternal anticipation). 
- The severe neonatal hypotonia improves with time (comparable to mater-
nal myasthenia gravis) 
- The occurrence of congenital DM in offspring correlates with the age at 
onset and severity of the symptoms in the mother, while carrier sisters 
also have a risk of having congenitally affected children appropriate to 
their disease status. 
Koch and coworkers pointed out that these findings are not easily reconciled 
with either genomic imprinting or mitochondrial effects (Koch et al. 1991). 
A completely different view was taken by Howeler, who showed that fertility 
is severly reduced in males with age at onset in the 2nd or 3rd decade 
compared to similarly affected females (Höweler, 1986; Howeler et al., 
1989). He therefore concluded, that the selective infertility in males causes a 
lack of paternal inheritance. In combination with continued anticipation on 
transmission through females, this at least partly explains the exclusively 
maternal inheritance of congenital DM. 
It has been shown that, on average, individuals with congenital DM have 
larger CTG trinucleotide inserts than patients with noncongenital forms of 
the disease (Harley et al. 1992b, Tsilfidis et al. 1992). However, based on 
the partial overlap of CTG repeat lengths between cases with congenital and 
noncongenital forms of DM, Harley et al. (1992c) believe that the simple 
correlation between repeat length and clinical phenotype does not entirely 
explain the most severely affected class of congenitally affected individuals. 
As discussed in paragraph 1.3.4, the chance of a severely affected offspring 
born to an affected male may be further reduced by contraction or even 
reversion of the mutation in the offspring. Therefore, we believe that 
selection against transmission of very large alleles may prevent males from 
having congenitally affected offspring. This view has also been taken by 
others (Mulley et al. 1993; Lavedan et al. 1993). Studies of CTG repeat 
length in various tissues from congenitally affected patients, as well as 
studies on sperm from affected males may further clarify this issue. 
1.6 Outlook 
1.6.1 Diagnosis 
The discovery of the mutation underlying DM has already changed diagnos-
tic practice for this disorder. Given the ease of diagnosis by DNA analysis, 
there is no doubt that this method will become the method of choice for 
37 
diagnosis as well as exclusion of DM. Moreover, the level of diagnostic 
accuracy obtained by DNA analysis of the CTG trinucleotide repeat expansi-
on is clearly higher than that previously attained using a combination of 
clinical examination, slit lamp examination and EMG (Brunner et al. 1992b; 
Brunner et al. 1991a; Harley et al. 1992b; Tsilfidis et al. 1992; Shelboume 
et al. 1992). It should be noted however, that each of these groups with 
extensive experience in the diagnosis of DM at the molecular level has 
encountered families in which an expanded CTG repeat sequence was not 
present. Although clinical misdiagnosis may explain at least some of these 
cases, detailed reexamination of such families is of great importance to 
determine whether other mutations of the DM gene exist that also lead to a 
DM phenotype. At least one group is currently examining the open reading 
frame of the DM gene for alternative mutations in a family with clinically 
diagnosed DM that does not show expansion of the CTG trinucleotide repeat 
(Mahadevan et al. 1992b). Analogous observations in fragile X syndrome 
may provide indirect support for the hypothesis of alternative mutations in 
DM (Wöhrle et al. 1992; Gedeon et al. 1992; De Boulle et al. 1993). 
We have reported a family with an unusual combination of myotonic dys-
trophy and peripheral neuropathy that appeared a promising candidate for an 
allelic mutation (Spaans et al. 1986; Brunner et al. 1991a). Notwithstanding 
the highly unusual presentation with a polyneuropathy, affected subjects in 
this family have an expanded CTG trinucleotide repeat (W. Nillesen, 
personal communication). Although this apparently excludes an allelic 
mutation, it remains possible that the phenotype in this family is modified by 
a second mutation in the DM gene region. 
An interesting example of such a two-mutation mechanism has been repor-
ted. Two distinct disease phenotypes (Creutzfeld-Jacob disease and familial 
fatal insomnia), have been reported in associon with a pathogenic Asn178 
mutation in the proteolipid prion protein gene on chromosome 21. However, 
further analysis of this gene has shown that the clinical phenotype in each 
family depends on a common polymorphism in the same gene. This poly-
morphism changes a methionine to a valine at position 129 of the prion 
proteolipid protein, and is not itself considered pathogenic. The possibility of 
an interaction between the two mutations was raised to account for the 
difference in expression of the disease (Goldfarb et al. 1992). 
Recently, two groups have stressed the importance of counselling potential 
DM mutation carriers before actual DNA testing is offered (Harper et al. 
1992b; Laberge, 1991). Our own experience suggests that this is indeed an 
important issue, since we have already detected unstable expanded alleles in 
two clinically normal spouses of DM family members in the context of 
preparatory DNA testing aimed at later prenatal diagnosis. 
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1.6.2 Prognosis 
A broad correlation has been observed between the size of the expanded 
CTG trinucleotide repeat and the severity of the clinical picture of DM 
(Harley et al. 1992b; Ashizawa et al. 1992b; Tsilfidis et al. 1992; Hunter et 
al. 1992). The fact that considerable overlap exists in DNA fragment length 
(assayed on peripheral blood cells) between individuals with markedly 
disssimilar clinical pictures shows that accurate prognosis cannot be provided 
by the current DNA diagnostic protocols. The exception to this rule may be 
the carriers who have less than 100 CTG trinucleotide repeats with little 
evidence for somatic mosaicism. Clinically relevant muscle involvement has 
not been noted in a sample of over 70 individuals with this type of expansion 
(HJM Smeets and H.T. Briiggenwirth, personal communication). Therefore 
it may be possible to reassure such individuals that cataract is the only 
complication that they are likely to develop as a result of being a DM 
mutation carrier. Extensive somatic mosaicism as well as differences in meao 
fragment length have been demonstrated in various tissues from affected 
individuals with severe forms of DM (G Jansen, В Wieringa, personal 
communications). This finding may explain some (and possibly most) of the 
discrepancies between clinical status and DNA findings in peripheral blood 
cells. However, presence or absence of specific symptoms in a given patient 
is most likely determined by a multitude of factors. These may not only 
include the size of the DM mutation, but also the possible modifying influen­
ces of other genes, as well as non-genetic influences from the environment 
(Ravin and Waring, 1939; Brunner et al. 1992a). For these reasons, a 
prognosis of disease progression based on DNA analysis alone is presently 
not very reliable and is unlikely to become accurate in the near future. 
1.6.3 Epidemiology 
Within the next few years, it can be anticipated that much more will be 
learned concerning the origins of the DM mutation, as well as the factors 
governing its transition from a putative semistable premutation (or protomu­
tation; Barceló et al. 1993) to the highly unstable expansion of 40-100 CTG 
trinucleotide repeats found in subjects with late onset forms of the disease. 
This process most likely involves several distinct steps, each of which is 
controlled by a specific factor or set of factors. The hypothetical ancestral 
DM premutation from which all DM mutations are derived may involve all 
chromosomes that carry the lkb insertion (D19S95; Harley et al. 1992a) that 
is present in an intron of the putative DM gene. Alternatively, the presence 
of this insertion in combination with allele lengths of 15 or more CTG 
trinucleotide repeats could constitute the original premutation (Imbert et al. 
1993; paragraph 1.3.3). Finally, the influence of another mutation (either on 
the lkb insertion fragment or in some other part of the gene) has not yet 
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been excluded as contributing to the instability of the DM trinucleotide 
motif. 
As discussed in paragraph 1.3.4, transmission by a male is more likely to 
result in the transition from a minimal mutation of 40-100 CTG trinucleotide 
repeats to a larger (>100 CTG trinucleotides) expanded allele than transmis-
sion by a female. For subjects with adult onset of the disease, the situation is 
probably influenced by selection against larger mutations in the male germ 
line. Contraction or even complete reversal of a DM mutation may be more 
frequent among paternally inherited mutations (Brunner et al. 1993; Shel-
bourne et al. 1992; O'Hoy et al. 1993; Mettler et al. 1992; Hunter et al. 
1993; Mulley et al. 1993; Lavedan et al. 1993; Ashizawa et al. 1992a; 
unpublished data). In contrast, female transmission is likely to result in 
further expansion of the mutation, possibly explaining the fact that congeni-
tal-onset DM is virtually limited to the offspring of females with adult-onset 
or childhood-onset DM (Mulley et al. 1993; Lavedan et al. 1993; Brunner et 
al. in press). 
Comparison of allele size in various tissues from congenital and non-conge-
nital DM with similar expansions in peripheral blood cells may at least 
determine whether the amplification of the DM allele is the decisive factor 
in determining clinical status. Determination of allele sizes in sperm from 
males with various clinical forms of DM could help to further clarify these 
issues. Analysis of unselected blood samples from populations with differen-
ces in the prevalence of DM may also help to determine the proportion of 
chromosomes at risk of eventually expanding to a DM mutation. 
1.6.4 Prospects for therapy 
With the discovery of the putative DM gene, and the recognition of simila-
rities to genes encoding serine-threonine protein kinases (Brook et al. 1992; 
Fu et al. 1992; Jansen et al. 1992b), we enter a new era of studies aimed at 
characterizing, and eventually correcting, the abnormalities at the cellular 
level in DM. At this writing, the effect of the expanded CTG repeat on the 
function of the putative DM gene (DM-kinase, Jansen et al. 1992b; myotonin 
protein-kinase, Fu et al. 1992; C28, Brook et al. 1992) or on neighbouring 
genes such as DMR-N9 (Jansen et al. 1992b) is still unclear. Furthermore, 
the putative DM gene has been shown to encode differently spliced mRNAs 
in brain and heart (Jansen et al. 1992b). It may well be that the DM gene 
has different functions in different tissues. Whether this means that eventual-
ly, DM will be amenable to treatment at the molecular level cannot be 
predicted at this time. Recent advances in gene therapy by intramuscular 
injection of genetically engineered myoblasts (Barr and Leiden, 1991; 
Dhawan et al. 1991) or of specific DNA constructs (Acsadi et al. 1991) 
suggest that, at least in principle, it is possible to have a modified gene 
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product expressed in muscle in vivo, but whether this will be of therapeutic 
relevance to DM is not at all clear. Recent experience with the intramuscular 
injection of human dystrophin constructs in dystrophin-deficient mdx mice 
(Acsadi et al. 1991) has not offered great hope in this regard. Before gene 
therapy or even pharmacological modulation of DM can be envisaged, 
animal model systems will have to be established (Harper, 1989). Gene 
targeting in embryonic stem cells has been successfully employed to con­
struct animal models for several other human gene defects, and the cloning 
of the mouse homologue of the putative DM gene (Jansen et al. 1992b) 
provides the first step in this direction (G. Jansen, В. Wieringa, personal 
communications). 
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CHAPTER 2 
Friedrich U, Brunner H, Smeets D, Lambermon E, Ropers HH. 
Three-point linkage analysis employing C3 and 19cen markers 
assigns the myotonic dystrophy gene to 19q. 
Human Genetics 75: 291-293, 1987. 
SUMMARY. 
In seven large families with myotonic dystrophy (DM) comprising 102 
individuals, linkage studies were performed employing restriction fragment 
length polymorphisms in the complement component 3 gene and the 19cen С 
banding heteromorphism as genetic markers. Three-point linkage analysis 
excludes DM from the 19cen-C3 segment and strongly supports its assign­
ment to the proximal long arm of chromosome 19. 
INTRODUCTION 
Linkage between the myotonic dystrophy (DM) locus, the Lewis (Le) and 
Lutheran (Lu) blood groups, and the secretor locus (Se) has been firmly 
established since the early 1970s through the pioneering work of Mohr 
(1951), Renwick et al. (1971), and Harper et al. (1972). The demonstration 
of linkage between Se, Lu, and the complement component 3 (C3) has 
assigned this linkage group to chromosome 19 (Eiberg et al. 1983). During 
the past S years numerous other genes have been added to this group, which 
now comprises some 40 gene loci (see Naylor et al. 1985, for compilation). 
Recently several nucleotide sequence polymorphisms have been detected on 
chromosome 19 employing cloned genes or random DNA sequences as 
probes, and a number of these have been used for linkage analyses in DM 
families, as compiled by Sherman et al. (1985). These and other studies 
suggest that the DM gene may be located near the middle of chromosome 
19, but its location relative to the centromere is still unknown. Part of this 
uncertainty derives from the fact that two of the most closely linked genetic 
markers of DM, peptidase D and apolipoprotein C2 (APO C2), map to the 
short and the long arm of chromosome 19, respectively (Hulsebos et al. 
1985; Lusis et al. 1985). Because the precise regional assignment of the DM 
gene is a prerequisite for the isolation of suitable diagnostic DNA markers 
and for attempts to characterize the DM gene itself, we have used the 19cen 
С banding heteromorphism (Friedrich 1985) and restriction fragment length 
polymorphisms detected with a genomic C3 probe to perform linkage 
studies in DM families. Three point linkage analysis of these data suggests 
that the DM locus maps on the proximal long arm of chromosome 19. 
MATERIALS AND METHODS 
Linkage studies were performed in seven large Dutch families, comprising 
102 individuals. For the analysis of restriction fragment length polymorp­
hisms (RFLPs) near the C3 gene, DNA was isolated from blood, cleaved 
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with the restriction enzymes SstI and TaqI, subjected to electrophoresis, 
blotted onto nitrocellulose filters, hybridized with a 32P-labeled 1.39 kb 
genomic C3 clone, and autoradiographed essentially as described previously 
(Wieacker et al. 1984). Analysis of the SstI and TaqI restriction patterns 
revealed no obvious linkage disequilibrium and as expected, no crossovers 
between these markers were detected. Therefore, the information from these 
two RFLP systems was combined to yield a complex C3 locus with four 
different haplotypes. In subsequent linkage analyses, these four haplotypes 
were treated as alleles at a single locus. 
To evaluate the 19cen C-banding heteromorphisms, chromosome preparati-
ons were made from peripheral lymphocyte cultures for 72 h. The preparati-
ons were stained consecutively with Q- and C-banding methods. Ten metap-
hases per individual were evaluated independently by two observers. Both 
the size (small or large) and the localization of the heterochromatic blocks (p 
arm, cen, or q arm) were considered, which resulted in six different centro-
mere types. 
These heterochromatin blocks were transmitted in a Mendel ian fashion and 
did not undergo conspicuous morphological changes during transmission. 
The potential use of the 19cen heteromorphism as a genetic marker has been 
emphasized earlier (Friedrich 1985). Three-point linkage analyses were 
performed employing the LINKAGE program package (version 3.5) which 
was kindly provided by Dr. Jürg Ott (Zürich, Switzerland). The available 
modification of this program was able to handle only up to four alleles at a 
single locus. To cope with this limitation, 19cen types had to be modified in 
a small branch of the largest DM family, which was possible without altering 
the genetic information. For DM we assumed a gene frequency of 0.0001, 
and non-affected first degree relatives of DM patients were subdivided into 
two different liability classes depending on their age and whether or not they 
had been carefully examined. Lod scores were calculated for various male 
recombination fractions assuming that in females genetic distances or the 
relevant segment of chromosome 19 are 2.5 times larger than in males. 
RESULTS AND DISCUSSION 
In six of the seven families studied segregation of discernible С banding 
heteromorphisms was observed, and four of these were informative with 
regard to linkage with DM. In two families conspicuously large markers 
were seen that extended towards the short arm of chromosome 19 and 
segregated with DM in the majority of cases. Four families were informative 
for DM and C3, and two families were informative for DM, 19cen, and C3. 
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Positive lod scores were obtained for all of the three possible gene pairs with 
peak values at θ=0.15 (DM-19cen), 0=0.15 (DM-C3), and 6 = 0 . 1 0 
(19cen-C3), respectively (Table 1). In view of the considerable genetic 
distances between the three markers, no attempt was made to localize the 
crossovers and to infer the probable gene order "by eye" because this was 
considered too unreliable. Instead, we decided to make use of the ILINK 
program of the LINKAGE package to assess the relative order and the most 
likely distances by three-point analysis. Results of this analysis are clearly in 
favor of the order C3-Cen-DM. The relative likelihood for this order is 
about 3 times that for the order DM-C3-Cen and almost 30 times that for 
C3-DM-Cen (Table 2). The C3 gene has been assigned to the distal half of 
19p (Ball et al. 1984; Hulsebos et al. 1986). In males C3 and DM are 
clearly but not tightly linked and in females linkage is very loose (Sherman 
et al. 198S). In contrast, linkage between APO C2 and DM is very close in 
both sexes with peak lod scores of above 23 for all recombination fractions 
between 0.01 and 0.05 (Hulsebos et al. 1985; Meredith et al. 1985; Peri-
сак-Vance et al. 1985). The APO C2 gene has been assigned to the long arm 
of chromosome 19 by two groups (Lusis et al. 1985; Hulsebos et al. 1985) 
and recently other closely linked DNA markers have been assigned to this 
region as well (Roses et al. 1986). In contrast, numerous distal short arm 
markers including the LDL-receptor and the insulin receptor are not closely 
linked to DM (see Nay lor et al. 1985). Therefore all available evidence 
excludes the DM gene from the short arm region distal from the C3 gene. 
Our three-point linkage data indicate that a localization of the DM gene 
below the centromere is about 30 times more likely than a localization 
between 19cen and C3 (Table 2). 
Table 2. Relative likelihoods for the gene orders C3-DM-Cen, DM-
C3-Cen, and C3-C'en-DM, respectively, as determined by three 
point linkage analysis. Genetic distances (in cM) correspond to 
maximum likelihoods for any given order of genes. The maximum 
likelihood for the order C3-Cen-DM is about 30 times higher than 
that for C3-DM-Cen 
Gene order Relative likelihood 
1 
2.99 
29.40 
12.6 _ 12.8 „ 
DM Cen 
17.2 10.4 „ 
DM Cj Cen 
C, 
10.6 „ 15.4 _ , 
Cen DM 
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Taken together this implies that we have excluded the DM gene from the 
short arm of chromosome 19. The assignment of DM to (the proximal part 
of) 19q should facilitate the identification of additional diagnostic markers oi 
the DM gene and thus may contribute to the reliable early diagnosis and 
prevention of this disorder. Combination of the estimated distance for 
C3-19cen and 19cen-DM gives a value of 25 cM for C3-DM. This is 
considerably higher than the distance that was measured by two-point linkage 
between C3 and DM in our material (15cM). This last value is in accordance 
with literature data as compiled by Sherman et al. (1985). Even more notable 
is the relatively large distance between DM and 19cen (15 cM, see two-point 
linkage data in Table 1), considering the fact that close linkage with DM has 
been reported for PEPD which is localized on 19p (O'Brien et al. 1983; 
Lusis et al. 1985) and in view of the relative scarcity of chiasmata in the 
pericentromeric region of chromosome 19 (Hulten 1974). Thus it may well 
be that the true distance between 19cen and DM may be smaller than our 
present estimate, which is supported by multi-point linkage analyses invol-
ving DM, 19cen, and various 19q markers (E. Lambermon, unpublished 
work). Therefore the 19cen heteromorphism may be useful as a diagnostic 
marker of DM. Follow-up linkage studies will be required for more reliable 
estimation of the distance between 19cen and DM. For the time being and 
irrespective of the outcome of such analyses, the 19cen heteromorphism is 
valuable as the most closely linked and most informative polymorphic 
marker known whose localization "north" of DM can be considered establis-
hed. 
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CHAPTER 3 
Brunner HG, Korneluk RG, Coerwinkel-Driessen M, MacKenzie 
A, Smeets H, Lambermon HMM, Oost van BA, Wieringa B, 
Ropers HH. 
Myotonie dystrophy is closely linked to the gene for 
muscle-type creatine kinase (CKMM). 
Human Genetics 81: 308-310, 1989. 
SUMMARY 
We have studied genetic linkage between the gene for creatine kinase muscle 
type (CKMM) and the gene for myotonic dystrophy (DM). In a panel of 65 
myotonic dystrophy families from Canada and the Netherlands,a maximum 
lod score (Zmax) of 22.8 at a recombination frequency (Θ) of 0.03 was 
obtained. Tight linkage was also demonstrated for CKMM and the gene for 
apolipoprotein C2 (ApoC2). This establishes CKMM as a useful marker in 
for myotonic dystrophy. 
INTRODUCTION 
Myotonic dystrophy (DM) is the commonest disorder within the myotonias, a 
genetically heterogeneous group of disorders characterized by delayed muscle 
relaxation (Becker, 1977). The disease was delineated as a separate entity at 
the beginning of this century (Steinert, 1909 Batten and Gibb, 1909) and has 
since been recognized to be the commonest muscular dystrophy of adult life 
(Harper, 1979). Apart from myotonia and wasting of skeletal muscles, 
associated symptoms are common and include cardiac and smooth muscle 
involvement, ocular cataracts, frontal balding, testicular atrophy, whole body 
insulin resistance and CNS involvement. Clinical diagnosis may be difficult 
because of the highly variable age of onset. The fundamental defect underly­
ing myotonic dystrophy is not known and therefore presymptomatic diagnosis 
is crucially dependent on reliable genetic markers. The myotonic dystrophy 
gene has been mapped to chromosome 19 by demonstration of linkage to the 
third component of human complement C3 (Eiberg et al. 1982) and subse­
quent localization of C3 on chromosome 19 by somatic cell hybrid studies 
(Whitehead et al. 1982). Regional localization of the DM gene on proximal 
19q has been suggested because of tight linkage to the gene for apolipopro­
tein СП (Shaw et al. 1985; Pericak-Vance et al. 1986; Hulsebos et al. 1985), 
which maps to the proximal long arm of chromosome 19 (Hulsebos et al. 
1985, Lusis et al. 1985) and by exclusion of the DM gene from proximal 
19p (Friedrich et al. 1987). 
Several polymorphic markers have been described from chromosome 19. 
RFLPs from the ApoC2 locus are now widely used for presymptomatic and 
prenatal DM testing (Meredith et al. 1986; Регісак-Vance et al. 1986). 
However, due to linkage disequilibrium between the different polymorphisms 
at the ApoC2 locus (Wallis et al. 1984, MacKenzie et al. 1988, van Oost, 
unpublished data) a proportion of families remain uninformative for ApoC2, 
precluding DNA diagnosis. We have studied two RFLPs from the gene for 
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creatine kinase muscle type (CKMM) in a sample of 65 families with 
myotonic dystrophy from Canada and the Netherlands, comprising approxi­
mately 600 individuals. Our results indicate that CKMM is closely linked to 
DM and that probes from this locus should be useful in both diagnosis and 
research of myotonic dystrophy. 
MATERIALS AND METHODS 
Patients 
A total of 65 families comprising approximately 600 individuals were 
studied. A person was considered affected if the family history was positive 
for myotonic dystrophy and at least one of the following was found: 
1. Myotonia 
2.Specific lens opacities on slit lamp 
examination 
3.Congenital myotonic dystrophy 
4.Transmission of the disorder through 
the person in question 
DNA isolation and southern blotting procedure 
Chromosomal DNA from peripheral blood was isolated according to Aldrid-
ge et al.(1984) with minor modifications. Chromosomal DNA (10-15μβ) was 
digested with the appropriate restriction enzymes under conditions specified 
by the manufacturer and then resolved by electrophoresis on a 0.7% (w/v) 
agarose gel. Gels were soaked in 0.25 M HCl for 10 min to partly depurina-
te the DNA. DNAs were subsequently denatured in 0.4 M NaOH and 
transferred onto Biotrace (Gelman Sciences) or Gene Screen TM Plus (New 
England Nuclear) membranes in the same solution over 6-12 hrs. DNA blots 
were washed in 2xSSC and dried at room temperature. 
DNA probes 
A 3.2 kbp human genomic fragment (BamHI-Sau3A) of the 3' untranslated 
and 3' flanking region of the CKMM gene (Coerwinkel et al. 1988) was 
used to identify CKMM alleles. This 
probe identifies a TaqI RFLP with alleles of 4.3 and 4.2 kbp (Putney et al. 
1984), and a Ncol RFLP with alleles of З.ЗкЬр and 2.3 + 1.0kbp, respecti­
vely (Coerwinkel et al. 1988). 
Two probes from the ApoC2 region were used in this study: a 530bp PstI 
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fragment from the ApoC2 cDNA (Myklebost et al. 1984), which recognizes 
a 3.8/3.2kbp TaqI RFLP (Humphries et al. 1983), a 14.5/11.5kbp Ncol 
RFLP (Frossard et al. 1986), a 2.5/1.6 kbp BanI RFLP (Frossard et al. 
1987), a 6.0/4.0 kbp BamHI RFLP (Meredith et al. 1986) and a 6,0/4.0 kbp 
Avail RFLP (Komeluk et al. 1987). In addition, the pSCll genomic 
subclone, located lkbp to the 5' end of the gene was used to detect a 
12/9kbp Bgll RFLP (Wallis et al. 1984). 
DNA inserts were excised from their vector plasmids, isolated on low-gel 
temperature agarose gels (Biorad) and labeled with Klenow DNA polymerase 
I in the presence of 32P-dCTP (Amersham, UK) and random sequence d(N)6 
hexamer primers (Pharmacia, P-L Biochemicals) (Feinberg and Vogelstein 
1984). 
Prehybridization and hybridization procedures 
Prehybridization and hybridization was performed at 65 °C for 16 hrs in 
6xSSC, 5xDenhardts, 0.2% (w/v) SDS, 10% (w/v) dextran sulphate and 
500pg/ml denatured herring sperm DNA. Washing was done at a final 
striongency of 65°C at O.lxSSC. All other conditions were as described 
earlier (Hulsebos et al. 1986). For re-use filters were stripped in 0.2 M 
NaOH (10 min) followed by neutralization in 2xSSC (30 min). For autoradi-
ography filters were exposed to Kodak XR-Omat X-ray film for 1-4 days. 
Linkage analysis 
Two-point linkage analysis was performed using the MLINK program of the 
LINKAGE program package (Lathrop and Lalouel 1984) version 4.7., 
assuming a gene frequency of 1 in 10,000 for the mutant DM allele. Persons 
at-risk for DM were assigned to liability classes depending on their age and 
the clinical examinations performed, as described previously (Friedrich et al, 
1987). For unaffected persons under age 20 years the DM genotype was 
considered unknown. 
For both the APOC2 and CKMM loci, information from different polymorp-
hic systems was combined to yield haplotypes which were subsequently 
treated as alleles at a single locus. For reasons explained in the text, recom-
bination frequencies were assumed equal for males and females in all 
calculations. 
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RESULTS 
Linkage analysis 
Two-point linkage analyses between DM and CKMM was performed in 65 
pedigrees, comprising approximately 600 individuals.The maximum lod 
score (Zmax) for DM-CKMM was 22.8 at a recombination fraction ( тах) 
of 0.03. (see Table 1). Linkage relationships with ApoC2 were determined as 
well yielding a lod score of 44.0 at a тах of 0.00. The DM-ApoC2 
relationship was studied in a subset of 20 families from the Netherlands 
generating a Zmax of 14.2 at тах=0.02. 
In three families, a cross-over was observed between DM and CKMM that 
could not be explained by non-penetrance for the disease gene. Owing to 
lack of phase information it was not possible to establish whether the 
recombination had taken place in a male or a female meiosis. Therefore, no 
attempt was made to calculate male and female recombination frequencies 
separately. 
Informativity of CKMM locus 
In 61 unrelated Dutch individuals, allele frequencies for the TaqI 4.3/4.2 kbp 
RFLP (TO were 0.24 and 0.76. For the Ncol 3.3/ 2.3 + 1.0 kbp RFLP (Nn) 
the allele frequencies were 0.375 and 0.625, respectively. Haplotypes were 
constructed at the CKMM locus for 20 unrelated individuals. The haplotype 
frequencies were 2.5% for TN, 25% for Tn, 37.5% for tn and 35% for tN. 
The chi-squared value for these allelic associations between the Ncol and 
TaqI polymorphic sites did not reach statistical significance (chi squa­
re =3.686, ρ¿0.05 df=l). Thus, no significant linkage disequilibrium 
between the two RFLPs was observed, although the sample was relatively 
small. The PIC value calculated from these haplotype frequencies is 0.616, 
which is close to the value obtained under the hypothesis of no linkage 
disequilibrium. 
71 
E 
О 
Ν 
с 
о 
я 
e 
J5 
ε 
о 
о 
с 
E 
•Ό 
e 
я 
s 
oo 
о 
¡* 
U 
•α 
с 
ϋ 
о 
α. 
< 
S 
Q 
с 
υ 
υ 
S 
ci 
s 
d 
α 
er 
υ 
С 
О 
.о E 
о 
« С 
S-В 
¿•а 
"US 
¡и л 
S.S 
Q _ 
и
 я 
-о э 
о er 
Ü E 
Ξ з 
β и 
Η S 
e 
о 
te 
с 
"Jo E 
о 
υ 
υ 
OS 
Г*1 
О 
О 
О 
О 
72 
DISCUSSION 
These results show that both DM and ApoC2 are closely linked to the gene 
for creatine kinase muscle type (CKMM). CKMM has been localized to 
19ql3.2-19ql3.3 on the basis of somatic cell hybrid and in situ hybridisation 
studies (Nigro et al. 1987). Both ApoC2 and DM have been localized to 
proximal 19q (Hulsebos et al. 1985. Lusis et al. 1985. Friedrich et al. 
1987). Therefore these loci appear to be close to each other both physically 
and genetically. 
The recombination rate of 0.03 between DM and CKMM observed in this 
study is similar to the recombination rate of 0.02 between DM and ApoC2, 
the latter being in agreement with data taken from the literature (Meredith et 
al. 1986. Pericak-Vance et al. 1986). The large LOD score and absence of 
recombination between CKMM and ApoC2 strongly suggests that the two 
loci are situated on the same side of DM. The precise ordering of the three 
loci as well as the establishment of their polarity on chromosome 19 is 
currently being established by multipoint linkage analysis in recombinant 
families (Brunner et al., Korneluk et al., unpublished). 
The low rate of recombination observed in this study (0.03) shows that 
probes from the CKMM locus may be applied profitably in presymptomatic 
diagnosis of myotonic dystrophy. In view of the small or absent linkage 
disequilibrium between the CKMM-TaqI and CKMM-NcoI RFLPs, a 
substantial proportion of families should be informative for CKMM-Ta-
ql/CKMM-NcoI. This is particularly important as substantial linkage disequi-
librium is found between the various ApoC2 RFLPs as noted by us and by 
others (MacKenzie et al. 1988; van Oost unpublished; Wallis et al. 1984). 
This explains why ApoC2 is uninformative in about 50% of families. 
D19S19, another closely linked marker (Bartlett et al. 1987) has allele 
frequencies of 0.15/0.85 and thus is informative in only a small proportion 
of families. However, if all three markers are tested, approximately 85% of 
families should be informative for at least one of the RFLPs, stressing the 
value of this approach. 
In conclusion, we suggest that the gene for creatine kinase muscle form 
(CKMM) is one of the most tightly linked markers of DM known to date and 
may be used for diagnostic as well as research purposes. Obviously, 
flanking markers are of great importance to improve diagnostic accuracy in 
DNA diagnosis of DM. Studies aiming at the construction of a complete 
genetic map around the myotonic dystrophy locus are currently underway 
(Korneluk et al. in preparation; Brunner et al. in preparation) and should 
soon reveal whether ApoC2 and CKMM map to the same side of, or flank 
the DM locus. 
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SUMMARY 
We have performed a genetic linkage study in 26 families with myotonic 
dystrophy, employing 16 polymorphic DNA markers as well as the chromo­
some 19 centromere heteromorphism. Fourteen of these markers had been 
assigned previously to one of five different intervals of the 19cen-19ql3.2 
segment by using somatic cell hybrids (Schonk et al. 1989, in press). Foi 
the long arm of chromosome 19, a genetic map has been constructed thai 
encompasses 9 polymorphic markers and the DM gene. Our studies indicate 
that the DM and CKMM genes map distal to the ApoC2-ApoE gene cluster 
and to the anonymous polymorphic markers D19S15 and D19S16, bul 
proximal to the D19S22 marker. The orientation of DM and CKMM remains 
to be determined. 
INTRODUCTION 
Myotonic dystrophy (DM) is an autosomal dominant multisystem disease 
characterized by progressive muscle weakness, myotonia, ocular cataracts 
and other symptoms. With an estimated incidence of 1 in 8000 it is the 
commonest of adult muscular dystrophies (Harper 1979). The myotonic 
dystrophy gene has been mapped to chromosome 19 through demonstration 
of linkage to complement component 3 (C3) (Eiberg 1982) and the assign­
ment of C3 to chromosome 19 by somatic cell hybrid analysis (Whitehead et 
al, 1982). Recently, we and others have established that unlike C3, which 
maps to 19pl3.2 (Ball et al., 1984), the DM gene is located on the long arm 
of chromosome 19. This is supported by tight linkage to ApoC2 ( Hulsebos 
et al, 1985; Shaw et al, 1985; Регісак-Vance et al, 1986) which has been 
localized to proximal 19q (Hulsebos et al, 1985; Lusis et al, 1985), by the 
re-assignment of the peptidase D gene, another closely linked DM marker, to 
19q (Davis et al., 1987) and by exclusion of the DM gene from proximal 
19p (Friedrich et al, 1987). 
In order to generate a genetic map around the DM locus, we have performed 
a linkage study in families with myotonic dystrophy, employing 16 regional­
ly assigned, chromosome 19-specific RFLP markers as well as the centrame­
ne С banding heteromorphism. This has enabled us to map the DM gone to, 
or near, band 19ql3.2 and to establish gene orders in the DM gene region. 
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MATERIALS AND METHODS 
Patients 
A total of 26 families were studied comprising approximately 300 individu-
als, and representing 190 potentially informative méioses. In accordance with 
guidelines, set forth by an international working group on the molecular 
defect in myotonic dystrophy (Griggs et al., 1989), a person was considered 
affected if he or she had transmitted the gene, or if the family history was 
positive and myotonia and muscular weakness or congenital myotonic dystro-
phy were found. 
DM4 isolation and Southern blotting procedure 
Chromosomal DNA from peripheral blood was isolated according to Aldrid-
ge et al.(1984), with minor modifications. Chromosomal DNA (10-15¿ig) 
was digested with the appropriate restriction enzymes as specified by the 
manufacturer and separated by electrophoresis on a 0.7% (w/v) agarose gel. 
Gels were soaked in 0.25 M HCl for 10 min to partly depurinate the DNA. 
DNAs were subsequently denatured in 0.4 M NaOH and transferred onto 
Biotrace (Gelman Sciences) or Gene Screen TM Plus (New England Nu-
clear) membranes as described (Brunner et al., 1989). DNA blots were 
washed in 2xSSC (0.3 M NaCl, 30 mM sodium citrate) and dried at room 
temperature. 
Chromosome 19 centromere polymorphism 
Variation in size and location of the constitutive heterochromatin of the 
centromeric region of chromosome 19 was used to defme alleles at the 19cen 
locus, as described previously (Friedrich et al., 1987). 
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Probes andRFLP's 
RFLP's used in this study are given in table 1. Fourteen probes had previ-
ously been regionally assigned to one of five intervals on the long arm of 
chromosome 19 (Schonk et al., 1989). The D19S22 marker has subsequently 
been assigned to the 19ql3.2-qter region defined as interval 5 (D.Schonk, 
personal communication). All probes were subcloned into either pSP64, 
pSP65, pGEM3 or pGEM4 vector plasmids (Promega Biotec) and grown in 
E.coli HB101. For details of insert size and cloning sites see Schonk et al. 
(1989). Insert DNA fragments were excised from their vector plasmids, 
isolated and subsequently labeled by primed synthesis with Klenow DNA 
polymerase I in the presence of 32P-dCTP (Amersham, UK) and random 
sequence d(N)6 hexamer primers (Brunner et al., 1989). 
Prehybridization and hybridization was performed at 65°C for 16 hrs in 
6xSSC, 5xDenhardts, 0.2% (w/v) SDS, 10% (w/v) dextran sulphate and 
500ííg/ml denatured herring sperm DNA. Washing was done at 65°C and 
O.lxSSC final stringency. All other conditions were as described earlier 
(Hulsebos et al., 1986b). For re-use, filters were stripped in 0.2 M NaOH 
(10 min) followed by neutralization in 2xSSC (30 min). For autoradiography, 
filters were exposed to Kodak X-Omat S X-ray film for 1 to 4 days. 
For ApoE typing, e3 and e4 specific oligonucleotides were employed as 
described previously (Smeets et al., 1988). For detection of a hypervariable 
(TG)m(AG)n tandem repeat in the first intron of the ApoC2 gene (Das et al., 
1987), DNA from the relevant portion of the gene was amplified by polyme-
rase chain reaction (Saiki et al., 1988), resolved on 10% (w/v) sequencing 
gels, blotted onto Gene Screen TM Plus (New England Nuclear) membranes 
and hybridized with a 32P-dCTP labeled 15-mer [(TG)4(AG)jA] oligonucleoti-
de. Details of this procedure will be presented elsewhere (H.Smeets et al., 
manuscript in preparation). 
Linkage analysis 
Two-point linkage analysis was performed using the LIPED program (Ott, 
1976) and the MLINK and LODSCORE programs of the LINKAGE pro-
gram package (Lathrop and Lalouel, 1984) version 4.7 . For multipoint 
linkage analysis, the ILINK program of the LINKAGE program package was 
used. This program calculates the maximum likelihoods for different gene 
orders by an iterative procedure that optimizes recombination frequencies. 
Healthy persons at risk for DM were assigned to one of two liability classes 
(with penetrances of 0.95 and 0.80, respectively) depending on their age and 
whether or not clinical examination had been complete. For unaffected 
persons under age 20 years the DM genotype was considered unknown. For 
DM, a gene frequency of 0.0001 was assumed. 
For the C3, ApoC2, D19S18, D19S15 and CKMM loci, which are charac-
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terized by more than one RFLP, information from different polymorphic 
systems was combined to yield haplotypes which were subsequently treated 
as alleles at a single locus. Haplotypes were constructed through careful 
inspection of the pedigrees. For the ApoC2 locus, significant linkage 
disequilibrium exists for the TaqI and Ncol polymorphisms (H.Brunner and 
B.A. van Oost, unpublished observations). Haplotype frequencies were 
estimated as 0.55, 0.35 and 0.10 for the 3.8/11.5kb, the 3.5/14.5kb and the 
3.8/11.5kb Taql/Ncol haplotypes respectively. The 3.5/11.5kb haplotype 
was not observed in our sample. For the ApoC2 hypervariable repeat 
sequence (VSSM), no information on allele frequencies is available, since 
this method has been used in only a small number of families. We therefore 
decided to use the same haplotype frequencies for the extended haplotypes 
obtained with the VSSM method. For the CKMM TaqI and Ncol polymorp­
hisms, the degree of linkage disequilibrium is small, with estimated haploty­
pe frequencies of 0.375, 0.35, 0.25 and 0.025 for the 4.2/2.3+l.Okb, the 
4.2/3.3kb, the 4.3/2.3 +l.Okb and the 4.3/3.3kb Taql/Ncol haplotypes 
(Brunner et al., 1989). For D19S15 the frequencies of the different alleles is 
given in table 1. These polymorphisms appear to be in full linkage equilibri­
um (p=0.95 by chi-square with 8 degrees of freedom). For C3, empirical 
haplotype frequencies of 0.50, 0.40, 0.05 and 0.05 were assigned to the 
2.5/12kb, the 2.5/9+3kb, the 1.8/12kb and the 1.8/9+3kb Taql/SstI 
polymorphisms. For D19S18, due to strong linkage disequilibrium, only a 
small amount of information was gained from the Mspl polymorphism in two 
families that were uninformative for the EcoRI polymorphism. We therefore 
entered the information in these families under the same allele frequencies as 
the EcoRI polymorphism. 
Equal recombination frequencies were assumed for males and females in all 
calculations, except where indicated otherwise. 
RESULTS 
Two-point linkage relationships between DM and various chromosome 19 
markers are given in table 2. Loose linkage was found for C3, which maps 
to 19pl3, for 19cen and for markers from interval 2 (19ql2-19ql3.1). In 
contrast, linkage is close for D19S18 from interval 3 (19ql3.1) and for all 
markers from interval 4 (19ql3.2). For D19S22 (interval 5, 19ql3.2-qter) a 
maximum lod score of 0.52 at θ=0.26 was obtained (male and female 
méioses combined). For recombination fractions up to 6% linkage between 
DM and D19S22 was excluded by a Lod score <-2. None of the differences 
between male and female recombination fractions was significant at the 5% 
level using Fisher's exact test. For DM-C3 and DM-Cen a higher female 
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than male recombination rate was suggested (p=0.09 and ρ=0.07 respective­
ly). Thus, no obvious difference between male and female recombination 
rates was detected, with the exception of the pericentromeric region which 
may be characterized by a marked excess of female recombination. Therefo­
re, equal male and female recombination rates were assumed for all subse­
quent calculations aiming at the delineation of gene orders in interval 3, 4 
and 5. 
TABLE 2 
Linkage Relationships between DM and 17 
Polymorphic Markers from Chromosome 19 
θ
α
 = Of Sex-specific analysis 
Locus 
C3 
19cen 
PM17.4 
D19S7 
D19S13 
20B18 
D19S9 
5B18 
D19S18 
Cyp2A 
D19S16 
D19S15 
D19S19 
ApoE 
ApoC2 
CKMM 
D19S22 
вщЫ 
0.17 
0.20 
0.13 
0.18 
0.18 
0.10 
0.17 
0.12 
0.08 
0.10 
0.07 
0.07 
0.00 
0.02 
0.02 
0.00 
0.26 
¿ B U I 
0.76 
2.02 
1.23 
1.49 
1.76 
2.12 
1.06 
2.82 
4.75 
2.94 
8.82 
7.66 
4.99 
7.97 
19.91 
11.26 
0.51 
Cm.niAi 
0.06 
0.09 
0.11 
0.16 
0.14 
0.13 
0.19 
0.11 
0.05 
0.10 
0.00 
0.06 
0.00 
0.00 
0.02 
0.00 
0.21 
0f,mu 
0.50 
0.50 
0.14 
0.26 
0.24 
0.07 
0.00 
0.13 
0.17 
0.10 
0.17 
0.08 
0.00 
0.08 
0.01 
0.00 
0.50 
2 m u 
1.87 
3.31 
1.24 
1.57 
1.85 
2.17 
1.25 
2.83 
5.10 
2.94 
10.19 
7.68 
4.99 
8.50 
19.98 
11.26 
0.91 
Note. Pedigrees were analyzed under the assumption of equal (left) 
or independent (right) male and female recombination rates. Marker 
loci are ordered in groups as shown in Table 1. 19cen refers to the 
chromosome 19 centromere heteromorphism (13). 
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A primary map of the relevant portion of 19q was obtained by performing 
four-point linkage analyses involving DM and three marker loci, D19S16, 
ApoC2 and D19S18. In a previous study (Schonk et al., 1989) we had 
assigned D19S18 to interval 3 and both D19S16 and ApoC2 to interval 4 
(see table 1). Likelihood estimates for all gene orders that are compatible 
with these assignments indicate that ApoC2 and DM map distal to D19S16, 
with odds against all other possible orders exceeding l&A (Table 3). The 
nuclear genetic map generated in this way, (cen-)D19S18-D19S16-DM/A-
poC2(-ter), was subsequently expanded by the addition of other loci, as 
outlined below. 
D19S15 was excluded from the DM-ApoC2 interval by three-point analysis 
(odds <1:10*). Four-point analysis with ApoC2, D19S16 and D19S18 
indicates that D19S15 is located between D19S16 and ApoC2 (relative 
likelihood >70:1). 
Four-point analysis with Cyp2A, an interval 3 marker, and ApoC2 and 
D19S16 from interval 4 suggests that DM is distal to ApoC2 since the 
likelihood for Cyp2A-D19S16-ApoC2-DM was found to be approximately 70 
times that for the alternative order Cyp2A-D19S16-DM-ApoC2 (Table 4). 
Recently, ApoE and ApoC2 were shown to be only 50kb apart (Myklebost 
and Rogne, 1988). The close physical linkage of these loci explains why 
recombination between ApoC2 and ApoE is very rare (Myklebost et al. 1984; 
Humphries et al., 1984; Berg et al., 1985; Smeets et al., 1988). Still, in one 
family we have observed such a recombination event, and this has enabled us 
to determine the orientation of the ApoC2-ApoE gene cluster. Four-point 
analysis indicates that ApoE is located proximal to ApoC2 (relative likeli-
hood 250:1, see Table 4). 
Finally, a relative likelihood of less than 1:1010 in a three-point analysis with 
ApoC2 excludes DM from a position distal to D19S22. This establishes the 
following map: (cen-)D19S18-D19S16-D19S15-ApoE-ApoC2-DM-D19S22(-
qter). 
D19S19 was only informative in a small number of families. Analysis oí 
individual cross-overs suggests that this marker is most likely located 
between D19S15 and ApoC2 (figure 2). 
For the highly informative CKMM marker, very tight linkage was found 
with DM, ApoC2 and ApoE. Recent physical mapping data argue for 
CKMM being distal to ApoC2, as discussed below. 
For D19S9, an interval 3 marker, a position proximal to D19S18 was 
favoured by odds of approximately 95:1 (Table 4). The other interval 3 
markers could not be positioned on this map since three- and four-point 
maximum likelihood calculations failed to favour specific gene orders. For 
interval 2 markers, the situation is similar. Each of these markers displays 
tight genetic linkage to all other markers from this group (data not shown), 
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TABLE 3 
Relative Likelihoods for Permutated Orders of DM 
and the Marker Loci ApoC2, D 1 9 S 1 6 , and D 1 9 S 1 6 
Order Relative likelihood 
D19Sl8-D19Sl6-ApoC2-DM 1 
D19S18-D19Sl6-DM-ApoC2 2.93 X 10_ 1 
D19Sl8-DM-ApoC2-Dl9Sl6 3.25 X Ю - 4 
D19S18-ApoC2-DM-D19S16 7.68 X 10 _ t 
DM-Dl9Sl8-D19Sl6-ApoC2 2 X 10 - 8 
D19Sl8-ApoC2-Dl9Sl6-DM 1 X 10_ e 
D19S18-DM-D19Sl6-ApoC2 9 X 10 _ ' 
DM-D19Sl8-ApoC2-D19Sl6 2 X 10"» 
Note. Only those permutations that are compatible with the phys­
ical data shown in Table 1 were evaluated. 
TABLE 4 
Relative Likelihoods for Gene Orders Involving* 
Other Loci from 1 9 q l 3 
Order Relative likelihood 
D19Sl8-D19Sl6-D19S15-ApoC2 
D19Sl8-Dl9Sl5-Dl9Sl6-ApoC2 
Dl9Sl8-D19Sl6-ApoC2-D19Sl5 
Cyp2A-D19Sl6-ApoC2-DM 
Cyp2A-D 19S 16-DM-ApoC2 
D19Sl6-ApoE-ApoC2-DM 
D19S16-ApoC2-ApoE-DM 
D19S16-Dl9S15-ApoE-ApoC2 
D19S16-ApoE-Dl9Sl5-ApoC2 
D19S9-Dl9S18-D19Sl6-ApoC2 
D19S18-D19S9-D19S 16-ApoC2 
1 
1.35 X 10" 
1.54 Χ ΙΟ­
Ι 
1.44 Χ ΙΟ­
Ι 
3.98 Χ ΙΟ­
Ι 
2.43 Χ ΙΟ­
Ι 
1.04 Χ 10' 
•2 
•3 
•2 
-3 
-3 
-2 
but all are only loosely linked to DM. Therefore, no extensive calculations 
were carried out to establish their order. A genetic map encompassing the 
19cen to D19S22 segment is shown in Figure 1. Its total length is 54 cM in 
males and 130 cM in females, with approximately equal male and female 
recombination rates distal to interval 2. Under this gene order, no double 
recombinants in interval 3 and 4 are required to explain the segregation 
patterns observed (see figure 2). 
I I 
4001 2SO 1 70 1 10.1 
I II ¡Í1Í I 
CEN-PMir 4-D1SS«-019Sie-01»S16-DI»S1S-ApoE-ApoC2-OM-019S21 
m 0 1 
Ι 47Θ 
f 2 6 2 
19 1 
4 1 0 
2? 1 
0 1 
1 2 0 
9 ι 
0 1 
0 1 
0 1 
2 2 
ο ι 
1 2 
5 1 
0 1 
2 8 
0 1 
6 1 
1 7 
2 2 
0 1 
1 6 
2 5 5 
26 6 
25 7 
FIG. 1. Genetic map of 19q. For designation of physically defined 
intervals, see Table 1. Genetic distances are given in centimorgans 
for independent and for equal male and female recombination rates, 
assuming Haldane's mapping function. For various pairs of loci, odds 
are presented for the most likely and inverted gene orders. Genetic 
and physical data support localization of D19S19 between D19S15 
and ApoE. CKMM could not be separated by recombination from 
either ApoC2 or DM. Physical data map this locus distal to ApoC2 
(see text). 
D19S9 
D19S18 
D19S16 
D19S15 
D19S19 
ApoE 
ApoC2 
CKMM 
DM 
D19S22 
FIG. 2 . Schematic representation of crossovers between various 
19ql3 loci. The order of DM and CKMM remains to be determined. 
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DISCUSSION 
This study provides a detailed genetic map of the DM gene region on the 
long arm of chromosome 19 and defines marker loci that flank the DM gene. 
On the proximal side, ApoC2, ApoE, D19S15, D19S16 and D19S18 are all 
tightly linked to DM which renders them suitable for diagnostic use. Taken 
together, this array of proximal markers should prove informative in virtual­
ly all families with a suitable pedigree structure. D19S22, the distally 
flanking marker on this map, appears to be very loosely linked to DM. On 
the other hand, recent data from another group (Nakamura et al, 1988) argue 
for a distance of 11 cM between D19S22 and ApoC2. This may indicate that 
the true genetic distance between DM and D19S22 is somewhat smaller than 
suggested by our study. Obviously, the identification of additional closely 
linked distal markers will be essential for both accurate genetic diagnosis and 
for progress towards isolation of the DM gene proper. 
As stated above, due to a very low degree of informativity of the D19S19 
marker, we are presently unable to unambiguously position this locus on the 
map presented here. However, as shown in figure 2, our data strongly 
suggest that it may lie in the interval between D19S15 and ApoC2. Two 
lines of evidence confirm that this locus is proximal to both ApoC2 and DM. 
First, a cross-over has been reported that separates the DM gene from 
ApoC2 and D19S19, indicating that these loci are on the same side of DM 
(Johnson et al, 1987). Secondly, recent experiments indicate that D19S19, 
D19S15 and D19S16 are absent from a somatic cell hybrid line (Stallings et 
al., 1988) carrying a 19q fragment that partly overlaps interval 4 and has 
retained ApoC2, ApoE and CKMM (M. Siciliano, personal communication; 
D. Schonk, personal communication). Therefore, D19S19 is located in the 
proximal portion of interval 4 in the vicinity of D19S15, which implies that it 
may be less closely linked to DM than previously assumed (Bartlett et al, 
1987). 
In contrast, a recent study indicates that the CKMM gene is very closely 
linked to DM (Brunner et al., 1989). In this study, which was performed on 
a combined set of 65 Dutch and Canadian families, the maximum lod score 
(Zmax) was 22.8 at a recombination fraction (Θ) of 0.03 (both sexes combi­
ned). No recombination was detected between CKMM and ApoC2 in a 
large number of méioses (Zmax = 44.0 at 6=0.00), indicating that these 
markers are probably on the same side of DM. CKMM has been assigned to 
19ql3.2-ql3.3 by in situ hybridisation (Nigro et al, 1987). 
Evidence from our laboratory indicates that the CKMM gene overlaps the 
distal breakpoint of a 19cen-ql3.2 chromosome fragment that carries all 
interval 4 markers (Wieringa et al, to be published). This implies that 
CKMM is the most distal marker of this group and consequently, DM may 
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be located in interval 5, just distal to the 19ql3.2 breakpoint. Confirmation of 
this gene order should come from analysis of recombination events separat-
ing DM and CKMM. 
Three markers in the genetic map presented here have been included in a 
map presented by Nakamura et al. (1988). Our data support the order 
D19S9-ApoC2-D19S22, that was proposed by these authors. D19S7 and 
D19S9 were placed on opposite sides of ApoC2 by Donis-Keller et al. 
(1987). However, our data support a localization of both D19S9 and D19S7 
proximal to ApoC2, which is in accordance with the findings of Nakamura et 
al. (1988). Comparison of our map with that proposed by Sherman et al. 
(1985) is limited by differences in methodology and the markers that were 
used. The larger female than male distance of our final genetic map is in 
accordance with previous findings (Sherman et al., 1985; Donis-Keller et al., 
1987; Nakamura et al., 1988). 
It might be argued, that a genetic map generated in disease families may not 
be applicable to the general population if the disease is caused by a structural 
rearrangement, such as a deletion or inversion. However, comparison of DM 
patients and normal controls by cytogenetic studies and long range physical 
mapping of the putative DM gene region has so far not produced any 
evidence in favour of such a hypothesis (D.Smeets, B.Wieringa, unpublished 
results). Thus, present data suggest that the putative DM gene mutation, is 
not caused by an abnormality within the resolution of the genetic map 
presented here. 
So far, attempts to isolate genes from neighbouring, closely linked markers 
has met little success. In fact, all (four) human genes that have been cloned 
on the basis of their known chromosomal location could be identified 
through chromosomal aberrations that were associated with recognizable 
clinical phenotypes (Orkin et al., 1986; Page et al, 1987). In the absence of 
specific translocations or deletions on chromosome 19 that are associated 
with myotonic dystrophy, there is no alternative to the genetic approach 
involving the search for, and analysis of, rare cross-over events between DM 
and very closely linked markers to direct the search towards the site of the 
DM gene. The genetic map presented here may provide a framework for 
future studies of this kind. 
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van den JBM, Joosten EMG, Pinckers AJLG, Hamel BCJ, 
Theeuwes AGM, Wieringa B, Ropers HH. 
Myotonie dystrophy. Predictive value of normal 
results on clinical examination. 
Brain 114: 2303-2311, 1991. 
SUMMARY 
Myotonic dystrophy (DM) is well-known for its highly variable clinical 
picture, including the age at which symptoms are first detected. In order to 
assess the proportion of asymptomatic gene carriers at different ages, we 
have used linked DNA markers to study individuals at 50% genetic risk of 
DM, in whom neurological examination, slit lamp examination and EMG 
had failed to show diagnostic signs. A total of 139 asymptomatic offspring of 
DM patients were studied. Our analyses identified 11 out of these 139 as 
probable gene carriers. Our data show that penetrance of the DM gene 
increases with age. After correction for the possibility of genetic recombina-
tion between the DM gene and the DNA markers used, we calculated the 
residual chance of carrying the DM gene as 8.3% for clinically normal 
offspring aged between 20 and 39 years. 
We evaluated several factors that might influence this figure. Neither the sex 
of the propositus nor that of the affected parent modified the risk of carrying 
the DM gene. Presence of aspecific lens opacities did also not correlate with 
the risk of having inherited the DM gene. 
Since a significant proportion of DM gene carriers are not detected by 
neurological examination, including slit-lamp examination and EMG, these 
results confirm the need for DNA analysis in asymptomatic offspring of DM 
patients. 
INTRODUCTION 
Myotonic dystrophy (DM) is an autosomal dominant multisystem disorder 
with variable expressivity and incomplete penetrance. A number of studies 
have documented that the proportion of symptomatic patients increases with 
age, the median age at onset of symptoms being 20-25 years (Harper, 1989). 
EMG studies and slit lamp examination are useful for the detection of 
subclinically affected individuals (Polgar et al., 1972). It has been suggested 
that the use of these ancillary investigations will allow the detection of most, 
if not all, gene carriers either by young adulthood (Harper, 1973; 1989), or 
by age 40 (Bundey, 1974). Nevertheless, it is likely that occasional gene 
carriers remain undetected. This is supported by reports of obligate gene 
carriers who failed to show diagnostic abnormalities at an advanced age 
(Höweler, 1986; Streib et al, 1987; personal observations). 
The assignment of the DM gene to chromosome 19, and the subsequent 
development of closely linked genetic markers have created the possibility of 
using DNA linkage analysis for predictive testing in DM families. We here 
report the use of DNA analysis to assess the predictive value of a full 
clinical evaluation, including EMG and slit lamp examination in a large 
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cohort of individuals at 50% risk of developing DM. 
MATERIALS AND METHODS 
Clinical data 
We have used data from a previous linkage study (Brunner, 1989b) and from 
the current diagnostic DNA service at our department to examine the value 
of a negative clinical examination in persons at risk for DM. We examined 
the DNA data for all individuals who fulfilled the following criteria: 
1. Prior risk of DM 50%. 
2. Absence of clinical or electrical myotonia, significant muscle 
weakness, multicoloured lens opacities or congenital myotonic 
dystrophy. 
In all cases, age given corresponds to the age at clinical examination. If 
clinical examination had been performed at different ages, only the age at 
first examination was used. 
With rare exceptions, individuals in our study had been examined clinically 
at one of the 8 Dutch university hospitals. 
DNA data 
DNA analysis was performed using previously described methods (Brunner 
et al., 1989a; 1989b; Smeets et al., 1989; 1991). Closely linked markers that 
were used defined the following loci: BCL3, АГОС1, APOC2, CKM, 
ERCC1, D19S63, D19S112, D19S51, D19S50, KLK and RRAS. Recombi­
nation frequencies used in risk calculations were as published elsewhere (Le 
Beau et al., 1989; Korneluk et al., 1989a; Johnson et al., 1990), with the 
following modifications: For APOC2 and APOC1, recombination frequencies 
were taken as 2% and 3% respectively. 
For D19S63, a recombination frequency of ^ 1 % was used, based on our 
own data as well as on data from other laboratories. So far, no recombinati­
on has been observed between the DM gene and this locus (Brook et al., 
1991). For D19S112, we used an estimated recombination frequency of 2% 
(H. Smeets, unpublished data). 
For both KLK and RRAS, we assumed a recombination frequency of 12%, 
based on map position and two-point linkage analysis (Smeets et al., 1991; 
and unpublished data). 
Linkage phase (i.e. the marker allele with which the DM gene segregates 
within a particular family) was always established through examination of 
affected individuals in accordance with published criteria (Griggs et al., 
1989). 
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Statistical evaluation 
In order to calculate the chance of a false negative diagnosis on clinical 
examination, we derived the following formulas. 
1. NOTATIONS 
DM+ Myotonic Dystrophy gene present 
DM' Myotonic Dystrophy gene absent 
DNA" Low risk marker allele 
DNA+ High risk marker allele 
CLIN" Clinical examination negative 
CLIN+ Clinical examination positive 
2. ASSUMPTIONS 
a. The prior risk of DM equals 50% for all individuals in the 
study. 
Ρ [DM+] = 0.5 
b. Using linked DNA markers, the chances of a false positive and 
of a false negative diagnosis are symmetric and known. 
Ρ [DNA" I DM+] = Ρ [DNA+ | DM] = q 
e. DNA diagnosis and clinical diagnosis are conditionally 
independent. 
Ρ [DNA+,CLIN+ | DM+] = Ρ [DNA+ | DM+] χ Ρ [CLIN+ | DM+] 
d. The specificity of a positive clinical diagnosis of DM is 1. 
Ρ [CLIN" | DM] = 1 
e. Call ρ = Ρ [CLIN+ | DM+] (the sensitivity of the clinical 
examination) the unknown parameter. 
3. FORMULA 
Using simple probability rules: 
Ρ [DNA" I CLIN ] . Ρ ΓΡΝΑ .CLIN Ί 
Ρ [CLIN ] 
_ Ρ ΓΡΝΑ .CLIN | DM+1 χ Ρ ГРМЧ + Ρ ΓΡΝΑ .CLIN | DM 1 χ Ρ ΓΡΜ1 
Ρ [CLIN | DM+] χ Ρ [DM+] + Ρ [Clin" | ΡΜ] χ Ρ [ΡΜ] 
- q fl-pì 'Λ + f 1-qì 1 · 'Λ . q-qp + 1-q „ b œ 
(1-p) · V4 + '/i 1 - ρ + 1 2-p 
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4. ESTIMATION OF SENSITIVITY AND NEGATIVE PREDICTIVE 
VALUE 
We estimated ρ from the equation: 
1-qp = sample fraction DNA" = ltd 
2-p η 
Where: 
d = number of individuals with a high risk marker genotype 
η = number of clinically normal individuals tested with DNA 
markers 
Also: 
1 is the negative predictive value of the clinical examination. 
2-p 
Using Taylor series expansion an approximation of the standard 
error can be calculated (Mood et al., 1974). 
Assumption a and b are met, because genetic recombination frequency is not 
dependent on clinical expression of the DM gene. 
Assumption с is met if strict diagnostic criteria are used (Griggs 
et al., 1989). 
Assumption d is correct because DM shows regular autosomal dominant 
inheritance, and only offspring of known gene carriers were included in this 
study. 
All comparisons were performed by X2-test. 
RESULTS 
A total of 151 fully investigated, clinically normal individuals were tested, 
using the DNA marker systems shown in table 1. A recombination event in 
the vicinity of the DM gene precluded accurate phase determination in 1 
nuclear family. This family was excluded from subsequent analyses. Other 
reasons for exclusion were: non-paternity shown by DNA analysis (4 
individuals in 2 families), and non-informativity of the DNA analysis, 
defined as > 5 % chance of incorrect genotype assignment (6 individuals in 5 
98 
families). The final analysis included 139 individuals (66 males and 73 
females) in 69 families. All individuals were at 50% prior risk of DM. None 
had unequivocal clinical or electrical myotonia, specific multicoloured lens 
opacities, significant muscle wasting or weakness, or signs of congenital 
myotonic dystrophy. DNA analysis was usually informative for either the 
CK.M, ERCC1 or D19S63 locus. On average, the diagnostic reliability of the 
DNA analysis was 98.44% (range 96% - >99%). 
In 11 individuals, DNA analysis indicated a high probability (mean 98.82%; 
range 98% - >99%) of carrying the DM gene (table 2). The number of 
expected false positive diagnoses due to genetic recombination in our sample 
equals only 2.16 (139 χ 0.0156). Therefore, approximately 9 (= 11 - 2.16) 
individuals tested should be asymptomatic gene carriers. 
TABLE 2. RESULTS OF DNA ANALYSIS IN 
139 CLINICALLY NORMAL OFFSPRING OF 
PATIENTS WITH DM 
DNA analysis 
Age 
0 - 9 
10-19 
20-29 
30-39 
40-49 
50-59 
60-69 
Total 
luw risk 
genotype* 
3 
12 
60 
25 
11 
12 
5 
128 
High risk 
genotype* 
0 
2 
4 
5 
0 
0 
0 
II 
*High anil low risk genotypes were defined as a > 9 5 % 
and a < 5 % chance of carrying the DM gene, respectively. 
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Using the equations given in the Materials and Methods section, we calcula-
ted the negative predictive value (i.e. the probability of not carrying the DM 
gene for a person with a prior risk of 50% and a negative clinical diagno-
sis). For the complete study, this was 93.4% (± 2.5%). In order to derive 
estimates that can be used for genetic counselling purposes, we then calcula-
ted the negative predictive value for persons <20 years, between 20 and 39 
years, and >40 years of age. In these age groups, the negative predictive 
value was calculated as 89.4% (± 8.9%), 91.7% (± 3.5%), and 99.8% (± 
2.6%), respectively. 
We also considered the possibility that other factors, such as sex of the 
propositus or of the affected parent, might influence the penetrance of the 
DM gene. Moreover, we compared individuals with high and low risk 
genotypes with regard to the presence of nondiagnostic signs, such as 
atypical cataract or mild muscular weakness without myotonia. As can be 
seen in tables 3 and 4, these parameters were equally distributed among 
persons with and without the DM gene. 
TABLE 3. DISTRIBUTION OF HIGH AND LOW RISK GENOTYPES 
ACCORDING TO OTHER VARIABLES THAT WERE ANALYSED 
Low risk High risk 
genotype* genotype* P-value 
(n = 128) (n = 11) by x2-test 
Propositus male/female 59/69 7/4 0.42 
Mother/father affected 51/77 5/6 0.96 
Non-specific features present/absent 24/104 3/8 0.77 
*High and low risk genotypes were defined as a >95% and a < 5 % chance of carrying 
the DM gene, respectively. 
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TABLE 4 FEATURES THAT WERE CONSIDERED SUGGESTIVE BUT 
NOT DIAGNOSTIC OF DM 
Non-specific lenticular opacities 
Ptosis 
Mild muscular weakness 
Equivocal clinical myotoma/normal EMG 
ECG abnormalities + 
Mental retardation 
EMG abnormalities other than myotonia 
Total present 
Absent 
*High and low risk genotypes were defined as a >95% and a <5% chance of carrying 
the DM gene, respectively +ECG abnormalities were not searched for systematically 
aOne individual with both aspecific lens abnormalities and equivocal clinical myotonia. 
bOne individual with both aspecific lens abnormalities and ptosis and one individual with 
both aspecific lens abnormalities and equivocal clinical myotonia. 
Low risk 
genotype* 
(n = 128) 
14 
I 
2 
4 
2 
1 
1 
24a 
104 
High risk 
genotype* 
in = 11) 
2 
1 
0 
1 
0 
1 
0 
3b 
8 
In order to further validate our results, we tried to obtain updated clinical 
data for patients with a high risk DNA genotype. Additional data were 
collected for 5 of the 11 individuals that had been indicated by DNA marker 
studies as putative carriers of the DM gene. 
A 39 year old male was found to carry the high risk allele for the flanking 
markers APOC2 and for D19S51. Upon clinical examination, EMG and slit 
lamp examination he was completely normal. Four years later, he is still 
completely asymptomatic. However, one of his sons now shows action and 
percussion myotonia and muscular weakness, thereby identifying him as an 
oligate gene carrier. 
EMG examination was repeated in 4 asymptomatic individuals identified as 
probable DM gene carriers by DNA analysis. In two females, EMG and slit 
lamp examination remained negative at ages 27 and 37 respectively, 3 years 
after first examination. In another female, EMG showed electrical myotonia 
at age 41 , 5 years after the first examination had been negative. In a male, 
clinical examination, including EMG was normal at age 33 and 35 years. 
However, another EMG at age 37 showed unequivocal myotonia. 
Follow-up data have thus confirmed the presence of the DM gene in 3 of 5 
individuals with a high risk genotype. 
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DISCUSSION 
Previous studies of penetrance in DM have relied largely on the age at which 
the expected 50% ratio of affected individuals was reached. These studies 
have suggested that most (if not all) DM gene carriers should be detectable 
by young adulthood (Harper, 1973; 1989) or by age 40 (Bundey, 1974). 
However, not all relatives were studied, and EMG studies were performed in 
only a minority of patients. Therefore, estimates of penetrance from these 
studies were necessarily imprecise. Another similar study (Schubert et al., 
1980) is difficult to interpret, since probands may have been included in 
the analysis (Bundey, 1982). Published curves of age at onset (Harper, 1989) 
refer to self-reported symptoms, and therefore lead to overestimation of the 
age at which the disorder becomes recognizable by clinical examination. 
All individuals in the study reported here had been previously 
examined clinically by an experienced neurologist and ophthalmolgist for 
signs of myotonic dystrophy. It is possible that a higher percentage of gene 
carriers might have been detected if all individuals had been investigated by 
a single investigator, including standardized EMG of muscles such as the 
Orbicularis Ori and Masseter (Streib and Sun, 1983). Nonetheless, we feel 
that our data give a realistic estimate of the diagnostic accuracy that is 
attained in tertiary care university hospitals. This is supported by the fact, 
that individuals with a high risk genotype appeared evenly distributed among 
the referring centers. 
TABLE 5. SENSITIVITY OF CLINICAL DIAGNOSIS OF DM AND 
PROBABILITY THAT A CLINICALLY NORMAL INDIVIDUAL DOES 
NOT CARRY THE DM GENE (NEGATIVE PREDICTIVE VALUE) 
Sensitivity 
of clinical 
diagnosis (p) 
(%) 
88.2± 10.0 
91.0±3.8 
99.8±2.6 
93.0±2.7 
Negative 
predictive 
value 
U/(2-p)i 
(%> 
89.4 ±8.9 
91.7±3.5 
99.8 ±2.6 
93.4±2.5 
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Age 
(yrs) 
0-19 
20-39 
40-69 
All ases 
Number of 
individuals 
tested (n) 
17 
94 
28 
139 
Number with 
high risk 
genotype (d) 
2 
9 
0 
11 
Overall sensitivity of the clinical assessment was 93% in our sample. 
Diagnostic accuracy increased with age. Since the number of individuals less 
than 20 years old is relatively small, the estimated negative predictive value 
for this age group (89.4% ± 8.9) is very tentative with wide confidence 
limits. Others have noted that a significant proportion of young DM gene 
carriers may be missed by clinical examination (including EMG and slit lamp 
examination) especially before 10 years of age (Harper, 1973). However, in 
sibships in which an older sibling has congenital myotonic dystrophy, early 
detection may be less difficult (Bundey, 1974; O'Brien et al., 1983). No sibs 
of congenitally affected individuals were studied here. 
Between the ages of 20 and 39 years, the negative predictive value of a 
normal clinical examination was 91.7% ( ± 3.4%). This figure is of particu­
lar importance, since genetic counselling is most often requested by individu­
als in this age group. Of 28 individuals aged 40 years or older, none had a 
high risk genotype. It is likely, that less cases are missed over the age of 40 
years than under the age of 40 (P = 0.08), but more data are needed to 
derive an accurate estimate of penetrance in the older age groups. 
The excess of affected fathers in our series (table 3) is largely due to 
individuals older than 40 years of age. For this age group, the father was 
affected in 21 out of 27 individuals tested. An excess of paternal trans­
mission of DM was found in another recent study (Veilette et al., 1989). As 
suggested by others (Harper, 1989), this may reflect a tendency for milder 
involvement in the offspring of affected males, thus bringing their families to 
medical attention at a relatively advanced age. This phenomenon is the 
reverse of the well-known overrepresentation of maternal transmission 
among cases of congenital myotonic dystrophy. In spite of these influences 
of parental sex on gene expression in DM, we found no differences in the 
proportion of high risk genotypes in the offspring of male and female DM 
patients (6/83 and 5/56, Ρ > 0.10). Sex of the propositus also had no 
apparent effect, 4/73 females and 7/66 males being identified as probable 
DM gene carriers (P > 0.10). 
In a study, reporting on diagnostic DNA analysis in DM, Norman et al. 
(1989) found that 4 out of 34 at-risk individuals carried a high risk genotype, 
as determined by studies with linked DNA markers. Although their results 
appear similar to ours (11 out of 139 positive by DNA analysis), more 
detailed comparison with that study is not possible, since clinical tests, age at 
diagnosis, prior risk, and sex of patients and affected parents were not 
specified. 
Some studies have emphasized the significance of additional symptoms 
that are compatible with a diagnosis of DM, but not specific for this 
disorder (e.g. Pryse-Philips et al., 1981). Our data suggest that the signifi­
cance of such a "partial syndrome" is limited, since the frequency of nonspe-
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cifîc abnormalities was similar for those with a positive and a negative 
diagnosis of DM by DNA studies (3/11 and 24/128 respectively, Ρ > 0.10, 
see tables 3 and 4). The same conclusion was reached in a recent study, 
which reported follow-up on 44 patients with nonspecific features of DM. 
After an average period of 2.4 years, 30 still showed only nonspecific signs, 
8 showed a typical form of DM, while б no longer presented any identifiable 
anomaly (Mathieu et al., 1989). 
In conclusion, our data show that for offspring of patients with DM, the risk 
of possessing the myotonic dystrophy gene is approximately 8% if upon 
complete clinical examination in young adulthood no abnormalities can be 
demonstrated. The likelihood of normal clinical findings in a DM gene 
carrier may be less after age 40 years, but more data are needed to confirm 
this. We suggest that DNA analysis should be part of the diagnostic work-up 
of persons at risk for myotonic dystrophy. 
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Brunner HG, Spaans F, Smeets HJM, Coerwinkel-Driessen M, 
Hulsebos T, Wieringa B, Ropers HH. 
Close linkage with chromosome 19 but not chromosome 17 in a 
family with myotonic dystrophy associated with hereditary motor 
and sensory neuropathy. 
Neurology 41: 80-84, 1991 
SUMMARY 
We identified a large kindred that shows classical myotonic dystrophy 
(MyD), together with hereditary motor and sensory neuropathy (HMSN) in 
some individuals and HMSN alone in others. A previous study of this family 
has shown cosegregation of the MyD and HMSN phenotypes with the 
Lutheran and Secretor loci in some branches of this family, indicating 
linkage to chromosome 19. We reanalysed this family with two recombinant 
DNA marker systems from the ApoC2 locus on chromosome 19. Our results 
demonstrate that all affected individuals have inherited a unique ApoC2 
haplotype that was not found in their clinically and electrophysiologically 
normal sibs. We also obtained evidence against involvement of the HMSN1 
locus on chromosome 17. In this family a moderately severe neuropathy may 
be the only clinical sign of MyD for many years. Our results are consistent 
with an unusually neuropathic mutation at the MyD gene. However, involve-
ment of two closely linked genes (one for MyD and the other for HMSN) 
can also explain our findings. 
INTRODUCTION 
Myotonic dystrophy (MyD) is an autosomal dominant disorder which is 
closely linked to the gene for Apolipoprotein C2 (ApoC2) on chromosome 
19. Hereditary motor and sensory neuropathy (HMSN) is a genetically 
heterogeneous disorder. Classification into several subtypes is based on the 
pattern of inheritance, peripheral nerve conduction velocity and associated 
clinical features. The main locus for HMSN1 is on chromosome 17, but a 
subset of families show linkage to the Duffy blood group locus on chromoso-
me 1. 
We have performed a genetic linkage study in a large kindred with features 
of both myotonic dystrophy (MyD) and hereditary motor and sensory 
neuropathy (HMSN) that was previously described by Spaans and colleagues 
[1]. In that study, out of 31 at-risk family members examined, 13 showed 
signs of HMSN, 8 of whom also showed signs of MyD. Results of nerve 
biopsies performed in 2 patients were suggestive of HMSN1. No patient was 
found with MyD alone. The pedigree structure suggested a single mutational 
event for both disorders in the deceased great-grandparents since upon 
examination neither MyD nor HMSN was found in several other branches of 
their respective families. Genetic linkage studies were performed with 
marker systems for chromosome 1 and chromosome 19. Although only 
partly informative, haplotype construction from the Secretor and Lutheran 
data indicated cosegregation of the HMSN phenotype with these chromosome 
19 loci. 
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No linkage was demonstrated with the chromosome 1 markers. Based on 
these results, the authors proposed that the syndrome could be caused by an 
allelic form of the 'common' MyD gene or by two closely linked loci on 
chromosome 19. The significance of these results was limited by the fact that 
the Lutheran and Secretor loci ecombine with the MyD gene locus in 
approximately 10-20% of cases and in some 10% with each other [2]. We 
therefore decided to reanalyze this family using recombinant DNA methods, 
focussing our attention on chromosome 19 (MyD) and chromosome 17 
(HMSN). 
MATERIALS AND METHODS 
Subjects 
The family we studied has been described previously [1]. In the affected 
family branch, out of 31 investigated family members, 13 persons were 
found to have impaired peripheral nerve conduction. The mean values of the 
median and peroneal nerve conduction velocities were 62 and 56% respecti­
vely of the mean values found in the unaffected family members. Median 
and sural nerve sensory action potentials were either not recordable or 
showed reduced amplitudes and increased latencies. Sural nerve biopsies in 
two individuals showed a considerable decrease in myelinated nerve fibre 
density. Many myelinated nerve fibres were surrounded by small concentric 
onion bulb-like structures. 
Of the 13 persons with a HMSN phenotype, 8 showed unequivocal signs of 
MyD. Electrical myotonia and cataract were found in all of them. Four 
individuals showed the characteristic multicoloured crystalline lens opacities. 
Other signs of MyD such as testicular atrophy, fromtal balding, myopathic 
facies and mental dullness were found in a few patients. None of the patients 
has any known cardiac involvement. 
The 18 other at-risk individuals showed no signs of either MyD or HMSN 
upon careful clinical examination including EMG and slitlamp 
examination [1]. 
Since the previous study 4 affected subjects were deceased (11-25, Π-28, ΠΙ-7 
and ΠΙ-12), whereas one affected person who refused participation in the 
previous linkage study (Π-24), could be included this time (compare the 
present Fig. 2 with Fig. 7 in the article by Spaans and colleagues [1] ). 
Physical examination, slit lamp and EMG studies 
Clinical studies were repeated in the 5 affected subjects who had shown no 
signs of MyD in the previous study (UI-1, Ш-16, Г -19, IV-21, Г -22). In 
11-31 and IV-20 these studies were performed for the first time. These 
individuals had a full neurological examination, slit lamp examination, motor 
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and sensory nerve conduction studies, and concentric needle EMG of at leas) 
two muscles (interosseous I and extensor digitorum brevis). In the median 
nerve, motor and sensory conduction was measured in the segment elbow-
wrist. Motor conduction in the peroneal nerve was measured in the segment 
knee-ankle and sensory conduction in the sural nerve between the ankle and 
the lower part of the calf (12 cm). The calculated conduction velocities were 
corrected to a skin temperature of 32 eC (2 m/s per deg. C). At this tempera-
ture conduction velocities are abnormal if below 50 m/s in the median nerve 
and below 40 m/s in the leg nerves. Absence of sensory nerve action 
potentials is always considered abnormal. 
DNA analysis 
Blood samples for DNA analysis were taken from 10 affected and 18 
unaffected family members and from 7 spouses (see Fig. 2). 
DNA was extracted from leukocytes using standard procedures as described 
[3]. Our analyses used DNA polymorphisms from the ApoC2 gene region, 
which has been shown to be about 2cM proximal to the MyD gene [3,4]. To 
increase informativity, a novel method for the detection of polymorphism 
within the ApoC2 gene [5], was used in conjunction with the well-known 
ApoC2-TaqI RFLP system [6]. For the ApoC2-TaqI RFLP [6], DNA was 
cut with the restriction enzyme TaqI, 
electrophoresed on 0.7% (w/v) agarose gels and blotted onto nylon membra-
nes. Hybridization was performed with a a-32P-dCTP labeled 300bp probe 
from the 3'end of the ApoC2 gene as described [3]. For detection of poly-
morphism in a highly variable [TGnAGm] repeat sequence (Variable Simple 
Sequence Motif, VSSM) in the first intron of the ApoC2 gene, DNA was 
amplified by the polymerase chain reaction [7] using oligonucleotides for the 
regions flanking the repeat. Amplified DNA was run on 10% sequencing 
gels, electroblotted on a nylon membrane and probed with aan end-labeled 
internally hybridizing (TG7T) oligonucleotide [5]. Autoradiography was 
performed for 2 hours, using double intensifying screens. 
Two markers were chosen, because they are closely linked to a gene for 
HMSN1 on chromosome 17 [8].For the pEW301 probe which defines the 
D17S58 locus on chromosome 17, the TaqI and Bglll polymorphisms were 
scored. For the pUC10-41 probe (D17S71), we tested the PvuII and Mspl 
polymorphisms. 
Linkage analysis 
For linkage analysis, the latest version (5.03) of the LINKAGE program 
package [9] was used. Penetrance was assumed to be complete for the 
HMSN phenotype in all individuals in this study. For HMSN a gene fre-
quency of 0.0001 was used. Allele frequencies for the different RFLP 
no 
systems were as described [3,8]. No recombination was detected between the 
ApoC2 TaqI RFLP and the internal [TGnAGm] repeat polymorphism. The 
two-point lod score between the two ApoC2 polymorphisms was 7.09 
without recombination, confirming that they indeed represent the same locus. 
Therefore, information from these polymorphic systems was combined to 
yield haplotypes, which were subsequently treated as alleles at a single locus. 
All haplotypes generated by this method have a low frequency in the popula­
tion, but their exact frequency remains to be determined. In our calculations, 
we arbitrarily estimated the frequency of each of the 7 haplotypes observed 
as 0.1 . 
RESULTS 
Physical examination, slit-lamp and EMG studies 
The relevant findings in the 7 newly investigated family members are given 
in table 1. For the previous findings in the reinvestigated subjects, as well as 
for the findings in the other affected members we refer to the article by 
Spaans and colleagues [1]. 
Only subject 11-31 had no clinical or electrophysiologic abnormalities. All 
others had distinct nerve conduction disturbances, which were most promi­
nent in Г -20. 
Weakness was limited to the toe extensors in III-16, TV-20 and Г -21, 
atrophy in these cases was limited to the intrisic foot muscles. The most 
serious nerve conduction abnormalities were found in Г -20 and Г -21. In 
the latter they were somewhat more pronounced than 6 years before. Subject 
Г -19 showed a distinct paresis of foot- and toe-extension and pronounced 
atrophy of the intrinsic hand muscles, lower leg and intrinsic foot muscles. 
Ш-16 lacked one ankle jerk whereas the other was normal. 
Nonspecific cataract was present in an early stage in ΙΠ-1. Ill-16 had been 
operated for cataract of the right eye and showed a distinct cataract of the 
left eye. On both sides the cataract never showed a specific myotonic 
character. 
Of the 5 subjects with HMSN and without signs of DM at the previous 
EMG-examinations, III-16 and Г -19 now showed a number of typical 
myotonic runs, which were found only in the intrinsic hand muscles. 
A large amount of aspecific spontaneous muscle fiber activity was found in 
several muscles of both Г -19 and Г -20, but typical myotonic discharges 
were not found in Г -20. However, because of a normal interference pattern 
on volition and the absence of atrophy in the relevant muscles, it is unlikely 
that the spontaneous activity was due to denervation. 
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DNA analysis 
Examples of the respective hybridization patterns of the ApoC2-TaqI and the 
ApoC2-VSSM polymorphisms are shown in Fig. 1. 
6 
A 
•ft Aa Aft AA AA Aft Aft 
44 14 24 12 12 24 14 
Η θ MyD 
Η θ HMSN 
Figure I. Inheritance of the ApoC2 Taq IRFLP (upper 
panel) and the ApoC2 VSSM polymorphism (lower panel) 
in 1 branch of the family. From left to right, data are shown 
for individuals 111-14, spouse of ΙΠ-17, IV-22, IV-21,111-17, 
11-27, and spouse of 11-27. Band sizes are: 3.8 and 3.5 kbp 
for the ApoC2 Taq IA and a alleles and approximately 108, 
104, and 96 bp for the 1, 2, and 4 ApoC2 VSSM alleles. The 
gene that causes HMSN cosegregates with the A and 2 
alleles for these 2 marker systems respectively (haplotype 
B). Circles represent females and squares represent males. 
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Results of the DNA analysis of the complete pedigree are shown in Fig. 2. 
All persons with reduced nerve conduction velocities shared a single haploty-
pe (designated В in the pedigree), that was not found in their unaffected 
relatives. The maximum Lod score was 7.04 without recombination, confir­
ming the tight genetic linkage between ApoC2 and the HMSN phenotype in 
this family. As expected from the ApoC2 haplotype results, no recombinati­
on was detected with either the ApoC2 TaqI or the ApoC2 VSSM polymorp­
hism (Lod scores of 3.76 and 6.92 respectively). 
Analysis of the chromosome 17 markers does not support linkage with 
HMSN in our family. The pEW301 Bgin polymorphism and both pUC10-41 
polymorphisms were not informative. Evidence against linkage was obtained 
with the pEW301 TaqI polymorphism. At least three recombinations have 
occurred with this locus. Lod scores for ApoC2 and for pEW301 (D17S58) 
are given in table 2. 
DISCUSSION 
The findings presented here indicate that all individuals in this family who 
have evidence of a polyneuropathy have inherited the same segment of 
chromosome 19, thereby confirming and extending the results of Spaans and 
colleagues [1]. The use of an extremely informative new polymorphic 
system within the ApoC2 gene has enabled us to completely elucidate the 
segregation of the ApoC2 gene region in this family. The ApoC2 gene has 
been shown to map at only 2cM proximal to the MyD gene [3,4]. Because 
recombination between MyD and ApoC2 is very rare it is highly likely that 
those individuals who show only the HMSN phenotype have in fact inherited 
the MyD gene. 
In 2 of S individuals (III-16 and Г -19) who previously showed signs of 
polyneuropathy only, myotonic discharges were demonstrated this time. 
Similarly, in our previous study of this family, one 35-year-old subject (III-
17) showed myotonic signs that had been absent 5 years earlier [1]. Therefo­
re, in this family, HMSN may be diagnosed at a very early age whereas 
signs of MyD appear much later. 
Four persons in the present study show only signs of HMSN. 
One 17-year-old boy (Г -20) who was not tested electrophysiologically 
before, showed severe slowing of nerve conduction (peroneal nerve MCV 
about 30% of normal, median nerve MCV less than 50% of normal). No 
typical myotonic discharges were recorded. Similar results to six years ago 
were obtained in a ten-year-old girl (Г -22), and her twelve-year-old brother 
(IV-21). In view of their young age and the results of the genetic linkage 
study, these individuals may be expected to develop signs of MyD at a later 
age. 
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Nonpenetrance of the MyD gene at the age of 51 (individual Ш-1) is 
unusual, but by no means impossible [10,11]. 
Given the apparent association between these two disorders, it appears, that 
in this family the finding of reduced nerve conduction velocities is a reliable 
indicator of the presence of both MyD and HMSN. Conversely, family 
members with normal nerve conduction velocities should not carry any of the 
two genes. Coir DNA studies confirm this, since out of 14 at-risk persons 
with normal conduction velocities, none has inherited the ApoC2 haplotype 
that is associated with the MyD gene in this family. 
As discussed by Spaans and colleagues [1], a number of studies have shown 
mild or moderate peripheral nerve involvement in MyD. One recent publica­
tion demonstrated increased heat and/or cold thresholds of the skin over the 
ankle in 79% of 24 MyD cases. Slowing of sural sensory conduction and 
peroneal motor conduction was found in 17% and 25% respectively, whereas 
median and ulnar sensory conduction velocities were not significantly 
decreased [12]. In another study, sural nerve biopsies showed reduced 
myelinated fibre density in 11 of 13 myotonic dystrophy patients with 
preferential loss of large myelinated fibers. The findings were considered 
consistent with a chronic axonopathy of moderate severity [13]. In these 
studies the differences in peripheral nerve conduction velocity between MyD 
patients and controls were small. 
The family reported here is unique because of the early expression of 
markedly reduced nerve conduction velocity in all 14 individuals that have 
inherited the MyD gene. Clearly, the polyneuropathy observed in the 
younger patients predates the onset of the classical features of MyD by many 
years. 
Several studies have shown that although some families with autosomal 
dominant HMSN show linkage to chromosome 1 markers [14-18], most 
families apparently do not [19-23]. It has recently been established that the 
large majority of families with HMSN1 map to chromosome 17 [8,24,25]. 
Our study shows no indication that a locus on chromosome 17 is responsible 
for the neuropathy in this family. The results are therefore compatible with 
an unusually neuropathic mutation of the MyD gene itself. For the neuropa­
thy in MyD the situation may be similar to what has been suggested for the 
cardiac involvement [26]. This feature of MyD is frequently found in some 
families, but is absent in others, suggesting that although all MyD families 
are due to mutations in a single gene on chromosome 19, the exact type of 
mutation may determine the clinical picture in that particular family. Obvi­
ously, other explanations are possible, such as modifying influences from 
other genes or environmental factors. However, these are less likely to 
produce such a constant picture throughout a large family. 
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Finally, HMSN is genetically heterogeneous and therefore genes on several 
chromosomes other than chromosomes 1 and 17 may be capable of inducing 
a hereditary neuropathy. Thus, the involvement of two closely linked genes 
on chromosome 19 (one for MyD, the other for HMSN) can also explain our 
findings. We suggest that chromosome 19q remains a candidate region for 
the mutation in those HMSN families that are not linked to either chromoso-
me 17 or chromosome 1. 
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CHAPTER 7 
Brunner HG, Nillesen W, Oost van B, Jansen G, Wieringa B, 
Ropers HH, Smeets HJM 
Presymptomatic diagnosis of myotonic dystrophy. 
J Med Genet 29: 780-784, 1992 
SUMMARY 
The discovery of an expanded (CTG)n repeat sequence in myotonic dystrop-
hy (DM) has greatly improved our ability to detect DM gene carriers who 
have few or none of the classical signs of this disorder. We here report our 
experience with two such groups of gene carriers. We used a PCR-based 
analysis that should be especially sensitive to small increases in CTG triplet 
number, that might escape detection by conventional Southern blot analysis. 
Our analyses show that on 100 non-DM chromsomes, the number of CTG 
triplets ranged from 5 to 37. We then studied 17 obligate gene carriers aged 
55 years and over, who showed no muscle weakness. All of the gene 
carriers in this group showed a relatively small increase in the number of 
CTG triplets (52 to 90 CTG triplets) with limited somatic mosaicism. We 
subsequently studied 11 individuals (aged 19 to 36 years) who had previously 
been identified as gene carriers by genetic linkage studies, but who lacked 
diagnostic signs. In this prospectively studied group, 9 individuals showed an 
expanded allele, confirming the earlier prediction from linked genetic 
markers. The other 2 individuals showed only 2 normal alleles, and an 
expanded allele was not detected. Revision of the clinical data casts doubt on 
the original diagnosis of DM in their families. Preferential amplification of 
the normal non-expanded allele was noted for 3 asymptomatic gene carriers 
in this study (as well as for 2 of their clinically affected relatives). We 
caution that at least in our hands, the DM mutation can be confidently 
excluded by this PCR-based method only if both normal alleles have been 
identified. If an expanded allele is not seen, and only a single normal allele 
is visualized on 6% PAGE, confirmatory testing with linked genetic markers 
or conventional Southern blotting of the (CTG)„ repeat is advocated. 
INTRODUCTION 
Myotonic dystrophy (DM) shows a wide range of clinical expressivity in 
affected individuals [1]. Severity of the disease is at least partly correlated 
with the number of CTG trinucleotide repeat units found in the 3' untrans-
lated region of a protein kinase gene located in band ql3.3 of chromosome 
19 [2-10]. There is a marked tendency for an increase in CTG triplet number 
from one generation to the next, which is paralleled by earlier onset of the 
disease in successive generations [11,12], a phenomenon known as anticipati-
on. Genealogical studies in DM families [11-15] suggest that in earlier 
generations additional asymptomatic gene carriers may have been present, 
presumably with only a minor expansion of the CTG motif. However, a 
premutation, not involving expansion of the CTG trinucleotide repeat, is 
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another possibility. This situation is highly reminiscent of the CCG-repeat 
expansion seen in the fragile X syndrome [16-18]. Our previous study using 
linked DNA markers has suggested that a considerable proportion of siblings 
and offspring of DM patients are asymptomatic in early adulthood [19]. 
Therefore, asymptomatic individuals may not be confined to the early 
generations of a DM family. 
We studied these issues in detail by assaying the CTG triplet number in 17 
obligate carriers of the DM gene as defined by pedigree analysis and 
genealogical studies. We further studied a group of asymptomatic offspring 
of DM patients who had been identified previously as probable gene carriers 
by the application of closely linked DNA markers. 
METHODS 
Families were ascertained through the DNA diagnostic service from our 
department. As of January 1992, this service has performed diagnosis with 
linked DNA markers in 164 DM families, of which 76% were referred by 
other genetic departments. Care was taken to assure that all families met 
previously defined diagnostic criteria [20]. For the purpose of this study, we 
selected 13 families that contained 1 or more obligate gene carriers aged 55 
and over who showed no muscular weakness. Obligate gene carriers were 
identified by pedigree analysis or through genealogical studies that linked 
independently ascertained pedigrees. There were 14 males and 3 females in 
this group, ranging in age from 55 years to 92 years (mean 69.8 years). 
Among 17 obligate gene carriers, 7 had undergone cataract surgery. The 
other 10 were considered asymptomatic. EMG and slitlamp examination had 
been performed in 6/10. Typical lenticular opacities were noted in 3/6. EMG 
was normal in all 6. In addition, 11 individuals from 9 families were 
restudied, for whom our previous study [19] had indicated a high probability 
of carrying a DM mutation in spite of normal results on clinical examination. 
We used data from 50 normal Dutch individuals (100 chromosomes) who 
had married into DM families to establish the normal range of CTG triplet 
number for controls. 
Chromosomal DNA was isolated from peripheral blood [21]. Genetic marker 
systems flanking the DM mutation have been described previously [22-26]. 
Using a recently described PCR assay [7], we tested the expansion of the 
CTG repeat in genomic DNA. The CTG repeat was amplified with flanking 
primers 406 and 409 reported by Mahadevan et al. [7]. The resulting DNA 
fragments were resolved on 1% and 4% agarose gels. A Southern blot, made 
from the 1% gel on Gene Screen Plus, was screened with a 32P end-labeled 
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(CTG)10 oligonucleotide as a probe, and the hybridizing fragments were 
subsequently visualized by autoradiography. Alleles containing up to ap­
proximately 140 CTG triplets could also be identified on a 6% Polyacryla­
mide / 7 M Urea sequencing gel after 32P end-labeling one of the amplifica­
tion primers. 
RESULTS 
Normal controls 
Data from 100 normal chromsomes are summarized in figure 1. Allele 
lenghts were found to range from 5 to 37 CTG triplets. The most common 
alleles in this sample were 5, 13 and 14 CTG triplets (38, 22 and 15% 
respectively). 
30 -
2 0 -
10 
» ~ i 
10 15 20 25 
Number of CTG triplets 
— ι — 
30 35 
Figure 1: 
Distribution of allele sizes for 100 non-DM chromosomes. Allele sizes are given as 
the number of CTG triplets. 
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Obligate carriers 
All of the 17 obligate gene carriers (14 males and 3 females) showed an 
expanded allele with multiple bands and weaker signals on 6% Polyacry­
lamide gels, different from normal alleles at this locus (5-37 CTG triplets). 
Allele size (estimated from the strongest signal among these multiple bands) 
ranged from 52 to 90 CTG triplets (Figure 2). 
7 6 - * 
6 4 - SK 
5 0 -
3 7 -
2 5 -
2 2 -
2 0 -
14-
13-
12-
•*·., 
· ' · 
* * * * * 
t-
1 2 3 4 5 6 7 8 9Ю1112 1314151617 
Figure 2: 
CTG repeat analysis of obligate DM gene carriers Ganes 1-5, 7, 8, 10-12 and 14-
17) by 6% denaturing Polyacrylamide gel electrophoresis. Expanded PCR-amplified 
alleles range from 52 to 76 CTG triplets. The larger alleles show up less well, 
probably due to differences in the efficiency of the PCR reaction. Lane 7 repre­
sents a 72-year old male who shows bilateral cataract as his only clinical feature. 
This individual has an expanded allele of 74 CTG triplets and a normal allele of 37 
CTG triplets. 
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The apparent instability of the expanded allele could represent an in vitro 
artifact of the PCR reaction. However, in view of the strikingly different 
appearance of the 37 and 52 CTG triplet signals, it is more likely, that the 
CTG repeat shows somatic mosaicism in vivo above a threshold of approxi­
mately 40-50 CTG triplets. With 1 exception (Π-7, figure 3), CTG repeats 
were found to be larger in offspring than in these obligate carriers, confir­
ming that the expanded repeat sequence was unstable. 
A striking example of anticipation is shown in figure 3. In this family, 2 
individuals (1-3 and II-7) aged 90 and 53 respectively are asymptomatic on 
full examination, including EMG and slit lamp examination, except for a few 
typical lenticular opacities in 1-3. A third individual (1-1) is also completely 
normal at age 85, but no EMG has been performed. These obligate heterozy­
gotes showed CTG triplet numbers of 52, 60 and 52 respectively, based on 
results of 6% PAGE (lanes 16, 15 and 17, figure 2). The 1% agarose 
Southern blot of the PCR product shows the expected band of approximately 
0.2 kb for these individuals. Above this band, a smear can be detected, 
which is frequently observed for alleles of this size, and which may be due 
to heteroduplex formation of normal and expanded alleles, rather than to 
somatic mosaicism. Symptomatic disease has been diagnosed in the descen­
dente of these obligate carriers (111-1,2,3; figure 3). These individuals all 
have expanded alleles exceeding 200 CTG triplets. 
126 
I Ö r O 
1 L - 2 — τ 
ή в^—è É ι о 3 Ö-гЧЗ 
1 2 Э І 4 5 І β 7 I 8 
kb 
6.7 
2.0-
1.1-
0.2-
ЯЫЕЕЕА· A É B A Ì 
Figure 3: 
Southern blot analysis of PCR-amplified CTG repeat sequence run on a 1 % agarose 
gel in a DM family. 
Transmission of DM through 3 clinically asymptomatic individuals (1-1, 1-3, II-7), 
aged 90 years, 85 years and S3 years, who show only mild expansion in this assay. 
CTG triplet numbers for these obligate carriers (determined from 6% Polyacryla-
mide gel electrophoresis) were 52, 52 and 60 respectively. Clinically affected 
individuals (Π-4, II-5, III-1, III-2, III-3) show more extensive expansion of the 
CTG repeat. 
Probable gene carriers identified by linkage analysis 
An expanded CTG repeat was demonstrated in 9/11 asymptomatic offspring, 
who carried the high risk haplotype for closely linked DNA markers (table 
1). 
These individuals ranged in age from 19 to 36 years. In 4/9 the size of the 
expanded allele fell within the range previously observed for asymptomatic 
(or cataract-only) individuals aged 55 years and older. In the other 5 asymp-
tomatic DM gene carriers, allele sizes were found to be considerably larger 
>200 CTG triplets). 
In the final 2 cases, a clinical diagnosis of DM in a key relative was not 
supported by the DNA studies. In the first family, the 34 year-old proband 
had received a clinical diagnosis of myotonic dystrophy on the basis oí 
electromyographical myotonia, typical multicoloured cataract, and muscle 
weakness (albeit in an unusual distribution for DM). This individual carries 2 
normal alleles for the CTG trinucleotide repeat. Electromyographical 
myotonia and multicoloured lens opacitites were reported for her father, who 
also showed a normal number of CTG triplets on both chromosomes. Either 
this family shows an unusal form of the disease, not associated with expansi-
on of the CTG repeat, or the original clinical diagnosis was incorrect. If the 
latter applies, the sister, who carries the same haplotype for markers flanking 
the DM locus (individual 8 in table 1) is probably not at risk of the disease. 
In the other family, several affected individuals showed a characteristic 
smear of expanded repeats. However, in a female in whom DM had been 
diagnosed based on mild muscular weakness and electromyographical 
myotonia, an expanded allele was not found. This puts the clinical diagnosis 
in doubt for this woman and indicates that her son (individual 6 in table 1) is 
probably not at risk of DM. 
Preferential amplification of the normal allele 
An expanded allele was not initially detected in 3 individuals with the primer 
pair (406 and 409 from Mahadevan et al.[7]) used in this study in spite of 
multiple (up to 5) attempts. These individuals had previously been predicted 
to be gene carriers by linkage analysis. Since only a single normal allele was 
seen on 6% poylacrylamide gel electrophoresis, we asssumed that an abnor-
mal allele was present but undetectable. By choosing another primer combi-
nation (primer 406 from Mahadevan et al. [7] and a new primer: GGC.A-
CA.GAA.GCC.CGG.CCC.ACC, nt position 11-32) the presence of an 
expanded allele was confirmed in 2 individuals. In the third individual an 
expanded allele could only be demonstrated by direct restriction analysis and 
Southern blotting of the genomic fragment containing the CTG repeat 
sequence. 
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DISCUSSION 
We show here that asymptomatic carriers of the DM gene mutation can be 
diagnosed by PCR-based analysis of the CTG trinucleotide repeat. This 
method is especially helpful in determining the origin of the mutation when 
both parents are clinically unaffected and the family history is negative [27]. 
Among 17 cases aged 55 years and over without muscle weakness, none 
showed an allele exceeding 90 CTG triplets. Larger alleles may not be 
compatible with absence of muscular symptoms in middle and old age. 
However, more data is needed before predictions are possible for individual 
cases. 
Our results confirm the paucity of new mutations in DM suggested by 
genealogical studies [11-15], since individuals identified as obligate gene 
carriers always carried an expanded allele. This is consistent with the results 
of studies showing linkage dysequilibrium in various populations [28-30]. In 
fact, the finding of linkage dysequilibrium in DM is difficult to explain, 
unless we assume that either the penetrance of the DM gene is virtually zero 
for many generations as suggested by the anticipation model, or that carriers 
of the DM mutation have increased fecundity, or both. The finding that all 
of the asymptomatic obligate carriers defined by pedigree analysis or 
genealogical studies showed only a small increase in CTG triplet number 
(52-90 CTG triplets) supports the anticipation model of DM. 
In spite of anticipation, the DM mutation may occasionally remain clinically 
silent, even among siblings and offspring of symptomatic cases. In five of 
our patients, (aged 19, 19, 21, 33 and 36 respectively) careful clinical 
examination including EMG and slitlamp examination failed to show any 
definite sign of DM. This may appear surprising since each showed an 
expanded allele which clearly exceeded 200 CTG triplets (individuals 1 ,2 , 
3, 7 and 11 in table 1). Follow-up studies are required to establish whether 
these individuals will develop muscular symptoms in later life. So far, 
repeated EMG studies (performed after the results from the DNA analysis 
were known), have demonstrated myotonic discharges in 2 of them 
(individuals 3 and 7, table 1). Neither clinical myotonia, nor significant 
muscle weakness was detected on re-examination. In the other asymptomatic 
cases, CTG triplet numbers of 60, 61, 74 and 88 were within the range 
found for obligate gene carriers without muscular symptoms after age 55. 
We currently estimate the chance that a clinically normal sibling or offspring 
of a DM patient carries a mutated gene to be 7.8% for those aged between 
20 and 39 years of age. This figure is very similar to our previous estimate 
in the same sample of DM families (8.3%) [19]. We have now excluded 2 
individuals because of unreliable diagnosis, while we had formerly anticipa-
ted the reclassification as low-risk of 2 individuals because of genetic 
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recombination with the marker loci [19]. In addition, our study confirms that 
at the molecular level anticipation is the rule in DM, since in our sample of 
9 asymptomatic offspring we always found a CTG triplet number equal to or 
exceeding that of the affected parent. Finally, we do not know the explana-
tion for the family in which expansion of the CTG repeat was not detected in 
either clinically affected member. Such families have been noted by others 
[7]. It remains to be seen whether the results in these families are due to 
diagnostic error, or to allelic mutation. The existence of allelic mutations, 
not causing expansion of the CCG repeat sequence, has been suggested for 
the fragile X syndrome [31]. 
Finally, we want to stress that in individuals with only a single normal band 
by PCR, the DM mutation should not be considered excluded, because of the 
possibility of preferential amplification of the normal allele. In such instan-
ces, additional studies are required, using either alternative primer combina-
tions, conventional Southern blotting of genomic fragments, or linked genetic 
markers. Only when such studies confirm the presence of normal alleles 
only, can the consultand be reassured that future offspring will not be at 
risk. 
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CHAPTER 8 
Brunner HG, Jansen G, Nillesen W, Nelen MR, de Die СЕМ, 
Höweler CJ, van Oost BA, Wieringa В, Ropers HH, Smeets 
HJM. 
Brief report: Reverse mutation in myotonic dystrophy. 
New Engl J Med 328: 476^80, 1993 
Myotonie dystrophy is a multisystem disorder that shows autosomal domi-
nant inheritance and is characterized by muscular weakness and atrophy, 
clinical and electromyographical myotonia, ocular cataract and various other 
abnormalities, such as cardiac conduction disturbances, smooth muscle 
involvement, testicular atrophy in males, premature balding, increased 
anaesthaetic risk, and mental retardation in early onset cases1. It is the most 
common inherited muscular dystrophy in adulthood, with an incidence of 
approximately 1 per 7500. The clinical expression of myotonic dystrophy is 
variable, ranging from neonatal lethality to complete absence of symptoms. 
Recently, the disorder has been shown to be caused by an increased number 
of Cytosine-Thymidine-Guanine (CTG) trinucleotide repeats in the 3' 
untranslated region of a protein kinase gene located in the ql3.3 band of 
chromosome 192"8. The normal gene has between 5 and 40 CTG trinucleotide 
repeats, while DM alleles have from approximately 50 to several thousand 
CTG trinucleotide repeats. The severity of the clinical symptoms of myotonic 
dystrophy usually increases with transmission to subsequent generations, a 
phenomenon that has been termed anticipation9. This is paralleled by an 
increase in the length of the CTG repeat 
sequence 2'5,7. It has been suggested that the progressively increasing severity 
of myotonic dystrophy eventually leads to the extinction of the disease from 
a given pedigree10. 
Genetic theory assumes that equilibrium exists between the incidence of 
new deleterious gene mutations and their subsequent loss from the population 
through reduced viability and fertility of carriers of the mutated gene. No 
allowance is made in human genetic epidemiology for mechanisms that 
change the mutation itself from abnormal to normal. Reverse mutation, i.e. 
the spontaneous correction of a deleterious mutation and its subsequent 
transmission to unaffected offspring, has not been reported in humans, 
although it has been observed at low frequencies in bacteria and cultured 
mammalian cells. 
We here report two families with myotonic dystrophy in which a reverse 
mutation has occurred. In the first family, an expanded CTG trinucleotide 
repeat found in a clinically affected male decreased to a normal allele of 24 
CTG trinucleotide repeats in his healthy infant daughter. Similarly, in the 
second family the expanded allele found in the clinically affected father 
decreased to a normal-sized allele containing 19 CTG trinucleotide repeats in 
his healthy 25-year old son. The normalization of the mutated myotonic 
dystrophy gene in these offspring can be explained by mitotic and (possibly) 
meiotic instability of the expanded CTG repeat sequence. 
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CASE REPORTS 
Family 1. 
Prenatal diagnosis was requested by a 25 year old woman (Subject Π-4, 
Family 1, Fig.l) and a 27 year old man (Subject II-3). Myotonic dystrophy 
had been diagnosed in the man 2 years earlier on the basis of mild muscular 
weakness, clinical and electrical myotonia, and a positive family history. The 
family was investigated with genetic markers closely linked to the myotonic 
dystrophy gene. All clinically affected family members carried the same 
haplotype for the ApoC2-VSSM and X75b-VSSM markers, which flank the 
myotonic dystrophy locus. The proband was heterozygous for these markers. 
Therefore, prenatal diagnosis was considered feasible. The first pregnancy 
(Subject Ш-1) was terminated after DNA marker analysis performed on a 
chorionic villus biopsy indicated that the fetus had inherited the DM mutati­
on. Examination of fetal tissues confirmed the results. The second pregnancy 
(Subject ΙΠ-2) was terminated when intrauterine death was diagnosed by 
ultrasonography, 6 days after a transcervical chorionic villus biopsy had been 
performed. DNA analysis indicated that this fetus would have been unaffec­
ted. In the third pregnancy, genetic marker analysis again indicated that the 
fetus (Subject IH-3) had received the abnormal DNA marker haplotype. In 
view of the small genetic distances between markers in the myotonic dystrop­
hy gene region1113, the chance that the fetus carried the myotonic dystrophy 
mutation was estimated to be greater than 99%. Mutation analysis7 was 
subsequently performed to determine the size of the CTG repeat in the 
myotonic dystrophy gene of this fetus in order to obtain more reliable 
prognostic information. 
Family 2. 
A 23-year old man (Subject Π-2, Family 2, Fig.l), and his 24-year old sister 
(Subject Π-1) were examined for signs of myotonic dystrophy because of a 
history of the disease in several family members, including their father 
(Subject 1-1). Clinical examination, including electromyography and slit lamp 
examination, was normal in both Subject Π-1 and Subject Π-2. However, 
analysis with genetic markers flanking the myotonic dystrophy gene locus 
showed that the son (Subject II-2) had inherited the paternal chromosome 19 
that carries the myotonic dystrophy gene in this family. Because Subject Π-2 
was now considered to be a carrier of the myotonic dystrophy gene, repeated 
clinical examination, including electromyography of 10 muscles, was 
performed at age 25. This reexamination again did not reveal any signs oí 
myotonic dystrophy. Because of the discrepancy between the clinical findings 
and the results of the DNA analysis, final diagnosis was deferred until direct 
detection of the myotonic dystrophy mutation was possible. 
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MATERIALS AND METHODS 
Chromosomal DNA was isolated from peripheral blood cells, cultured fibro­
blasts or chorionic villi as described14. Spermatozoa were isolated from 
semen using single-layer Percoli centrifugation. DNA was isolated from the 
sperm pellet as described11. Genetic markers flanking the myotonic dystrophy 
mutation and their respective detection methods have been described previ­
ously n"1 3. All markers were tested at least twice. Using a recently described 
Polymerase Chain Reaction (PCR) assay7, we tested the expansion of the 
CTG trinucleotide repeat in genomic DNA. The CTG trinucleotide repeat 
was amplified with flanking primers and the resulting DNA fragments were 
separated by electrophoresis on 1 percent and 4 percent agarose gels. A 
Southern blot, made from the 1 percent gel, was probed with a 32P end-
labeled (CTG),o oligonucleotide and the hybridizing fragments were visuali­
zed by autoradiography. Normal alleles were identified by the same PCR 
assay, using a 3 2P end-labeled amplification primer. The PCR amplification 
product was separated by electrophoresis on a 6 percent Polyacrylamide - 7 
M urea sequencing gel and visualized by autoradiography. For purposes of 
paternity testing, several highly polymorphic loci were tested on chromoso­
mes 3, 15, 17 and 19 с2·17-23*. Allele sizes were determined for each locus by 
comparison with control samples of known size, as well as by measurement 
on an automated sequencing system (АБІ 373A), using the Gene Scanner™ 
software (Applied Biosystems, Foster City, Ca). An internal-lane size 
standard (Gene Scan- 2500 Rox) was added as a reference control for alig­
ning peak data. The paternity index (I) and the probability of paternity (W) 
were calculated as described 24. The research plan was approved by the 
medical ethics committee of the Nijmegen University Hospital. 
RESULTS 
In Family 1, genetic markers flanking the myotonic dystrophy mutation 
indicated that the third fetus (Subject Ш-3; Figure 1) had received the 
abnormal chromosome 19 from the father. Analysis of the causative myoto­
nic dystrophy mutation showed an abnormal expanded allele in the father, 
but not in a chorionic villus sample from this fetus (Figure 1). This fetus had 
2 normal alleles (Figure 2), the larger of which (24 CTG trinucleotide 
repeats) was apparently inherited from the father. However, this allele was 
clearly different from the father's normal chromosome 19, which carried an 
allele of 11 CTG trinucleotide repeats. This suggested that a reverse mutati­
on had occurred through which the abnormal expanded CTG trinucleotide 
repeat in the father (approximately 150 to 600 CTG trinucleotide repeats; 
Fig. 1) had decreased to a normal-sized allele of 24 CTG trinucleotide 
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repeats in this fetus. After the birth of a normal girl, identical results were 
obtained on a sample of cord blood and on fibroblasts from the umbilical 
cord. Attempts to detect mosaicism for the reverted allele in other tissues 
from the father were unsuccessful. Additional reverted alleles were not found 
on analysis of DNA from either cultured skin fibroblasts or sperm from 
Subject Π-3 (Figure 3). Nonpaternity could be excluded using several highly 
polymorphic systems from chromosomes 3, 15, 17 and 19 . The probability 
that Subject 11-3 was the biological father of Subject ΠΙ-3 was calculated as 
greater than 0.99998 (Table 1). 
In Family 2, an asymptomatic 25 year old man (Subject Π-2), had inherited 
the abnormal chromosome 19 from his father. However, expansion of the 
CTG trinucleotide repeat could not be demonstrated (Figure 1). Instead, 2 
normal alleles were present (Figure 2), the larger of which (19 CTG repeat 
units) was inherited from the affected father. Therefore, the father's mutated 
myotonic dystrophy gene, which contained approximately 150 to 500 CTG 
trinucleotide repeats had changed to a normal-sized allele of 19 CTG 
trinucleotide repeats in the son. The reverted allele was present also in skin 
fibroblasts and semen from Subject Π-2 (Figure 3). Abnormal expanded 
alleles were not present in these tissues. Thus, no evidence for either somatic 
or germline mosaicism was found in this subject. Nonpaternity was excluded 
using several highly polymorphic DNA markers ffom chromosome 3, 15, 17 
and 19. The probability that Subject 1-1 was the biological father of Subject 
Π-2 was calculated as greater than 0.99999 (table 1). 
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Figure 1. Linkage Analysis and Mutation Analysis in Two Families with Myotonic 
Dystrophy. 
The squares denote male family members, and the circles female family members 
The slash denotes a deceased family member Prenatal diagnoses are indicated by 
diamonds. The shaded symbols indicate clinically affected subjects. Subjects carrying 
a reverted myotonic dystrophy gene are marked by an asterisk. In Family 1, all the 
affected subjects carry the 3 allele for the APOC2-VSSM marker and the 1 allele for the 
X75b-VSSM marker at locus D19S112 (boxed) Subject III-3 has also received these 
alleles from her father In Family 2, Subject II-2 has inherited the 1 allele for the pD10 
marker at locus D19S63 and the 4 allele for the X75b-VSSM marker at locus D19S112 
This haplotype (boxed) carries the myotonic dystrophy mutation in several affected 
family members, Including the father (Subject 1-1). Mutation analysis (lower panel) 
detected both normal alleles (with 5 to 40 CTG trinucleotide repeats) and abnormal 
alleles (with > 5 0 CTG trinucleotide repeats). The size of the alleles, expressed as the 
number of CTG trinucleotide repeals, is shown beside the blots In Family 1, Subject 
III-3 does not have an expanded allele However, the marker haplotype suggests that 
she has inherited the myotonic dystrophy mutation from her father In Family 2, Subject 
1-1 has an abnormal expanded allele of 150 to 500 CTG trinucleotide repeats, whereas 
his son (Subject II-2) does not have an expanded allele, although this would be 
expected on the basis of the marker haplotype 
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Figure 2. Precise Sizing ol СТО Trinucleotide Repeats in Two 
Families with Myotonic Dystrophy. 
Only normal alleles (with 5 to 40 CTG trinucleotide repeats) are 
visualized on 6 percent polyacrylamide-gel electrophoresis. The 
abnormal expanded (Exp) alleles fall outside the range ol frag­
ments detected in this assay. Affected subjects (Subjects 11-2, II-
3, and If I-1 in Family 1 and Subject 1-1 in Family 2) have only a 
single band, representing their single normal chromosome 19 
Normal subjects (Subjects I-2,11-1, II-4, II-5, and III-2 in Family 1 
and Subject 11-1 in Family 2) have two bands; Subject I-2 in Family 
2 has only a single band, since she inherited identical normal 
alleles of five CTG trinucleotide repeats from both her parents. In 
Family 1, Subject III-3 Inherited a new normal allele of 24 CTG 
trinucleotide repeats from her affected father. In Family 2, the 
mutated allele has decreased in size, from approximately 150 to 
500 CTG trinucleotide repeats (Fig. 1) In the affected father (Sub­
ject 1-1) to 19 CTG trinucleotide repeats in his son (Subject M-2). 
The pedigree symbols are as described in Figure 1. 
Family 1 
W
-ö 
ІІ-З ІІІ-З 
S F CV СВ CF 
Family 2 
И-2 
В S F 
Figure 3 Tissue Testing in Two Families with Reversal of the 
Myotonic Dystrophy Mutation 
The pedigree symbols are as described in Figure 1 The reverted 
(normal) allele Is indicated by arrows In Family 1, the reverted 
allele was not found in either sperm (S) or cultured fibroblasts (F) 
from the father (Subject II-3) In both families the reverted allele 
was present in various tissues from the healthy offspring These 
included a chorionic-villus sample (CV), umbilical-cord blood 
(CB), and umbilical-cord fibroblasts (CF) from Subject III-3 in 
Family 1 and peripheral-blood cells (B), cultured skin fibroblasts, 
and sperm from Subject II-2 in Family 2 
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DISCUSSION 
Recently, a new class of genetic disease mutations has been described that is 
characterized by amplification of preexisting trinucleotide repeat units22. 
Apart from myotonic dystrophy28, the Fragile X syndrome26"27, and X-linked 
spinal and bulbar muscular atrophy28 have been shown to be associated with 
this type of mutation. In both fragile X syndrome and myotonic dystrophy, 
the length of the respective trinucleotide repeats tends to increase in subse­
quent generations, and there is a positive correlation between the length of 
the repeat and the severity of the disease. Although transmission of the 
fragile X mutation is occasionally accompanied by a reduction in repeat 
length27, this has never resulted in an allele of normal size. In our analysis of 
over 100 carriers of the myotonic dystrophy mutation, a decreasing repeat 
length has been found in only a single further family. Therefore, complete 
reversal of the mutated allele, yielding a CTG trinucleotide repeat sequence 
of normal size must be an exceptional event. 
The mechanism causing the change from an abnormal expanded allele to a 
normal-sized allele is unknown. Single genetic recombination is excluded in 
these cases, since this would change the DNA marker haplotype surrounding 
the mutation. Double recombinants are also highly unlikely in view of the 
small genetic distances in this segment of chromosome 19. Either gene 
conversion (substitution of one parental allele for the other29) or direct 
deletion of the expanded repeat could explain the mutation reversal that we 
found in these two families. 
We considered the possibility that the instability of the expanded CTG 
trinucleotide sequence in somatic tissues was also present in the fathers' 
germline, in the form of a large array of different sized alleles that included 
some normal-sized alleles. However, DNA analysis of cultured skin fibro­
blasts and of a sperm sample of the father (Subject II-3) in family 1 showed 
a similar (though not identical) distribution of expanded repeats as was found 
in his peripheral blood. Moreover, this analysis failed to detect the presence 
of reverted alleles (Figure 3), indicating that if germline mosaicism is present 
in Subject II-3, the frequency of reverted myotonic dystrophy mutations is 
very low. Alternatively, the reversal of the mutation in his daughter (Subject 
Ш-3) may have occurred in the early embryo. 
The fact that the allele lengths in the 2 subjects reported here are entirely 
within the range found in normal subjects suggests that they should not 
develop myotonic dystrophy in the future. Thus, they represent true reverse 
mutations, rather than non-penetrance of an abnormal gene. Yet, it remains 
to be established whether their chromosomes have regained the normal stable 
state, since it is presently unknown whether the expanded trinucleotide repeat 
sequence is the only cause of the DNA instability in myotonic dystrophy. 
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Analysis of cultured skin fibroblasts and of a sperm sample of individual II-2 
in family 2 showed 5 and 19 CTG trinucleotide repeats, identical to those 
detected in his peripheral blood cells (Figure 3). This suggests that the 
revertant allele containing 19 CTG trinucleotide repeats is stable in this 
subject's somatic tissues as well as in his germline. 
In conclusion, the two subjects reported here are examples of complete 
spontaneous corrections of myotonic dystrophy mutations. These results 
should be taken into account when using flanking DNA markers for genetic 
diagnosis30 since it is possible that other 
genetic conditions in which the phenotype is highly variable will also prove 
to be associated with inheritance of unstable DNA sequences31. 
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CHAPTER 9 
Brunner HG, Brûggcnwirth HT, Nillesen W, Jansen G, Hamel 
BCJ, Hoppe RLE, de Die СЕМ, Höweler С J, van Oost BA, 
Wieringa В, Ropers HH, Smeets HJM 
Influence of sex of the transmitting parent as well as of parental 
allele size on the CTG expansion in myotonic dystrophy. 
Am J Hum Genet (in press) 
SUMMARY 
In patients with myotonic dystrophy (DM), the severity of clinical signs is 
correlated with the length of a (CTG)„ trinucleotide repeat sequence. This 
sequence tends to expand in subsequent generations. In order to examine the 
kinetics of this process and in particular the influence of the mutant allele 
size and the sex of the transmitting parent, we have studied (CTG), repeat 
lengths in the offspring of 38 healthy carriers with small mutations (<100 
CTG trinucleotides, mean length [CTG]67). In these studies, we found a 
weakly positive correlation between the size of the mutation in the carrier 
parents and their offspring. Furthermore, we observed that in the offspring 
of male transmitters, repeat lengths exceeding 100 CTG trinucleotides were 
much more frequent than in the offspring of carrier females (48 out of 52 
[92%] vs. 7 out of 16 [44%], p=0.0002). Similarly, in genealogical studies 
performed in 38 Dutch DM kindreds, an excess of non-manifesting male 
transmitters was noted, which was most conspicuous in the last generation 
preceding phenotypic expression of DM. Thus, two separate lines of eviden-
ce suggest that the sex of the transmitting parent is an important factor 
determining DM allele sizes in the offspring. On the basis of our data we 
estimate that when both parents are asymptomatic, the odds are approximate-
ly 2:1 that the father carries the DM mutation. Because expansion of the 
CTG repeat is more rapid with male transmission, negative selection during 
spermatogenesis may be required to explain the exclusive maternal inheritan-
ce of severe congenital-onset DM. 
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INTRODUCTION 
The mutation underlying myotonic dystrophy (DM) has recently been 
characterized as an expanding CTG trinucleotide repeat sequence in the 3' 
untranslated region of a protein kinase gene (Harley et al. 1992a; Buxton et 
al. 1992; Aslanidis et al. 1992; Mahadevan et al. 1992; Brook et al. 1992; 
Fu et al. 1992; Jansen et al. 1992). Repeats containing over 40 CTG units 
tend to expand further in successive generations and both age at onset and 
the clinical phenotype correlate with the size of the mutation (Harley et al. 
1992b, Hunter et al. 1992). These findings have provided a biological basis 
for the progressively earlier onset of DM in consecutive generations, i.e. 
anticipation (Fleischer, 1918; Ravin and Waring, 1939; Bell, 1947; Klein, 
1958; Hòweler et al. 1989). However, the factors governing the transition 
from minimally expanded CTG trinucleotide repeats found in subjects who 
are asymptomatic or have cataract as their only feature, to larger mutations 
associated with muscle weakness and clinical myotonia have not yet been 
elucidated. We performed DNA analysis in DM families to evaluate whether 
the size of the CTG trinucleotide repeat sequence in the parent might 
influence the size of the mutation in the offspring. A parental size effect had 
already been documented by several groups for the CCG trinucleotide 
expansion associated with the fragile X syndrome (Fu et al. 1991, Yu et al. 
1992, Heitz et al. 1992). Because there appears to be an excess of mildly 
affected or asymptomatic male transmitters in DM families (Bell, 1948; 
Klein, 1958; Harper, 1989; Brunner et al., 1991), we performed genealogi-
cal studies in 38 DM families and analysed previous reports of such studies 
to examine whether this male excess is specifically associated with the first 
appearance of the clinical phenotype in the family. We also studied the 
molecular basis for this phenomenon by analysing the influence of the sex of 
the transmitting parent on the size of the DM mutation in their offspring. 
MATERIALS AND METHODS 
Genealogical studies: 
Over a 5-year period (1987 through 1991), all patients with myotonic 
dystrophy (DM) seen at the Nijmegen clinical genetics unit were asked to 
complete a pedigree form that included names, dates and places of birth and 
of marriage of their parents, grandparents and great-grandparents. Pedigrees 
were constructed which included all affected family members known to the 
proband. Whenever possible, this information was confirmed by reviewing 
the medical records or by clinical examination of family members. Affected 
individuals were considered to belong to a single pedigree if they were 
linked together through no more than 3 apparently unaffected individuals. 
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For technical reasons, we limited our studies to pedigrees which originated 
wholly or partly from the Province of North-Brabant. There has been no 
major emigration from, or immigration into, this area over the last 200 
years. Its population (approximately 300.000 in 1800 and 2 million in 1991) 
shows little evidence of inbreeding, similar to the Dutch population as a 
whole (van Straaten, 1986). A total of 38 pedigrees were studied. For each 
particular pedigree, genealogical studies started at the common ancestral pair 
and were extended to approximately 1780 (6-8 generations). Sex and age at 
death were recorded for the obligate carriers that were thus identified. 
Obligate gene carriers were considered asymptomatic if no muscle weakness 
or cataract had been noted until at least age 50. In the normal population 
between age 45 and 55 years, approximately 12% of individuals have lens 
opacities, and approximately Vh.% have lens opacities causing visual loss 
(Leske and Sperdato, 1983). Therefore, subjects who developed cataract as 
the only symptom after the age of 50 years were also classified as asympto-
matic. Generally, medical records or reliable clinical information or both 
were available for 2 to 3 generations preceding the appearance of clinical 
DM in a family. However, for individuals born prior to 1880 documentation 
was generally lacking. 
In addition, data from 4 published clinical and genealogical studies of DM 
were included in our analysis (Fleischer, 1918; Klein, 1958; Höweler, 1986; 
Mathieu et al., 1990). For the study of the sex ratio, we excluded families 
that showed multiple alternative links. 
Statistical significance was tested using either the normal approximation to 
the binomial distribution (two-tailed) or the XMest where appropriate. 
DNA studies: 
Families were ascertained through the DNA diagnostic service of our 
department. Care was taken to ensure that all families met previously defined 
diagnostic criteria [Griggs et al. 1988]. Chromosomal DNA was isolated 
from peripheral blood (Miller et al. 1988). Using a recently described PCR 
assay (Mahadevan et al. 1992) we determined the length of the CTG repeat 
in genomic DNA. The CTG repeat was amplified with flanking primers 406 
and 409 (Mahadevan et al. 1992). Alleles containing up to approximately 90 
CTG triplets were resolved on a 6% Polyacrylamide / 7 M Urea sequencing 
gel after 32P end-labeling one of the amplification primers (Brunner et al. 
1992). Expanded alleles appeared on the Polyacrylamide gel as a mosaic 
pattern of DNA fragments differing by one or a few trinucleotide repeats. 
The size of the most prominent band was estimated by comparison with a 
known sequencing ladder. Accurate sizing was also possible using fluores-
cently labeled PCR primers and subsequent analysis on an automated 
sequencer (ABI, 373), using Genescanner software and internal lane stand-
152 
ards (Genescan 2500 ™ROX). Size estimates for larger alleles were obtained 
from analysis of PCR products on 1% and 2% agarose gels blotted onto 
Gene Screen Plus filters and hybridized with a 3 2P end-labeled (CTG)10 
oligonucleotide. In general, the PCR products produced a smear and the size 
of the small end of the smear was determined by comparison with a mixture 
of lambda χ Hindlll and Phi X 174 χ Hae Ш digestions as a marker. 
Finally, unsizable, large smears, partly resulting from heteroduplex formati­
on in the PCR products, were checked by conventional Southern blot 
analysis of Hind III digested genomic DNA, using probe pGB2.6 (Mahade-
van et al. 1992). The same size marker was used. 
For statistical evaluation, Fischer's exact test, the XMest, Spearman corre­
lation coefficient, Student's t-test and Wilcoxon's rank sum test were used 
where appropriate. 
RESULTS 
Genealogical studies: 
We found that 22 out of 38 DM pedigrees (56%) were linked to at least one 
other DM pedigree. In 8 instances, 2 families were linked together, in 2 
instances, 3 families were linked by the genealogical studies. Genealogical 
links involved between 4 and 10 apparently unaffected individuals (average 
6.6 individuals). Genealogical linkage of 3 independently ascertained pedig­
rees is shown in figure 1. Analysis of our data indicated that genealogical 
links involve males more frequently than females (62 males vs. 38 females; 
p=0.02). Analysis of published DM pedigrees (Fleischer, 1918; Klein, 
1958; Höweler, 1986; Mathieu et al., 1990) shows an excess of male 
transmission in each study. For all studies combined, genealogical links 
involved 387 males and 267 females (p<0.001). As shown in table 1, this 
difference is caused by a disproportionate excess of males in the last asymp-
tomatic generation. Comparison of the sex ratio between individuals in the 
last asymptomatic generation and those in all preceding generations shows a 
highly significant difference (177/90 vs. 210/177, respectively; ρ <0.005). 
This was still true when a large French Canadian pedigree study (Mathieu et 
al., 1990) was excluded (ρ<0.01). This study classified individuals only as 
affected or unaffected without further details and identified a common 
ancestral pair for 746 DM patients from a highly inbred area. Inbreeding 
increases the chance of finding spurious genealogical links, although this is 
unlikely to be relevant in this case of extensive and detailed genealogical 
studies of a very large number of patients. 
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Figure 1: 
Genealogical connections between 3 independently ascertained DM kindreds. 
Only DM patients and their siblings and offspring are shown. Probands are 
indicated. Shaded symbols denote clinically affected individuals. Clinically 
unaffected individuals were counted as belonging to the last asymptomatic 
generation if they had a clinically affected offspring. All other unaffected 
individuals that linked together different pedigrees were counted only once as 
belonging to the previous generations. 
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DNA studies: 
We studied the offspring of 38 subjects (28 males and 10 females) with 
a CTG repeat size of less than 100 (range 41-95, mean 67 CTG trinu-
cleotide repeats) and their offspring. Carriers of this type of mutation 
usually have cataract as their only feature, or no symptoms at all 
(Brunner et al. 1992, Reardon et al. 1992, and H.T.Brüggenwirth, 
unpublished results). These 38 subjects (only 3 of whom were included 
in the genealogical studies) had transmitted the DM mutation to a total 
of 68 offspring. In all but 2, the CTG repeat had increased in size upon 
transmission, confirming the general tendency for anticipation in this 
disorder (Fleischer, 1918; Höweler et al. 1989; Ashizawa et al. 1992). 
As shown in table 2, in 55/68 offspring (81%) the DM mutation had 
undergone expansion to at least 100 CTG trinucleotides. As expected, 
the size of the mutation in offspring correlated with the size of the 
parental mutation when all data were analysed together (r=0.278, 
Ρ=0.02 by Spearman's rank correlation). However, results were not 
significant when paternal and maternal inheritance were considered 
separately (father-child, r=0.129, p=0.36; mother-child, r=0.626, 
p=0.094). 
Apart from this weak effect of parental allele size, the sex of the parent 
was more important in determining the size of the mutated allele in the 
offspring. In the complete sample, a large mutation in the offspring. 
To rule out the possibility that genetic factors other than the sex of the 
transmitting parent were responsible for similar allele sizes in siblings, 
we repeated these calculations, this time restricting our analysis to the 
transmitting parents and the oldest offspring carrying the mutation. In 
this analysis, 23/28 offspring of males and 2/10 offspring of females 
had inherited a mutation ^100 CTG trinucleotides (P=0.0017, Fi­
scher's exact test). Given the effect of parental allele size on the size of 
the mutation in their offspring, we next examined whether the apparent 
effect of parental sex was caused by a difference in allele size between 
fathers and mothers in our study. However, the number of CTG trinu­
cleotides was not different between male and female transmitters (66.9 
± 10.2 vs. 66.9 ± 8.8, not significant). Moreover, when we restricted 
our analysis to parental alleles of 60-79 CTG trinucleotides, there was 
again a significant difference between paternal and maternal transmis­
sion (41/42 vs. 3/11 offspring large mutation, ρ < 0.0001 by Fischer's 
exact test, table 2). A significant difference between paternally and 
maternally inherited mutations was also found when we used a threshold 
of 200 or 300 CTG trinucleotide repeats to define large expansions 
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(table 2). When the absolute size of the repeat sequence was compared, 
paternally inherited DM mutations were found to be larger than mater-
nally inherited DM mutations (310 ± 29.9 vs. 105 ± 40.7 CTG 
trinucleotide repeats, p=0.0008 by Student's T-test, 2-sided). While the 
sex of the parent appeared to influence the CTG expansion, no differen-
ce in CTG repeat size was noted when male and female sex of the off-
spring were compared (X2= 0.14, not significant). 
CTG repeat CTG repeat Sex of transmitting parent ρ-Value* 
of parent of offspring Male Female 
40-59 
60-79 
80-99 
TOTAL 
£100 
£200 
£300 
£100 
£200 
£300 
£100 
£200 
£300 
£100 
£200 
£300 
6/9 
5/9 
1/9 
41/42 
36/42 
26/42 
1/1 
1/1 
1/1 
48/52 
42/52 
28/52 
1/2 
0/2 
0/2 
3/11 
2/11 
2/11 
3/3 
1/3 
1/3 
7/16 
3/16 
3/16 
n.s. 
n.s. 
n.s. 
<0.0001 
0.0001 
0.019 
n.s. 
n.s. 
n.s. 
0.0002 
<0.0001 
0.026 
TABLE 2: Proportion of offspring with a DM mutation exceeding 100, 
200, and 300 CTG trinucleotide repeats. 
* p-Values for male versus female transmission were calculated by 
Fischer's exact test (2-tailed). 
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DISCUSSION 
We have performed genealogical studies as well as DNA studies in an 
attempt to elucidate some of the factors that are associated with the transition 
of small CTG expansions at the myotonic dystrophy (DM) locus (with 
limited phenotypic effect other than ocular cataract) to larger CTG expansi­
ons that cause more severe disease. 
First, we confirmed previous reports (Lavedan et al., 1993; Harley et al., 
1993; Redman et al., 1993) that the size of the parental allele correlates with 
the size of the DM mutation in the offspring. 
Second, our study shows that the onset of clinical expression in DM families 
is preferentially associated with paternal transmission of the DM mutation. In 
the genealogical studies, an excess of males was found among subjects that 
linked independently ascertained DM kindreds. Male transmission was 
especially increased in the last generation preceding onset of clinical symp­
toms (177 of 267 transmitters male, ρ < 0.005 for last asymptomatic generati­
on versus all previous generations combined, table 1). This apparent effect 
of the sex of the transmitting parent was also observed in the DNA studies. 
A marked difference in CTG trinuclotide repeat size in offspring was found 
when we compared the proportion of mutations exceeding an arbitrary 
threshold of 100 CTG trinucleotide repeats in offspring of male and female 
mutation carriers (table 2). The differential influence of paternal and mater­
nal transmission persisted when we restricted our analysis to the firstborn 
affected offspring, or to offspring of carriers of mutations between 60 and 79 
CTG trinucleotide repeats. The same conclusions were reached when the 
threshold separating small and large mutations was set at of 200 or 300 CTG 
trinucleotide repeats. We conclude that, although an increase in CTG trinu­
cleotide repeat size is the rule for both sexes, the degree of this expansion is 
clearly greater for paternally transmitted mutations of this size range. 
Our data do not allow to estimate in absolute figures the risk that a small 
mutation will evolve into a large mutation. However, both the results of the 
genealogical studies as well as the DNA studies suggest that expansion from 
a DM mutation <100 CTG trinucleotide repeats, causing only cataract and 
no muscular disease (Brunner et al. 1992, Reardon et al. 1992; H.T.Brüg-
genwirth, unpublished data) to a mutation ¿100 CTG trinucleotide repeats, 
usually causing muscular symptoms, is approximately 2 times as frequent 
with paternal as with maternal transmission. 
Although we have taken great care to exclude measurement errors, the 
somatic heterogeneity of the DM mutation precludes complete accuracy of 
allele size measurements. Nevertheless, a significant difference for maternal-
ly and paternally derived mutations was evident in each of our analyses. For 
this reason, the difference in CTG repeat size in paternally 
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versus maternally transmitted minimal DM mutations most likely constitutes 
a true biological phenomenon. 
Our finding that the increase in CTG repeat size is larger with paternal than 
with maternal transmission of minimal DM mutations explains previous 
observations of an excess of males in the earliest generations of a clinically 
ascertained DM pedigree (Bell, 1947; Klein, 1958; Harper, 1989; Brunner et 
al. 1991; Harley et al. 1993). In our total DM family sample of more than 
200 families, when both parents of a DM patient are clinically normal, the 
odds are approximately 2:1 that the father is the transmitting parent (unpu-
blished data). 
If alleles <100 CTG trinucleotides enlarge to a greater extent on paternal 
than on maternal transmission, then only the last asymptomatic generation 
should show an exces of male transmissions, and the previous generations 
should show a small excess of female transmissions. As shown in table 1, a 
small (but not significant) excess of male transmissions was found instead in 
the previous generations. This discrepancy may reflect biases that are 
inherent to these genealogical studies. Most importantly, if indeed paternal 
transmission of small alleles is associated with greater instability, then the 
number of transmissions will be larger if many transmissions are through 
females. Such long genealogical chains would obviously have a smaller 
chance of being detected in these studies. Also, our own study, and those of 
Höweler (1986) and of Mathieu et al. (1990) included all ancestors of a 
patient. In contrast, Fleischer (1918) and Klein (1958) most likely extended 
their genealogical studies preferentially along the male line once the same 
surname had been detected in two families. This may account for the 
relatively large excess of male transmission in previous generations found by 
Klein (1958). However, we emphasize that this male bias should be much 
stronger for the previous generations than for the last asymptomatic generati-
on. Consequently, this bias cannot explain (and indeed is at variance with) 
our finding of a significant excess of male transmission in the last asympto-
matic generation versus previous generations. 
Two studies have concluded that female transmission results in greater 
enlargements, even for small alleles (Lavedan et al. 1993; Redman et al. 
1993). However, in these studies the data were not analysed separately for 
parental alleles of less than 100 CTG trinucleotides (0.3kb). Therefore it 
cannot be stated that the greater instability on paternal transmission noted by 
us for these small alleles was or was not present in their data. Moreover, 
close inspection of the data presented in these papers suggests that the 
proportion of parental alleles of <0.3kb (100 CTG trinucleotides) that 
enlarged by less than 0.5 kb in the offspring may in fact be larger for 
maternal transmission in both studies. Another study that reported that 
increases in size of the CTG trinucleotide repeat are not different between 
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male and female carriers of a DM mutation summarized data on the trans-
mission of mutations of all sizes (Tsilfidis et al. 1992). 
Harley et al. (1993) have recently suggested that the excess of minimally 
affected males might be due to a greater tendency to initial instability with 
male transmission. This suggestion is supported by our findings. However, 
data supporting that hypothesis were not presented, and the authors conclu-
ded that increase in repeat size is similar for both paternal and maternal 
transmissions when the increase is expressed as a proportion of the parental 
repeat size (Harley et al. 1993). The data in that paper are presented in a 
way that does not allow direct comparison between maternal and paternal 
alleles between 60-79 CTG trinucleotides; i.e. the group that showed the 
largest difference in our study. 
We would like to suggest that the conflict between the conclusions in our 
study and those of others may be more apparent than real, and may reflect 
the fact that the other studies did not specifically compare maternal and 
paternal inheritance of alleles less than 100 CTG trinucleotides that were 
matched for size. 
We postulate that the situation could be different for these categories because 
the transmission of larger paternal mutations may be under negative selection 
during spermatogenesis. It is obvious that there is selection against transmis-
sion of very large mutations by males, since males with onset of muscular 
weakness in early adulthood are usually infertile or celibate or both (Klein, 
1958; Hòweler et al. 1989). In addition, we believe that negative selection 
could also operate at the level of individual sperm cells, thereby effectively 
limiting the range of 
mutated alleles to those with relatively smaller expansions. Indirect support 
for this hypothesis comes from studies documenting a decrease in CTG 
trinucleotide number from parent to child. In the large majority of cases of 
decreasing CTG repeat length the transmitting parent has been the father 
(Ashizawa et al. 1992; Hunter et al. 1993; Shelbourne et al. 1992; O'Hoy 
étal. 1993; Brunner et al. 1993; Lavedan et al. 1993; Harley et al. 1993; 
Redman et al. 1993; Abeliovich et al. 1993). It is tempting to speculate that 
a combination of male infertility and selection against individual sperm 
bearing large expansions at the DM locus could be involved in the exclusi-
vely maternal origin of the severe congenital form of DM. In this regard, it 
is of interest that in the segregation distorter (SD) system in Drosophila 
allele-specific male gamete dysfunction is dependent on an expanded repeat 
sequence (Lyttle, 1993). 
Most of the dynamics of the CTG trinucleotide repeat expansion in DM are 
presently unknown. It is possible that the increased instability associated with 
male transmission noted in our study simply reflects the larger number of 
cell divisions in spermatogenesis than in oogenesis. On the other hand, it is 
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equally possible that expansion of the DM mutation is predominantly a 
postzygotic event. This would then suggest the possibility that the differential 
influence of materaal and paternal transmission on trinucleotide repeat length 
is influenced by genetic imprinting (Reik, 1988). In both humans and mouse, 
the DM-kinase gene is expressed from both chromosomes (Jansen et al. in 
press). This finding does not, however, exclude another type of imprinting 
characterized by differential mutability. 
Finally it should be noted that in Fragile X syndrome the risk of transition 
from a small parental mutation ("premutation") to a large mutation in 
offspring also depends on the size of the parental trinucleotide repeat but that 
a large increase in allele size is virtually restricted to maternally inherited 
mutation (Fu et al. 1991, Yu et al. 1992, Heitz et al. 1992), again sugge­
sting negative selection during spermatogenesis, genetic imprinting or both. 
Studies of trinucleotide repeat length in sperm from DM and fragile X 
patients should be of great value for further elucidation of the dynamics of 
these unstable mutations. 
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Brunner HG, Hamel BCJ, Rieu Ρ, Höweler CJ, Peters FTM 
Intestinal pseudo-obstruction in myotonic dystrophy. 
J Med Genet 29: 791-793, 1992 
SUMMARY 
We describe 4 myotonic dystrophy (DM) patients who developed recurrent 
intestinal pseudo-obstruction. Some episodes were associated with gastroente-
ritis, while abdominal crowding may have occurred in 1 case during the 3rd 
trimester of pregnancy. In most instances, however, no apparent cause could 
be identified. Intestinal pseudo-obstruction may occur at any stage of DM. In 
1 of our cases intestinal pseudo-obstruction preceded significant muscle 
weakness by 15 years. Intestinal pseudo-obstruction is usually treated 
effectively with conservative measures. These include restriction of oral 
intake, intravenous fluids and multiple enemas or colonoscopy. Improved 
intestinal function was noted in 1 case treated with the prokinetic agent 
cisapride. A partial sigmoid resection was performed in 3 cases with dolicho-
megacolon. No abnormalities were reported on histological examination. 
Since intestinal pseudo-obstruction is a rare complication of DM, it is of 
interest that 2 of our cases are siblings. Review of the literature reveals 
several reports of familial occurrence of specific complications. These 
include cardiac conduction disturbances, focal myocarditis, mitral valve 
prolapse, pilomatrixomas, polyneuropathy, normal pressure hydrocephalus 
and dilatation of the urinary tract. Myotonic dystrophy may show a tendency 
to familial clustering of organ-specific involvement. 
INTRODUCTION 
In myotonic dystrophy (DM), smooth muscle involvement can be demonstra-
ted in most patients. Swallowing difficulties are a major concern and may 
lead to aspiration [1]. Symptomatic disturbance of colonic motility may 
occur with colicky abdominal pain similar to spastic colon. X-ray studies 
may be normal, or show frank megacolon. Occasional patients develop a 
severe disturbance of intestinal motility such as volvulus or intestinal pseudo-
obstruction [2-6]. We here report on 4 DM patients who developed this 
complication. 
CASE REPORTS 
Case 1: 
This man was bom in 1941. He first noted myotonia at age 15. He was a 
conscript in the army at age 18, when he developped acute lower abdominal 
pain with abdominal distension. A temporary colostomy was performed. 
During the following year he experienced several episodes of abdominal 
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pain. X-ray studies showed a megasigmoid. On laparotomy, about 30 cm of 
sigmoid colon was resected. Microscopic examination showed normal 
ganglion cells without other abnormalities. At age 34 he presented with distal 
muscle weakness. Percussion myotonia of the thenar muscles and of the 
tongue was noted. EMG showed electrical myotonia and mild conduction 
delay. A diagnosis of myotonic dystrophy was made. At age 42, he develo-
ped fever, abdominal distension and pain. Plain abdominal X-ray showed 
marked dilatation of many small bowel loops. The patient was admitted to 
the hospital. The erythrocyte sedimentation rate increased from 12 to 42 
mm. 
Cultures of peripheral blood and of faeces were negative. The patient 
improved with conservative measures. At age 43 he was again admitted with 
vomiting, abdominal distension and bowel dilatation. The clinical picture 
again resolved with conservative measures. A contrast barium enema showed 
loss of haustra throughout the colon. Several subsequent episodes of 
constipation and crampy abdominal pain have led to 2 more admissions to 
the hospital. No further abdominal surgery has been necessary. 
Case 2: 
This woman was born in 1947. She is the sister of case 1. Her first pregnan-
cy was complicated by polyhydramnios. A son was born, who died of 
respiratory insufficiency. A cardiac defect was suspected, but no abnormality 
was identified at autopsy. The patient became pregnant again, and delivered 
a normal daughter. At age 28, myotonic dystrophy was diagnosed during 
family studies. During her 3rd pregnancy at age 29, she developed acute 
ileus at 28 weeks, believed due to pressure of the uterus against the rectosig-
moid. A temporary colostomy was performed. She delivered a healthy girl 
on the same evening. The child weighed 1880 grams and subsequently did 
well. The colostomy was closed 2 weeks after delivery. At age 30 years, she 
was admitted with crampy abdominal pain, constipation and vomiting, which 
resolved spontaneously. X-ray studies showed megacolon. A rectal biopsy 
showed no evidence of Hirschsprung's disease. Two years later, she was 
readmitted with ileus thought due to a volvulus of the sigmoid. A laparotomy 
was performed during which the obstruction was relieved. X-ray studies 2 
months after operation showed an elongated sigmoid. A sigmoid resection 
was performed. The resected segment showed a normal anatomy, with 
ganglion cells in both Auerbach's and Meissner's plexuses. At age 37, the 
patient was again admitted because of Subileus. Plain abdominal X-ray 
showed dilataton of multiple small bowel loops with air-fluid levels. She 
was treated with intravenous fluids and multiple enema's. At age 39, an 
episode of gastro-enteritis necessitated another admission for intestinal 
pseudo-obstruction. At age 41 years, she experienced her 6th episode of 
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intestinal pseudo-obstruction, which again resolved with conservative 
measures. 
Case 3: 
This man was born in 1963. At age 14, myotonic dystrophy was diagnosed 
on the basis of myotonia and positive family history. Both his father and 
paternal aunt have classical myotonic dystrophy. His paternal grandfather is 
mildly affected. The patient works in a sheltered environment. At age 19 
years, he experienced several periods of abdominal pain. Evaluation at age 
20 years showed reduced oesophageal motility and gastritis. Oesophageal 
manometry did not register a high pressure zone at the level of the lower 
oesophageal sphincter. Abdominal ultrasound studies were reported normal. 
No diagnosis was made. At age 25 years the patient was admitted because of 
abdominal pain and constipation of 1 week's duration. The abdomen was 
distended with high-pitched bowel sounds. Plain abdominal X-ray showed a 
dilated descending colon. Colonoscopy showed a distended rectum and 
colon, connected by a collapsed segment of approximately 10 cms. Follo-
wing endoscopy, normal intestinal motility was restored. X-ray studies of the 
colon showed dilatation and elongation of the sigmoid. Pressure recording of 
the anal sphincter was normal. Rectal biopsy showed presence of ganglion 
cells. A partial sigmoid resection was performed 6 months later. No abnor-
malities were noted on histological examination. 
Case 4: 
This woman was first diagnosed as having myotonic dystrophy at age 20 
years during family studies. She had been admitted as an infant because of 
hypotonia, insufficient respiration and swallowing difficulties. Her motor and 
mental development were delayed and she did not learn to read and write 
during 12 years of special schooling. She is considered to have the congeni-
tal form of DM. Since the age of 9 she had alternating diarrhea and constipa-
tion with abdominal cramps. No cause was identified during a pediatric 
examination. At the age of 21 she was admitted to the surgical department 
because of bilious vomiting and abdominal pains for 3 days. The abdomen 
was distended with high-pitched bowel sounds. A diagnosis of ileus was 
made. After 24 hours of conservative treatment, a laparotomy was perfor-
med. Both the small and large bowels were distended. No obstruction was 
found. Her postoperative course was complicated by pneumonia, necessita-
ting artificial respiration for 8 days. She was discharged from the hospital 
after 4 weeks. With cisapride medication, there has been normal daily 
defecation for 6 months. 
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DISCUSSION 
In DM, abnormal motility has been demonstrated of the oesophagus, sto-
mach, small intestine, colon and anal sphincter [7]. Swallowing difficulties 
are common, as well as disturbances of oesophageal motility which put these 
patients at increased risk of aspiration [1]. Also common are attacks of 
abdominal pain, accompanied by constipation or diarrhoea, caused by 
reduced colonic motility [1]. However, only a few reports exist of major 
abdominal problems in DM patients. The patients reported here, developed 
signs and symptoms of intestinal obstruction as a complication of myotonic 
dystrophy. In case 1, intestinal problems predated significant muscle weak-
ness by 15 years. Reduced intestinal motility is a likely factor that leads to 
this complication. Furthermore, elongation and distension of the sigmoid 
colon may have predisposed our patients to volvulus and invagination, and 
thus contributed to the risk of ileus. Other predisposing factors in our 
patients were bacterial gastroenteritis and pregnancy. Routine histological 
examination of resected colon showed no abnormalities in our patients, but 
special studies were not performed. Yoshida et al. [8] reported pathologic 
studies in a DM patient in whom a hemicolectomy was performed because of 
a megacolon. They found normal smooth muscle but marked abnormalities 
of the myenteric plexus, indicating a possible neuropathic origin of the 
intestinal motility. However, smooth muscle abnormalities of small and large 
intestine have been reported by others [9]. 
Conservative measures were usually successful in the treatment of episodes 
of intestinal pseudo-obstruction in our cases. Treatment consisted of restricti-
on of oral intake, intravenous fluids, and multiple enemas or colonoscopy. If 
abdominal surgery cannot be avoided, care should be taken to prevent the 
possible complications of general anaesthesia in DM patients [10], as 
exemplified by our case 4. Maintenance therapy with prokinetic agents may 
be considered. Cisapride has been shown to stimulate gastric and colonic 
motility in DM patients [11], and was effective in our case 4. 
Intestinal pseudo-obstruction appears to be a rare complication of DM. A 
few case reports can be found in the literature [1-6]. We have seen this 
complication in 3/130 patients (2.3%) in the course of genetic linkage 
studies. In view of the low frequency of this complication it is striking, that 
our cases 1 and 2 are sibs. Another sib pair with prominent gastrointestinal 
involvement has been described [6]. An interesting model that may explain 
such clustering of apparently rare complications was recently proposed by 
Beggs et al. [12], who found deletions in the dystrophin gene in 3 out of 23 
patients with a clinical diagnosis of Fukuyama congenital muscular dystrophy 
(FCMD). They suggested that the FCMD phenotype in these patients should 
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be explained on the basis of an interaction of heterozygosity for FCMD with 
hemizygosity for the dystrophin mutation. Similarly, our cases could have a 
specific genetic susceptibility for intestinal pseudo-obstruction, which is only 
uncovered by the additional presence of the DM mutation. Interaction of a 
major gene mutation and the genetic background may explain familial 
clustering of specific phenotypes in several other disorders [13-18], and 
could well turn out to be an important determinant of variable expressivity in 
inherited disease. 
Familial occurrence of specific complications of DM has been reported 
before [19-23,27,28,30-32] (table). However, a number of these reports 
concerned features that may be more common in DM than was originally 
realized. This is certainly the case for mitral valve prolapse [22], and for 
cardiac conduction abnormalities [24], and could even apply to pilomatrixo-
mas and ureteral dilatation, since their prevalence in DM patients is not 
known. The siblings with normal pressure hydrocephalus, reported by 
Christensen [28] were incompletely documented, while a report of focal 
myocarditis in a mother and son [27] could represent a relatively aspecific 
inflammatory reaction due to many possible causes, including infection. On 
the other hand, the finding of markedly decreased conduction velocities in a 
large family with otherwise classical DM [20,21] may represent an unusual 
allelic mutation, since all 14 carriers of the DM mutation in this family also 
showed a polyneuropathy. 
In conclusion, both allelic mutations of the DM gene proper and unlinked 
modifying genes may influence the clinical picture in individuals with DM. It 
may be worthwhile to not only be aware of the many possible complications 
of DM in general, but also to document unusual complications in a given 
pedigree. Such complications may show a tendency to recur, especially in 
close relatives. 
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CHAPTER 11 
SUMMARY 
Myotonie dystrophy (DM) is an autosomal dominant multisystem disorder 
with a number of features that are not usually observed in other genetic 
conditions. Earlier age at onset in successive generations, called anticipation, 
as well as effects of the sex of the transmitting parent on the disease severity 
in offspring are examples of such features. In order to study the genetic basis 
of myotonic dystrophy, several groups, including our own, embarked upon 
projects aimed at isolating the myotonic dystrophy gene. Cloned polymorphic 
markers that had been assigned to specific loci on the physical map of 
chromosome 19 were used to localize the DM gene to 19ql3 (paragraph 1.2 
and chapters 2-4). A few crucial recombinant families and strong linkage 
disquilibrium then sufficiently narrowed the physical localization of the DM 
gene to allow its identification (paragraph 1.3). The unstable mutation 
underlying myotonic dystrophy consists of an expanded CTG trinucleotide 
repeat sequence in the 3'-untranslated region of a gene encoding a serine-
threonine protein kinase family member. This gene has been termed DM-
kinase. The expansion of the CTG repeat sequence presumably changes the 
activity of the DM-kinase. However, a change in activity of other genes in 
this area has not yet been excluded. 
The myotonic dystrophy mutation can be demonstrated directly by Southern 
analysis of genomic fragments, or by PCR amplification of the unstable 
repeat. This method is now the preferred diagnostic test for myotonic 
dystrophy, especially since previous strategies based on clinical, ophthalmo-
logical, and electromyographical examination failed to identify approximately 
8% of mutation carriers (Chapter 5). 
The application of direct mutation analysis has explained phenomena that 
have puzzled geneticists and clinicians alike. The DM mutation is unstable 
and tends to expand further in successive generations. This explains the 
previous observations of earlier onset in successive generations (anticipation) 
in this condition. 
The myotonic dystrophy mutation is in complete linkage disequilibrium with 
a lkb insertion in an intron of the DM kinase gene. This linkage disequi-
librium probably results from a shared ancestry of many (if not all) DM 
mutations. This suggests that new mutations rarely, if ever occur in myotonic 
dystrophy. Consistent with this hypothesis is the finding of common ances-
tors for independently ascertained DM families by genealogical studies 
(paragraph 1.3.4; chapter 9). Also, a small expansion of the CTG trinucleo-
tide repeat is consistently found in asymptomatic obligate carriers (Chapter 
7). Starting with such a small increase in CTG number, further expansion is 
more rapid with male transmission compared to female transmission. This 
finding explains the excess of asymptomatic male transmitters in genealogical 
studies of DM (paragraph 1.3.4; chapter 9). Reductions in the size of the 
DM repeat sequence occur only rarely. Occasionally, they may result in a 
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complete reversal of the myotonic dystrophy mutation (Chapter 8). The fact, 
that reductions in the size of the CTG trinucleotide repeat sequence occur 
predominantly with male transmission may point to selection against alleles 
containing large CTG trinucleotide expansions, either during spermatogenesis 
or in the early zygote (paragraph 1.3.4; chapter 9). Negative selection may 
also help explain the exclusively maternal transmission of the congenital 
form of myotonic dystrophy (paragraph 1.5). 
Preliminary evidence for aditional genetic factors that modify the clinical 
expression of the DM mutation has been obtained in a family in which each 
of 14 affected subjects presented with a demyelinating neuropathy (Chapter 
6). The occurrence of a rare complication such as intestinal pseudo-obstructi-
on in siblings with DM also points in the direction of modifying factors, 
possibly of genetic origin (Chapter 10). 
On the one hand, the story of the myotonic dystrophy mutation illustrates the 
successful application of molecular genetics to inherited disease. On the 
other hand, we should now recognize that clinical observations in the first 
half of this century had accurately predicted many of the surprising genetic 
features of the DM mutation. Such observations may yet uncover new 
aspects of genetic theory. 
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Samenvatting 
Myotone dystrofie (DM) is een autosomaal dominant erfelijke aandoening die vele 
orgaansystemen kan treffen. De efelijkheid van de ziekte vertoont enkele 
bijzondere kenmerken die bij de meeste genetische aandoeningen niet worden 
gevonden. Zo is er het fenomeen van de anticipatie, waarmee wordt bedoeld dat 
de ziekte zich in opeenvolgende generaties op jongere leeftijd manifesteert. 
Daarnaast is de ernst van de aandoening mede bepaald door het geslacht van de 
ouder waarvan de ziekte is geërfd. Meerdere onderzoeksgroepen, waaronder de 
Nijmeegse, zijn daarom rond 1985 begonnen met projecten gericht op het 
ophelderen van de genetische basis van de myotone dystrofie. Met behulp van 
gedoneerde DNA merkers, die eerst aan een specifiek gedeelte van chromosoom 
19 waren toegewezen, kon worden vastgesteld dat het gen voor de myotone 
dystrofie moest liggen in band ql3 van chromosoom 19 (paragraaf 1.2 en 
hoofdstuk 2-4). Op grond van enkele zeldzame families waarin er recombinatie op 
trad tussen het DM gen en de dichtst gekoppelde DNA merkers, kon dit gebied 
vervolgens zodanig worden ingeperkt, dat het mogelijk bleek om het DM-gen te 
isoleren (paragraaf 1.3). De (instabiele) mutatie die aan het ziektebeeld van de 
myotone dystrofie ten grondslag ligt bestaat uit een toename in het aantal CTG 
trinucleotiden in het 3' uiteinde van een gen dat codeert voor een eiwit dat 
gerelateerd is aan de serine-threonine proteine kinases. Dit gen wordt wel DM-
kinase genoemd. Men veronderstelt dat de toename van het aantal CTG 
trinucleotiden leidt tot een verandering van de activiteit van het DM-kinase. Het 
is echter ook mogelijk dat de mutatie de activiteit van andere genen in dit gebied 
eveneens beïnvloedt. 
De myotone dystrofie mutatie kan zichtbaar worden gemaakt met behulp van 
Southern analyse, dan wel door PCR amplificatie van de instabiele repeterende 
sequentie. Dit onderzoek geldt nu als de meest betrouwbare diagnostische test voor 
de aandoening. Uit eerder onderzoek was gebleken dat klinisch neurologisch 
onderzoek van mogelijke gendragers, in combinatie met oogheelkundig en 
electromyografisch onderzoek, bij ongeveer 8% van de gendragers geen 
afwijkingen aantoonde (hoofdstuk 5). 
Het toepassen van directe mutatie-detectie heeft enkele van de eerder genoemde 
bijzonderheden in de overererving van de myotone dystrofie opgehelderd. Zo is 
de DM-mutatie instabiel, en blijkkt het aantal CTG trinucleotiden in opeenvolgende 
generaties toe te nemen. Dit verklaart de klinische waarneming van de anticipatie, 
dat wil zeggen het in opeenvolgende generaties vroeger optreden van de 
aandoening. 
De DM-mutatie erft altijd samen over met een 1 kb insertie in een intron van het 
DM-kinase gen. Het is aannemelijk dat dit berust op een gezamenlijke afstamming 
van alle DM-mutaties in de populatie. Als dat inderdaad zo is, dan zou dat 
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betekenen dat nieuwe mutaties zelden of nooit voorkomen bij de myotone 
dys trofie. Inderdaad blijken verschillende families met myotone dystrofie vaak af 
te stammen van dezelfde voorouders (paragraaf 1.3.4; hoofdstuk 9). Bovendien is 
bij de gezonde personen die als verbindende schakels tussen deze families fungeren 
altijd een (zij het geringe) toename van het aantal CTG trinucleotiden aantoonbaar 
(hoofdstuk 7). Beginnend met zo een geringe toename in het aantal CTG 
trinucleotiden is er juist dan sterke een sterke verdere toename van het aantal CTG 
tripletten in de volgende generatie als de mutatie door een man wordt 
doorgegeven. Dit betekent dat in de laatste generatie vóór er klinische 
verschijnselen optreden meer mannen dan vrouwen worden gevonden. Dit 
verklaart de relatief frequente paternale overerving bij stamboom-onderzoek van 
myotone dystrofie. 
Vermindering van het aantal CTG trinucleotiden komt weliswaar voor, maar 
slechts in een minderheid van de gevallen. In uitzonderlijke gevallen gaat het om 
een zodanige afname, dat het aantal CTG trinucleotiden bij het kind in het normale 
bereik komt te liggen (5-37 CTG trinucleotiden). Dan is de DM-mutatie 
teruggemuteerd naar een normaal allei van het DM-kinase (hoofdstuk 8). Dat 
verminderingen in het aantal CTG trinucleotiden vooral optreden wanneer de 
mutatie door een man wordt overgedragen, zou kunnen wijzen op een negatieve 
selectie gericht tegen de allelen met het grootste aantal CTG trinucleotiden tijdens 
de Spermatogenese of in de eerste celdelingen na de bevruchting (paragraaf 1.3.4; 
hoofdstuk 9). Deze negatieve selectie zou mede kunnen verklaren waarom de 
meest ernstige (congenitale) vorm van de aandoening zich uitsluitend voordoet bij 
transmissie via een vrouw (paragraaf 1.5). 
Er zijn voorzichtige aanwijzingen dat het klinisch beeld van de myotone dystrofie 
niet alleen afhankelijk is van het aantal CTG trinucleotiden, maar eveneens van 
bijkomende genetische factoren. De waarneming van een familie waar de DM-
mutatie steeds samen gaat met een demyeliniserende Polyneuropathie wijst in deze 
richting (hoofdstuk 6). Het optreden van een zeldzame complicatie als de 
intestinale pseudo-obstructie (paralytische ileus) bij een broer en zuster met 
myotone dystrofie kan eveneens verklaard worden door aan te nemen dat het 
klinisch beeld van de ziekte wordt beïnvloed door bijkomende factoren van 
mogelijk genetische aard (hoofdstuk 10). 
Enerzijds is het verhaal van de DM-mutatie een illustratie van de succesvolle 
toepassing van moleculair genetische technieken bij de opheldering van een erfelijk 
bepaalde ziekte. Anderzijds doen wij er goed aan om ons te realiseren dat de 
verrassende eigenschappen van de DM-mutatie in belangrijke mate al voorspeld 
waren door klinische observaties in de eerste helft van deze eeuw. Dergelijke 
observaties kunnen ook nu nog leiden tot de ontdekking van nieuwe elementen in 
de genetica. 
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STELLINGEN 
behorend bij het proefschrift 
"Genetic studies in myotonic dystrophy" 
van H.G. Brunner 
I 
Het klinisch gedefinieerde begrip "anticipatie" is afdoende verklaard door de in 
opeenvolgende generaties toenemende lengte van de CTG repeat. 
Π 
Dat er meer mannen dan vrouwen worden gevonden onder mild aangedane DM 
patiënten wordt veroorzaakt door ascertainment bias, in combinatie met een grotere 
instabiliteit van de DM mutatie bij overerving via de man. 
ΙΠ 
Dat bij de congenitale vorm van myotone dystrofie de mutatie vrijwel altijd van 
de moeder is geërfd, is ten dele een gevolg van de infertiliteit van mannen met de 
ernstiger vormen van deze aandoening. Belangrijker is echter de invloed van 
negatieve selectie tijdens de Spermatogenese of de fertilisatie. 
IV 
De waarneming, dat een teruggemuteerd allei van 19 CTG eenheden ££¿'uiei 
overerft naar de volgende generatie, suggereert dat de instabiliteit van de DM 
mutatie in eerste instantie afhangt van de lengte van de CTG repeat. 
V 
Negatieve selectie tegen langere allelen op het DM locus tijdens 
spermatogenese/fertilisatie leidt tot een situatie die vergelijkbaar is met het 
"segregation distorter" systeem bij Drosophila. 
VI 
Door aan te nemen dat de DM mutatie onderhevig is aan segregatie distonie kan 
afdoende verklaard worden dat één enkele schadelijke mutatie met zo een hoge 
frequentie wereldwijd voor komt. 
VII 
Het samengaan in één grote familie van myotone dystrofie en een demyeliniserende 
Polyneuropathie kan berusten op het gelijktijdig voorkomen van de geëxpandeerde 
CTG trinucleotide repeat en een modificerende mutatie elders in het DM-kinase 
gen. 
VIII 
Het Camey complex berust op een mutatie die een G-eiwit-effector keten 
stimuleert. 
IX 
Het syndroom van de hypofysaire resistentie tegen schildklierhormoon kan ook 
verklaard worden door aan te nemen dat de TRH-receptor bovenmatig actief is. 
X 
Voor het syndroom van de autosomaal dominant erfelijke leiomyomatose is het 
COL4A4 gen een goede kandidaat. 
XI 
Aangezien bijna de helft van alle publicaties in wetenschappelijke tijdschriften 
nooit zal worden geciteerd, is de ermee verbonden ijdelheid niet zelden misplaatst. 
XII 
Er zijn geen onsterfelijke wetenschappers. En ook de wetenschappelijke vondst 
overleeft maar zelden zijn schepper. 
XIII 
Het verdient overweging, om naast het reguliere toernooi om de 
wereldkampioenschappen atletiek nog een toernooi voor niet gedrogeerde atleten 
te organiseren. 


